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Abstract 
 
Increased knowledge into the molecular pathways disrupted in tumours has led to the 
development of various therapies that can target specific mediators of these cascades.  
Such therapies have proven successful in patients or demonstrate significant potential 
for clinical use.  However, this better understanding is undermined by the continued 
prevalence of cancer and the limitations of these drugs. Therefore, it is possible 
signalling networks could be influenced by as yet unknown molecules or known 
mediators with function that have not yet been described.  As a result of this, work 
must continue to improve knowledge yet further to allow the design of novel therapies 
to aid in the treatment of cancer patients.  In the present study, work was performed 
on the helicase antigen (HAGE), a cancer/testis (CT) antigen and DEAD-box protein 
found to be present in numerous types of malignancy.  As with the majority of CT 
antigens, the role of HAGE remains unclear.  In this instance, studies were carried to 
discover the function of HAGE in malignant cells. 
 
Preliminary in vitro proliferation studies following HAGE gene knockdown or cDNA 
transfection strongly indicated an association between HAGE expression and 
increased tumour cell proliferation.  This was supported by results gained from in vivo 
work performed within an immuno-compromised murine model.  Expression profiling 
analysis of data gained from using the Genechip oligonucleotide microarray platform 
found significant changes to genes linked not only with proliferation but other cell 
processes altered during tumorigenesis.  Confirmation using real-time qPCR 
suggested change in expression of certain genes could be recognised in other HAGE-
expressing tumour cell lines.  This analysis also indicated a possible interaction 
between HAGE and the oncogene N-RAS.  Subsequent genetic and protein studies 
implicated HAGE acting upstream of N-RAS, markedly increasing the N-RAS level 
in cells.  Very preliminary work has begun to demonstrate a role not just in 
proliferation, but in immune escape, apoptosis inhibition and metastasis, all processes 
potentially influenced by the RAS oncogenes. The data presented here strongly 
supports the hypothesis of HAGE having a significant role in malignant biology and 
warrant continued investigation to further confirm its role in cancer and possibly use 
as a target for malignancy in the future. 
Chapter 1  
 
Introduction 
 
1.1 Tumorigenesis and the Basis of Cancer 
 
Cancer remains one of the leading causes of both morbidity and mortality worldwide 
and is a disease that is especially evident in western civilisations.  In 2008, there were 
156,723 reported cancer deaths in the U.K., which is an increase from the 155,484 
deaths recorded in 2007 (Cancer Research U.K).  Disconcertingly, large numbers of 
people die as a result of tumours in spite of massive advancements in the diagnosis 
and treatment of malignancies.  Progress in detection and therapy has been achieved 
alongside considerable investment in the education of the public regarding cancer risk 
factors and encouraging lifestyle changes.  It is perhaps recognition of how complex a 
disease cancer is that it continues to represent such a prominent public health concern 
in the face of improved techniques and attitudes.   
 
Cancer is a disease born out of a disruption in homeostasis, the systems of control that 
exist to maintain a rigorously balanced environment in cells (Bertram, 2001).  
Behavioural aspects of cells such as proliferation are kept in check by a highly 
complex series of molecular networks (Weinstein et al., 1997; Weinstein, 2000; 
Pedraza-Fariña, 2006).  These consist of a vast array of molecules with highly 
divergent functions, which themselves are subject to strict levels of control in normal 
circumstances.  A great deal of evidence now exists to highlight that during the 
development of tumours, homeostatic control systems undergo disturbance and are 
undermined (Weinstein, 2000; Bertram, 2001; Pedraza-Fariña, 2006).  As a result, 
malignant cells display characteristics that almost represent a mirror image of their 
healthy counterparts.  They can exhibit uncontrollable proliferation, resistance to 
apoptosis, are capable of invasion, self-sufficiency with regards to growth factors, 
increased resistance to the attentions of the immune system and abnormal 
angiogenesis.  Such traits are referred to as the ‘hallmarks’ of cancerous cells 
(Hanahan and Weinberg, 2000).    
 
The loss of stringent regulation and acquisition of novel function is a key stage in the 
development of a malignant tumour; the phenomenon known as tumorigenesis.  This 
is an immensely intricate series of events that sees the transformation of a cell to 
attain a malignant phenotype, which has the potential to occur over a very long period 
of time.  The widely held belief is that for a tumour to begin growing, at some point 
healthy cells must be exposed to materials/factors that are able to inflict damage to 
the genomic material within them, referred to as carcinogens.  In the duration of their 
lifetime a person is subjected to countless different carcinogenic influences that are 
provided not only from the external environment but internally as well (Stratton et al., 
2009).  It is thought that DNA could be exposed to as many as 10,000 events per day 
capable of causing damage (Fortini et al., 2003; Sandhu et al., 2010).  Examples of 
these include: 
 
Environmental Carcinogens:  
Humans readily come into contact with huge numbers of factors present in their 
immediate environment that have the ability to modify the physical structure of genes 
and are arguably the most common group of carcinogens encountered by them.  
Carcinogens in this category are diverse, ranging from industrial chemicals through to 
dietary intake.   Cigarette smoke, where chemicals such as benzo[a]pyrene and 4-
(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) have been associated with lung 
carcinoma (Shopland, 1995; Hecht, 1999), is perhaps the best known instance.  
Another well known example, radiation, can have profound effects on the structure of 
DNA, either through prolonged exposure to ultra-violet radiation (Pfeifer et al., 2005) 
or even through the use of therapeutic radiotherapy. 
 
Viral Carcinogens:  
As part of their infection cycle, viruses integrate their genome with that of the host.  
Numerous viruses posses genes that once unified with human genetic material induce 
malignant characteristics (Butel, 2000; Carillo-Infante et al., 2007).  This comes from 
viral proteins being able to modify various aspects of cell behaviour.  Human 
papilloma virus (HPV) infection is the major cause of cervical cancer and can lead to 
the development of head and neck carcinoma (Schiffman et al., 2007; Lajer and von 
Buchwald, 2010).  The E6 and E7 gene products of HPV are able to modify different 
host cell molecules including p53 and retinoblastoma (Rb) along with AP-1 and E2F 
transcription factors.  These interactions immortalise cells and induce proliferation 
through increased cell cycle progression (Antinore et al., 1996; Hwang et al., 2002; 
Malanchi et al., 2002; Malanchi et al., 2004; Schiffman et al., 2007; Ghittoni et al., 
2010).   
 
Similar relationships can be seen with other viruses with tumorigenic properties.  
Epstein Bar virus (EBV) bears the EBNA and LMP gene products, which have been 
implicated in the generation of immortalisation, proliferation by interacting with c-
MYC and affecting signalling pathways.  This virus is thought to be a cause of 
lymphomas including Burkitt’s lymphoma (Young and Murray, 2003; Thompson and 
Kurzrock, 2004).  The TAX protein, generated from the human T lymphotrophic 
virus type-1 (HTLV-1) interacts with NF-B to immortalise cells and with AP-1 
transcription factors and represses the actions of cyclin-dependent kinase (CDK) 
inhibitors including p21CIP1 and p27KIP1 to promote proliferation (Grassmann et al., 
2005; Boxus and Willems, 2009).  The hepatitis C virus (HCV) core protein, 
implicated in hepatocellular carcinoma (HCC) can prevent apoptosis by affecting 
p53, induce cell cycle progression by interacting with Rb and CDK inhibitors and has 
been linked with angiogenesis (Hassan et al., 2009; Tsai and Chung, 2010). 
 
Epigenetic Events:  
Whereas the factors above cause changes to the coding sequence in genes, it is 
possible that chromatin material as a whole can be altered to bring about cancer 
through epigenetic modifications (Feinberg and Vogelstein, 1983; Cui et al., 2002).  
A large proportion of human gene promoter regions contain CpG islands, which may 
be subject to spontaneous demethylation/methylation.  This can lead to the expression 
of genes that promote malignant behaviour or inhibit the action of those that act to 
inhibit transformation respectively, though the mechanisms that cause it still remains 
unclear (Esteller et al., 2001; Ehrlich, 2002; Eden et al., 2006).  During 
embryogenesis, the gene alleles inherited from one parent are inactivated (imprinted) 
to stop their expression.  In tumours, certain genes can lose this repression, called 
‘loss of imprinting’ (LOI), resulting in the over expression of certain genes that may 
lend weight to transformation, as seen with insulin growth factor II (IGF-II) (Murrell, 
2006).  Conversely, it may be that the alleles of other genes needed to maintain cell 
integrity may be randomly lost, causing ‘loss of heterozygosity’ (LOH), reducing the 
activation of that gene.  If the other allele of that gene is lost via deletion or mutated, 
then combined LOH effectively results in the loss of that gene’s expression. This is 
especially evident with BRCA1/2 mutations in breast carcinomas (Palacios et al., 
2008). 
 
If repair mechanisms cannot repair the initial damage to DNA, there is a significant 
risk in the primary cell acquiring yet more modifications.  Cancer is a condition that 
develops over many years and consists of different phases: the so-called ‘multi-stage’ 
course (Vogelstein and Kinzler, 1993; Ito et al., 1995; Duesberg and Li, 2003).  If the 
primary affected cell is not removed from the population by apoptosis, then it will 
continue to proliferate and its daughter cells will retain this initial mutation (Bertram, 
2001).    Cancer is considered to be a clonal disease, as all tumour masses are derived 
from this primary affected cell (Greenman et al., 2007; Stratton et al., 2009).  This 
clone could be derived from a particular stem cell population in a tissue, expanded on 
later.  Over a prolonged period of time, these cells will acquire increasing number of 
mutations and other modifications.  This is highlighted in Figure 1.1.  If modification 
occurs in a significant genetic region, then over time the transformed cell accumulates 
mutations and other subtle modifications that contribute to the development of a 
malignant cell (Futreal et al., 2001). 
 
Until recently the number of mutations required for cells to be classified as truly 
malignant was unknown.    Recent studies involving the use of Next Generation 
Sequencing (NGS) analysis, allowing the interrogation of the entire genome of cancer 
cells in relatively short periods of time, have started to shed light on this question.  It 
has been proposed that a specific malignancy may involve anything from 1000 to 
100,000 mutations depending on the individual and tumour type (Stratton et al., 
2009).  NGS has been employed alongside other technology to discern that specific 
mutational number required for tumour transformation in lung cancer and melanoma 
is 29,910 and 32,325, respectively (Pleasance et al., 2010a; Pleasance et al., 2010b).  
This work has highlighted how extensive genetic damage needs to be for a cell to be 
fully transformed and further emphasises the complexity of the disease. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.1: Basic overview of events involved in the formation of a malignant cell, charting 
progress from initial genetic change to acquirement of full malignant phenotype.  The 
increasing number of mutation that occur during progression are highlighted, as are steps 
involved to promote or prevent malignant development.  Adapted from Betram, 2001. 
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1.2 The Genetic Origins of Tumours 
 
1.2.1 Concepts of Cancer Genomics 
As previously alluded to, initiation of tumorigenesis is brought about genetic and 
epigenetic changes to genomic material.  This can come in the form of somatic 
mutation induced by carcinogens or by the inheritance of germline mutations 
transmitted vertically from parent to offspring.  It is a widely held belief that in the 
majority of instances, a cell can withstand certain levels of damage to its genome 
thanks to the existence of various safeguards such as damage checkpoints, DNA 
repair systems and the presence of tumour suppressor genes.  Carcinogenic exposure 
has several different ways of potentially harming genes, whether it is through 
physical mutation or structural modifications to chromosomes.  These range from 
point mutations (RAS, p53) affecting individual or very small number of nucleotides, 
or chromosomal alterations including translocations (BCR-ABL, PML-RAR), 
inversions, or amplification (MYC) that disrupt larger genomic regions (Futreal et al., 
2004; Weir et al., 2004; Stratton et al., 2009).   
 
There is an array of different proofreading and repair mechanisms within cells.  These 
include homologous recombination (HR), a slower but very precise process that 
swaps damaged/incorrect bases for what is required (Whyman et al., 2004). However, 
in some instances the existence of these safeguards is still not sufficient to inhibit 
tumorigenesis, as shown by base excision repair (BER), which is prone to error and 
can actually create more chance of mutation (Fortini et al., 2003).  The transition of a 
cell from healthy to malignant state is essentially dependant on the corruption of 
genes that can allow the development of cancerous hallmarks in addition to the 
inactivation of those genes whose products act to inhibit transformation: the proto-
oncogenes and tumour suppressor genes respectively.  
 
1.2.2 Proto-oncogenes and Impact of Their Activation 
 
The very earliest studies into cancer genetics involved the examination of those 
viruses that can induce tumour formation as result of their infection of cells (Der, 
1987).  Over time, beginning with the discovery of the H-RAS and K-RAS genes 
(Der et al., 1982), it was found that humans bear genetic regions homologous to those 
viral genes capable of cancer initiation, the human homologues being collectively 
termed proto-oncogenes.  They are normal genes that are expressed to a normal level 
in healthy cells, their functions predominantly centred on cell signalling pathways 
involving proliferation, cell cycle progression, response to growth factors and 
angiogenesis.  However, as a result of carcinogenic exposure, they become altered to 
form oncogenes, whereby their normal function is disrupted and utilised to induce 
tumorigenesis (Polsky and Cordon-Cardo, 2003).  They are one of the most prevalent 
and influential groups of genes in cancer, not least due to their activation resulting in 
a significantly raised chance of tumorigenesis taking place (Der, 1987).  Conversion 
of a proto-oncogene to its oncogenic state results in a ‘gain of function’ characteristic 
whereby their biological function, which is stringently controlled in a healthy 
environment, is allowed unrestrained activity, thus promoting malignant 
transformation (Hirota et al., 1998; Hirota et al., 2003).     
 
Activation of oncogenes comes about through alterations to the regions of genetic 
code in which they reside.  This can be through point mutations, affecting the protein 
product of the gene, increasing its activation level as in the case of B-RAF or JAK 
(Hingorani et al., 2003; Percy and McMullin, 2005; Kaushansky, 2007; Kilpivaara 
and Levine, 2008; Nucera et al., 2009), increasing its half-life or increasing its 
resistance to degradation species or inactivation, exemplified by RAS (Downward, 
2003; Omerovic et al., 2007).  It may also involve the physical modification of 
chromosomal regions that contain these genes, removing inhibitory regions via 
deletion thereby increasing gene expression, or transporting genes from one 
chromosomal region to another by way of translocation or inversion to situate a 
oncogene next to a highly active promoter, leading to near-constant transcription and 
translation of that gene (Polsky and Cordon-Cardo, 2003).  This can be seen with the 
formation of the BCR-ABL and PML-RAR fusion genes central to chronic myeloid 
leukaemia (CML) and acute promyelocytic leukaemia (APML) respectively 
(Pandolfi, 2001; Hehlmann et al., 2007).   
 
Since proto-oncogenes are actively involved in processes that increase cell 
populations, their mutation/conversion to an oncogenic form is considered to be an 
almost forceful step in the development of malignancy in cells.  In this sense, such 
mutations can be referred to as ‘driver’ mutations as such alterations compel 
transformation towards malignancy (Greenman et al., 2007; Stratton et al., 2009).  
Deregulation of pro-growth molecules provides a transformed cell with the necessary 
ability to uncontrollably proliferate, produce its own growth factors and potentially 
synthesise new vascular bundles.  In this manner, it is possible for a transformed cell 
to achieve neoplastic expansion, however safeguards do still exist in these cells, 
meaning that if tumours are to develop, they must interrupt these in order to realise 
their full potential. 
 
1.2.3 Tumour Suppressor Genes and Consequences of Their Loss 
 
A cell has numerous ways in which it can protect itself from transformation.  One of 
the most powerful is the existence of a group of genes who generate products capable 
of preventing cells that undergo genetic damage from furthering their progression: the 
so-called tumour suppressor genes (TSG).  Whereas proto-oncogenes are involved in 
proliferation and other characteristics that can be used to the advantage of tumours, as 
their name would suggest, TSG function centres on those actions that aims to prevent 
the advance and further transmission of genetic damage (Stanbridge, 1990; Gao and 
Honn, 1995; Krug et al., 2002).  These functions include cell cycle arrest, DNA repair 
and promotion of apoptosis.  Inactivation of TSG is an arguably more significant 
event in tumour cell transformation, since their presence in cells still allows tumour 
development to be curtailed, possibly even in the face of oncogene activation.   
 
TSG are subject to the same genetic modifications as proto-oncogenes, however 
whereas these events act to potentiate the latter, with TSG such events serve to 
restrain their activity, hence leading to a ‘loss of function’ situation (Wang et al., 
2006a).  Point mutations can render the protein product of the gene with shorter half 
life or impair its function, perhaps best shown by p53.  This highly potent TSG acts as 
a transcription factor and can activate or inhibit specific genes in order to halt cell 
cycle progress in order to allow DNA repair or permit apoptosis if damage is too 
great.  At the same time is also the most mutated TSG present in tumours.  Mutations 
to p53 affect the function of its protein product, reducing its potency in preventing 
tumour formation (Farmer et al., 1992, Chen et al., 1993, Miyashita and Reed, 1995, 
Levine and Oren, 2009).  Alternatively, genes can be deleted, such as PTEN and with 
the obvious effect that no protective protein is present to prevent transformation 
(Martelli et al., 2006).  In certain instances, genes that act to inhibit TSG can undergo 
up-regulation, leading to inactivation of their targets, as seen with the hyper-
phosphorylation of Rb, promoting a pro-tumorigenic situation (Weinberg, 1995). 
 
The initial theory into TSG inactivation in tumours stated that both alleles of the gene 
had to be affected, Knudson’s proposed ‘two-hit hypothesis’ (Knudson, 1971).  For 
example, germline mutations in genes can be inherited from parents, which primarily 
affects one of the alleles.  If the second allele is affected by mutation, deletion or 
another modification, then the expression of that gene is lost.  This is found with loss 
of BRCA expression in both breast and ovarian carcinomas (Payne and Kemp, 2005).  
While this premise is still thought to be true for a large number of TSG, there is 
increasing collections of work that indicate that for certain members of this group, 
inactivation of a single allele is sufficient to inhibit the action of the gene.  Examples 
of these included NF-1 and ATM (Krug et al., 2002; Payne and Kemp, 2005).     
 
1.3 Tumour Progression  
 
1.3.1 Angiogenesis 
 
Like healthy tissues, tumours require a vascular system in order to be provided with 
oxygen and nutrients that will allow them to survive while having waste products 
removed (Makrilla et al., 2009).  It is generally considered such a system needs to be 
established once a tumour reaches a size of approximately 1-2mm3 in order for it to 
survive and expand (Keyhani et al., 2001; Liekens et al., 2001).  Angiogenesis is also 
found in haematological tumours, with strong evidence in multiple myeloma (MM) 
(Keyani et al., 2001).  The generation and maintenance of new vascular bundles 
comes from a complex series of relationships involving various molecules that are 
exploited to bring about this situation (Nassenbaum and Herman, 2010).  Evidence of 
angiogenic proteins in patients has been linked to poor disease prognosis due to 
increased risk of tumour spread (Makrilla et al., 2009).  Angiogenesis is closely 
associated with metastasis.  This stands to reason, since formation of new vessels 
eases the dissemination of tumour cells to other regions of the body.  However, some 
of the proteins involved in metastasis also play a role in neo-vascular formation 
(Ahmad and Hart, 1997).   
 
The formation of new vessels is stimulated through hypoxic conditions, thus 
increased demand of oxygen by tissues.  In their infancy, tumours are examples of 
such environments.  However, angiogenesis comes from a fine balance between 
signals promoting or inhibiting the process.  Therefore, there must be disruption of 
this balance to synthesise a novel vascular system.  Vascular endothelial growth 
factor (VEGF), for example can be up-regulated by hypoxia-inducible factor 1 (HIF-
1), a molecule generated in response to oxygen deprivation in tissues (Shweiki et al., 
1992; Otrock et al., 2009; Nussenbaum and Herman, 2010).  So here, a normal 
molecular interaction is replicated in tumour tissue in order to continue malignant 
development.  Aside from this, VEGF mRNA can be up-regulated by growth factors 
including fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) 
and other cytokines such as transforming growth factor- (TGF-) (Enholm et al., 
1997; Nussenbaum and Herman, 2010).  Additionally, signalling molecules such as 
RAS and AKT can increase VEGF expression (Kerbel et al., 1998; Okada et al., 
1998).  This means that aberrant signalling, either cytokine-induced or through the 
action of oncogenes can also drive new vessel formation.   
 
The importance of VEGF is also highlighted by its relationship with molecules 
implicated in metastasis.  VEGF helps to up-regulate matrix metalloproteinases 
(MMP), which acts to dissolve the extracellular matrix (ECM) (Leikens et al., 2001; 
Nussenbaum and Herman, 2010).  Destruction of ECM causes the release of VEGF-
A, which is normally bound to the matrix, promoting neo-vascularisation (Bergers et 
al., 2000; Nussenbaum and Herman, 2010).  This not only demonstrates the closeness 
of angiogenesis and metastasis, but also the necessity for a tumour to create a 
relationship with its surrounding environment in order to progress. 
 
Though vessel formation is important, it is vital for a tumour to be able to mature and 
maintain them.  This is mediated by the angiopoietins and their receptors, known as 
Tie (Klagsbrun and Moses, 1999; Karemysheva, 2008; Nassenbaum and Herman, 
2010).  These too are up-regulated in response to hypoxia and are found to have 
distorted expression in tumours (Bach et al., 2007; Shim et al., 2007).  In this manner, 
it is possible for cancerous lesion to not only initiate the formation of new blood 
vessels, but to also sustain their presence. 
 
Due to its importance in cancer progression, angiogenesis has been the subject of 
focus for therapy that could potentially be used to inhibit its actions.  Various 
inhibitors have been designed to act against those molecules involved in different 
stages of the process.  These include Batimastat, which target most MMP members, 
whereas VEGF and FGF therapies have been used to limit the action of these proteins 
(Sledge Jr. et al., 1995; Goldman et al., 1998; Liekens et al., 2001).  Some of these 
have demonstrated promise and have reached the clinic, though so far they have had 
very limited effect and clinical trials with Batimastat has been halted as a result of its 
insolubility (Liekens et al., 2001).  The major implication of treatments against 
angiogenesis is that a large proportion of its effectors are in fact vital and are still 
required to perform their actions in regions of the body unaffected by malignancy.  
This makes this type of therapy very difficult to implement and as such, it means that 
tumour progression still remains difficult to halt.  
 
1.3.2 Immune Escape 
 
The human body contains a highly sophisticated system that is utilised to defend itself 
against pathological harm.  This system is a collection of many different cells, 
proteins and other factors that function alongside each other to stop the actions of 
foreign pathogens and the effects of other influences that may threaten its survival.  In 
its broadest sense, immunity is driven by two very different aspects that function in 
different ways.  One aspect is innate immunity, a broad spectrum form of protection 
involving cells such as neutrophils and macrophages that destroy cells via physical 
ingestion (Phagocytosis) (Chaplin, 2003).  This form of immunity also includes a 
subset of lymphocytes without typical lymphocytic receptors known as natural killer 
(NK) cells that are highly efficient at targeting both virally and malignantly 
transformed cells (Cooper et al., 2001; Moretta et al., 2002; Chaplin, 2003; Zamai et 
al., 2007).  Whereas other lymphocytic cells interact with MHC, NK cells specifically 
target cells that lack MHC expression (Chávez-Galán et al., 2009).  These cells are 
assisted by the complement group of serine proteases that act to lyse the membranes 
of target cells (Frank and Fries, 1991; Chaplin, 2003). 
 
The other aspect of the immunity is the more precise adaptive immunity concerning 
the role of the receptor-bearing lymphocytes of which there are two basic forms; B (B 
cells) and T (T cells), which perform humoral/immunoglobulin (Ig) and cellular-
based killing, respectively (Alam and Gorska, 2003).  For this to take place, the 
receptors found on the surface of these cells interact with immunogenic molecules 
presented to them referred to as antigen.  More specifically, they react with peptide 
sequence derived from proteins that can vary in their level of immunogenicity.   
 
In the case of B cells, their receptor is surface bound IgM antibody that can recognise 
vast numbers of different antigens.  Upon detection, these cells undergo maturation 
and clonal proliferation of the cells to their mature form (Plasma cells), which secrete 
specific Ig molecule to coat target cells.  Conversely, T cells possess a T cell receptor 
(TCR) complex that recognises peptides offered to them when bound to major 
histocompatibility complex (MHC) of cells (Hennecke and Wiley, 2001; Alam and 
Gorska, 2003).  MHC molecules are broadly found in two forms.  The first, class I, is 
possessed by all cells excluding erythrocytes and presents endogenously processed 
antigens.  These interact with CD8+ T cells that activate a cytotoxic T cell (CTL) 
reaction, which induce apoptosis via the action of the enzyme granzyme (Chávez-
Galán et al., 2009).  The other form of MHC molecules, class II, present exogenous 
antigen peptides captured and processed by antigen presenting cells (APC).  These 
antigens are recognised by CD4+ T cells that initiate a ‘helper’ (Th) response, which 
directs immunity in specific ways.  MHC class II is only found on this specific group 
of cells, including macrophages, B cells and most potently, dendritic cells (DC) 
(Hennecke and Wiley, 2001; Assundani et al., 2007).   
 
Both the innate and adaptive arms overlap to maximise the efficiency of the immune 
response.  This is evident from Ig secretion by plasma cells binding to transformed 
cells, instigating opsonisation.  Opsonisation attracts innate cells such as neutrophils 
and macrophages and activate mediators like complement proteins to bring about 
complement-mediated cell destruction.  NK cells traffic to Ig-bound cells, where they 
can use the antibody to initiate apoptosis by antibody-dependent cytotoxicity (ADCC) 
or by recruiting complement to kill targets by means of complement-mediated 
cytotoxicity (CMC) (Chaplin, 2003). 
 
The immune system is highly efficient at protecting the body from damage, both 
foreign and endogenous.  As it is possible that cells are able to counteract 
transformation through TSG and so forth, it is entirely feasible that during their life, a 
person’s immune system eliminates transformed cells, preventing cancer from 
occurring.  Knowing such information, one can therefore draw the conclusion that at 
some point, there must be a lapse in immune surveillance that allows malignancy to 
take place.  Evidence collected over many years of research alludes to the fact that 
tumours are very capable of avoiding detection by immune cells and even able to 
destroy any cells that may recognise them (Whiteside, 2003).   
 
Cancerous cells have been shown to have significantly lower expression levels of 
MHC molecules meaning that they do not present antigenic peptides to T cells.  This 
effectively renders them ‘invisible’ to the immune system (Hicklin et al., 1999).  
Evidence from genomic studies into invasive glioma indicates that this may be due to 
the direct down-regulation of the genes encoding MHC proteins (Zagzag et al., 2005).  
Alternatively, decreased MHC expression could be due to mutations and 
abnormalities in proteins that are involved in antigen presentation, for example beta-
2-microglobulin (2M) or transport-associated protein (TAP) (Chang et al., 2006; 
Ferris et al., 2006; Setiadi et al., 2007).  To compound this, other work has indicated 
that the majority of peptides that are presented by tumour cells are not sufficiently 
immunogenic to generate a substantial reaction from immune cells.  Additionally 
these cells down-regulate the expression of co-stimulatory molecules such as B7.1 
and B7.2 that act as the ‘second signal’ required for T cell activation.  Without this 
essential communication, T cells enter a state of anergy and are unable to target cells, 
meaning that tumour cells can survive (Macián et al., 2004).    
 
The affinity and avidity of T cells to the presented antigen is an important aspect of 
immunity.  Affinity refers to the extent of interaction between the TCR to the 
MHC/peptide complex, while avidity is a term used to explain the potency of 
interaction occurring between a T cell and the antigen (McKee et al., 2005).  Both are 
vital for the optimal priming of T cells, but the concept is highly complex.  It has 
been proposed T cells with high affinity for certain MHC/peptide complexes lead to 
increased T cell avidity.  However this is countered by work stating affinity of T cells 
is not related to their reactions against an antigen (Derby et al, 2001; Dutoit et al., 
2001; Dutoit et al., 2002; Kerry et al., 2003; McKee et al., 2005).  Studies have 
indicated T cell clones with identical TCR have varying avidity to antigen presented 
by APC (Cawthon et al., 2001).  This is made more complicated by evidence 
implying T cells with low avidity having strong MHC/peptide complex affinity and 
vice versa (McKee et al., 2005).  In terms of tumour immunology, the belief is that 
high avidity T cells are required to eliminate malignant cells.  Complications 
surrounding avidity comes from the concentration of antigen needed to generate a 
high avidity T cell clone.  For example it has been shown priming with high doses of 
antigen results in formation of low avidity T cells.  It can also lead to the death of the 
cells through over-exposure.  Conversely, T cells primed with lower doses of antigen 
leads to the formation of a high avidity clone (Alexander-Miller et al., 1996a; 
Alexander-Miller et al., 1996b).  This makes the production of CTL with high avidity 
for tumour antigen very complicated, especially if one considers the issues 
concerning malignant cells issues with antigenic peptides and MHC down-regulation. 
 
Conversely, a cancer cell may significantly up-regulate expression of surface 
molecules such as FAS-ligand (FAS-L/APO-1-L/CD178) to bring about a 
‘counterattack’ against immune cells.  When ligated to its respective surface antigen 
FAS (CD95), FAS-L initiates pro-apoptotic signalling within the FAS-expressing 
cell, thus killing it (Nagata and Golstein, 1995; Minas et al., 2007).  Since T cells 
express FAS as a safeguard to ensure they can be destroyed in order to avoid potential 
auto-immune reactions, tumours can exploit this to create immune tolerance (Daniel 
et al., 1994; Alderson et al., 1995; Griffith et al., 1996; Bennett et al., 1998).  In this 
manner, as with all systems affected by cancer, there is a manipulation of installed 
failsafe mechanisms that a tumour uses to its advantage. 
 
Cytokines play a vital role in immune reactions, both in their initiation and inhibition.  
Certain ones such as interleukin 2 and 12 (IL-2/12) have been linked with very strong 
immunity against cancer cells thanks to their actions in promoting the activity of CTL 
(Borish and Steinke, 2003). Certain sites in the body such as the brain and heart are 
considered immune-privileged due to their importance in the body.  To maintain this 
status, amongst other practices including FAS-L expression (Francavilla et al., 2000), 
immune-suppressive cytokines are secreted to reduce the activity of immune cells in 
these regions.  Tumours have been shown to secrete high levels of specific cytokines, 
for example transforming growth factor  (TGF-), IL-4 and IL-17 amongst others.  
Paradoxically, in the initial stages of tumorigenesis, these cytokines were found to 
promote anti-tumour responses, however after prolonged periods; they can aid the 
cancerous cells in their progression (Li et al., 2009a; Murugaiyan and Saha, 2009; 
Nagaraj and Datta, 2010).  This again may link to acute-versus-chronic events that 
seem so pivotal in malignant transformation. Through the control of these proteins, a 
tumour aims to create an immuno-privileged environment.  Another cytokine, IL-10, 
plays an important role in regulating adaptive immunity.  It expressed by both CTL 
and Th cells as well as innate cells such DC, which act as APC for T cells, as part of a 
negative feedback system.   Therefore, IL-10 acts to repress the immune system to 
help prevent inflammation and possible auto-immunity (Saraiva and O’Garra, 2010).  
It is possible if this is cytokine could be secreted by tumour cells, it could help 
prevent action by a large proportion of the adaptive immune response. 
 
Perhaps one of the more sinister aspects of cancer comes from indications that the 
immune system can contribute to tumour initiation and progression.  This is evident 
from the role of regulatory T cells (TReg), a specific subset of T lymphocyte that act as 
inhibitors of adaptive immunity (Groux, 2001; Ichihara et al., 2003; Sakaguchi et al., 
2010).  These exist naturally in the T cell pool or can be induced by the action of 
certain situations in the body (Sakaguchi et al., 2009; Sakaguchi et al., 2010).  Their 
ability to inhibit immunity can be from direct contact, using granzyme or FAS-L to 
kill T cells (Grossman et al., 2004; Strauss et al., 2009; Sakaguchi et al., 2010).  TReg 
can also inhibit immunity by employing various cytokines, including the 
aforementioned IL-10 (Roncarolo et al., 2006; Belkaid, 2007; Sakaguchi et al., 2010).     
There is strong belief that during immune reactions, the homeostatic action of TReg 
may act to allow tumours to form unnoticed.  It is also possible that tumours may be 
able to use cytokines such as TGF- and IL-17 to induce their presence, thereby 
inhibiting any potential anti-tumour immunity (Chen and Wahl, 2003; Chen et al., 
2003; Beriou et al., 2009; Murugaiyan and Saha, 2009).  
 The above issues exemplify not only the extent to which the immune system must be 
able to monitor and react to its environment, the principle of immuno-surveillance, 
but also how a tumour is able to interact with and possibly alter immune reaction; so-
called immuno-editing (Dunn et al., 2002; Dunn et al., 2004).  This is highlighted in 
Figure 1.2.  In spite of the array of mechanisms malignant cells might use to avoid 
elimination by the immune system, it is entirely possible they can be targeted and 
removed by immune effectors.  However, at the same time there is the possibility of 
immuno-sculpting taking place (Dunn et al., 2002; Dunn et al., 2004; Reiman et al., 
2007).  The premise behind this concept is the possibility that certain tumour cells are 
indeed recognised and eliminated by CTL.  However, it is thought more aggressive 
malignant cells existing within the tumour have the benefit of remaining unnoticed by 
immune cells and thus avoid deletion.  This produces a problem whereby the body is 
able to rid itself of a certain degree of tumour mass, however it leaves behind a group 
of cells with a relatively more aggressive phenotype.  Therefore as such immune 
reactions against a tumour could essentially cause an increase its aggressiveness.  If 
this takes place, malignant cells can subsequently utilise escape mechanisms to avoid 
immune reactions, maintain the integrity of the tumour and progress from there 
(Dunn et al., 2002; Dunn et al., 2004).   
 
The action of inflammation and phagocytic cells can involve the use of reactive 
oxygen species (ROS) such as hydrogen peroxide (H2O2), NAPDH oxidase and 
superoxide anion (O2-) can induce genetic changes.  Production of these may not only 
be induced by physiological conditions like those mentioned above, they can be 
generated through the action of certain genes such as RAS (Heyworth et al., 1993; 
Komatsu et al., 2008; Pan et al., 2009).  The action of ROS can lead to changes in the 
genetic structure of genes, and may contribute towards mutations in p53 (Pan et al., 
2009), which is a significant inaction of the normal function of this TSG. 
   
Ultimately, once a tumour gains the ability to avoid attention of the immune system, 
there is no host defence against its progression, hence why patients demonstrating 
such mechanisms may have poorer prognosis (Wang et al., 2006b).  This renders the 
tumour with the opportunity to invade, metastasise and further its influence in other 
regions of the body. 
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Figure 1.2: Overview of the principles of immuno-editing in tumours.  Following changes to genetic 
material, and formation of cell transformation various immune phenomena can occur.  The combined 
efforts of the innate and adaptive arms of the immune response can eliminate transformed cells, 
returning tissue to a healthy state (A).  However, it could be a balance is established (B), with acute 
immune reactions inducing tumour clearance or the formation of immuno-sculpting where immune 
cells only eliminate the least aggressive cells and promote generation of more severe phenotype.  This 
could lead to the formation of immune-escape mechanisms, which allow a tumour to avoid 
elimination, possibly compounded by the actions of TReg cells.  It is also possible for the latter to take 
place during their transformation (C).  Adapted from Dunn et al., 2004.    
1.3.3 Metastasis 
 
Dissemination of tumour cells from the site of origin to other distant sites in the body, 
referred to as metastasis, is the turning point in cancer progression and is the reason 
why the majority of patients succumb to their disease (Meyer and Hart, 1998; Geiger 
and Peeper, 2009).  Until this point, tumours are confined to one distinct region that if 
eligible can be removed or treatment can be concentrated to that area.  Following 
invasion of surrounding tissues, cancerous cells can enter blood or lymphatic vessel 
to travel to other bodily regions.  If they can establish themselves in these locations, 
then secondary tumours may begin to form, making it difficult to not only locate 
them, but remove them.   
 
In order to carry out this invasion, cancerous cells are able to initially down-regulate 
adherent proteins such as the cadherins and cytokeratins (Geiger and Peeper, 2009) 
allowing them to detach from the main mass.  The action of matrix metalloproteinases 
(MMP), thought to play a key role in invasion (Westermarck and Kähäri, 1999), 
subsequently permits dissolution of the basement membrane (BM) and entry into the 
ECM (Shapiro, 1998).  Certain members of this group are heavily linked with 
malignant invasion.  MMP-2 and 9 (Gelatinase A and B) are highly expressed in 
different cancers, undergoing up-regulation to promote metastasis (Ahmad and Hart, 
1997; Basset et al., 1997; Johnsen et al., 1998; Westermarck and Kähäri, 1999; 
Hoffman et al., 2005).  It has been shown certain MMP can associate with one 
another to perform their action, as demonstrated by MMP-2 binding to MT1-
MMP/MMP-14, which is found on the surface of malignant cells (Sato et al., 1994; 
Ahmad and Hart, 1997; Gilles et al., 1997; Hoffman et al., 2005).  MMP are naturally 
inhibited by the tissue inhibitor of metalloproteinases (TIMP) family of proteins 
(Woessner Jr., 1991).  These can undergo down-regulation during malignancy, 
thereby promoting MMP activity in both angiogenesis and invasion (Ahmad and 
Hart, 1997).  However, an interesting point is that when still present, TIMP can 
inhibit invasion even following increased MMP expression, therefore emphasising 
how the balance of signals can influence this process (Ahmad and Hart, 1997).  
 
Migration is encouraged through the up-regulation of proteins such as focal adhesion 
kinase (FAK) and this promotes invasion into surrounding areas.  In the case of FAK, 
this is due to its involvement with the organisation of adhesion molecules in cell 
migration and interaction with proteins such as p130Cas that can promote invasive 
phenotype (Cary et al., 1998; Tilghman et al., 2005; van Nimwegen and van der 
Water, 2007).  Should malignant cells be able to reach blood or lymphatic vessels, 
then they have the potential to migrate to much more distant locations in the body.  In 
order to generate new tumour lesions in these new areas, the cells must   then re-
expresses adhesion molecules to establish a new mass formation, again exploiting 
FAK and other adhesion molecules to bring this about (van Nimwegen and van der 
Water, 2007).   
 
Though it represents the greatest danger to patient welfare, paradoxically it appears 
that metastasis is actually a very inefficient process.  Studies in mice have shown that, 
of the cells that manage to disseminate from the original tumour mass, only a very 
small minority of these seem capable of settling in a new location (Luzzi et al., 1998).  
Additionally, cells that do graft in new regions seem to display dormancy.  It has been 
suggested that this depends heavily on the capacity of single metastatic cells to 
proliferate and create secondary masses (Luzzi et al., 1998).  However, one should 
note that this dormancy could reflect the possible situation in humans where cells 
may well invade surrounding tissues and organs but remain idle for long periods of 
time before beginning to proliferate, potentially awaiting the correct influence by 
signals. 
 
Further to this, the use of multiphoton microscopy on mice injected with tumour cells 
is beginning to generate a better understanding of how metastasis takes place within 
an in vivo system (Alexander et al., 2008; Friedl, 2009).  Some emerging evidence 
has indicated cells on the periphery of the tumour may be carrying out invasive 
migration (Friedl et al., NCRI Conference, 2009).  This concept differs from the 
traditional view of cells in the core of tumours being more likely to metastasise due to 
them being considered more aggressive.  This change of view as to a process central 
to tumour progression forces one to reassess the biological properties of cancerous 
cells.  It begs the question as to what specific malignant cells are capable of satisfying 
the criteria for displaying the most aggressive phenotype.   
 
 
1.4 The Cancer Stem Cell Theory 
 
For a long period of time, the dogma central to the origins of cancer stated that 
tumours emanate from a single cell that is subject to genomic damage wrought by 
carcinogens and that all cells in the body have an even chance of being affected by 
this insult.  It has been known for many years that certain tumours, for example CML 
and acute myeloid leukaemia (AML), are caused by mutations that take place in stem 
cells.  Studies into leukaemias proposed that a specific subset of pluripotent stem cells 
present in the bone marrow were responsible for this group of tumours, labelled 
‘leukaemia stem cells’ (LSC) (Warner et al., 2004; Bonnet, 2005; Abdel-Wahab and 
Levine, 2010).  Bonnet and Dick (1997) then showed that such cells injected into 
non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice were 
capable of causing leukaemia, but not more mature, differentiated white cells.  This 
data formed the basis of their argument that all tumours, solid and fluid, were derived 
from stem cells present in their tissues of origin.  This has now been christened the 
‘cancer stem cell theory’. 
 
The cancer stem cell (CSC) theory counters the traditional tumour basis model in that 
it states that specific cells (i.e. CSC) are present in tissues throughout a person’s 
lifetime.  In a similar fashion to how healthy cells are all derived from stem cells, the 
belief in that tumour cells originate from CSC (Ailles and Weissman, 2007; Bjerkvig 
et al., 2009). They are suggested to posses all the characteristics of healthy stem cells 
such as self-renewal and the ability to differentiate into any cell type.  At some point, 
certain triggers will stimulate these cells and from them, malignant cells are derived 
to form tumours.  These daughter cells then themselves proliferate to continue tumour 
expansion, presumably acquiring further mutations as they do so.  Studies have 
shown that in many instances, it has been possible to isolate CSC from a variety of 
different tumour types including breast, prostate and head and neck carcinoma (Al-
Hajj et al., 2003; Ponti et al., 2006; Signoretti and Loda; 2006; Prince et al., 2007).  
Though it is possible to recognise them, as yet it is unknown if these cells are mutated 
forms of normal stem cells or another variation of them (Huang et al., 2007).  Work is 
now in progress to investigate these cells as fully as possible.  Not only is there the 
potential to finally understand the possible root causes of tumours, there is massive 
therapeutic implications to cancer patients (Shipitsin and Polyak, 2008).   
 The CSC theory is highly credible and entirely possible for most cancer types.  It is 
believed that they are the aggressive cells present in poor prognosis cases.  This is 
feasible as stem cells are more resistant to drug treatments as well as apoptosis (Ailles 
and Weissman, 2007).  The expression of telomerase, a protein that maintains 
chromatid length following cell division is expressed by all stem cells (Shay and 
Wright, 2010), and accounts for the ‘immortal’ nature of aggressive tumour cells.  
Likewise, being able to ‘self renew’ following division necessitates them being 
continuously present in tumour tissue.  The theory also means that certain cancers, for 
example teratocarcinomas, may harbour cells with the potential to differentiate into 
any cell type and would go a significant way to explain this tumour (Andrews, 2002; 
Chambers and Smith, 2004).  Additionally, lack of MHC expression by stem cells 
would explain the ability of tumours cells to escape the immune system (Shufaro and 
Reubinoff, 2004).  Indeed, this has been shown on suspected CSC isolated from 
patients suffering from glioblastoma (Di Tomaso et al., 2010). 
 
In spite of this, there are certain aspects of this theory that can be challenged.  It states 
that all initiators only affect CSC to bring about all forms of cancer.  However, it is 
very notable that this theory cannot explain the aetiology of those tumours induced by 
viruses.  Specifically, it cannot argue a case as to why viruses should only enter CSC.  
For example, EBV enters B cells to cause lymphoma by binding to CD21 (Young and 
Murray, 2003; Thompson and Kurzrock, 2004).  This marker is only expressed by 
these cells at the early-B cell stage of differentiation, long after the primitive stages of 
a cell’s development.  An obvious counter argument is maybe CSC may aberrantly 
express cell surface markers.  The theory also states that CSC must exist due to their 
ability to self-renew, effectively making them immortal and a hallmark of cancer 
cells.  This, as previously mentioned is due to the action of telomerase.  However, it 
has been shown that telomerase is frequently mutated in cancer cells (Deng and 
Chang, 2007), thus permitting them immortality, therefore bringing the existence of 
CSC into question.  Moreover, the notion of CSC means that there are cells present 
that already have multiple mutations/abnormalities in genes such as RAS, p53, and 
PTEN amongst others, yet are able to somehow keep very strong pro-proliferative 
signals in check until a specific trigger is encountered (Bjerkvig et al., 2009).   
 
Ultimately, controversy alongside argument and counter-argument in this field has 
led to a divergence in the CSC theory.  It is now stated that cells develop stem cell-
like abilities during the course of their transformation and progression (Passegué et 
al., 2003; Bjerkvig et al., 2009).  In many ways, this acts to marry the more 
traditional beliefs with the more modern way of interpreting cancer biology.  While 
many parts of the theory are still very unclear, work continues and is shedding light 
on many aspects of the disease. 
 
1.5 Cancer Therapeutic Strategies  
 
That cancer remains a public health concern is testament to the notion that for the 
most part, it continues to exist as a disease that cannot be prevented.  In response, 
concentration has been placed on therapeutic protocols in order to combat tumours.  
Due to this focus, massive advancement has been made in all aspects of cancer 
treatment, from detection to palliative care.  In combination with research using 
genomic, proteomic and immunological techniques, this has gone further to the point 
where the first prophylactic vaccines are now in use and the prospect of personalised 
therapeutic regimens is a possibility.  However, while all treatments currently in use 
have many advantages, a number of drawbacks exist with each regimen and if one is 
to use these therapies effectively, one must fully understand and respect these 
disadvantages.   
 
1.5.1 Surgery 
 
Of all the treatments used to combat cancer, surgery remains the preferential first line 
option and is the one that arguably poses least risk to a patient’s wellbeing.  If a 
tumour is accessible and still present in its place of origin, then the best option is to 
remove it using surgical intervention.  In this manner, the removal of malignant tissue 
en masse prevents prolonged treatment, meaning a reduction in the time taken from 
diagnosis to remission (Tsim et al., 2010).  If different surgical techniques can be 
used for a specific malignancy, then algorithms are employed to determine which 
procedure would best suit a specific patient (Tsim et al., 2010).  The same principle is 
used to consider if a patient is suitable for surgery in the first instance.   
 
Like all cancer therapies, there are complications to surgery.  In certain 
circumstances, for example the nature of the organ where the tumour resides, a large 
number of considerations must be made to ensure surgery is successful as possible 
but not cause harm to the patient.  This is found with colorectal carcinoma (Yoshida 
et al., 2010).  Additionally, post-operative complications including haemorrhage can 
occur, which can be life-threatening and must therefore be taken into account 
(Yoshida et al., 2010).  Furthermore, it is possible not all of a tumour is removed by 
surgery (Tsim et al., 2010), leading to relapse. 
 
Additionally, surgery has limitations in so much that in following healthcare 
guidelines for surgery, it is possible that patients with less aggressive tumours that 
could be treated topically, undergo removal of bodily areas which is entirely 
unnecessary, a practice referred to as ‘over-diagnosis’.  This has been seen in breast 
cancer, where women have undergone mastectomy since they satisfy surgical criteria, 
only to find that it was not needed.  This can be highly traumatic to the patients 
concerned.  A similar situation is seen with prostate cancer patients.  Ultimately, a 
balance is required to further investigate a person’s malignancy to fully assess if 
surgery is the true option for them (Etzioni et al., 2002; Draisma et al., 2003; Day, 
2005: Moss, 2005). 
 
1.5.2 Radiotherapy 
 
The use of radiation to combat tumours is one of the oldest forms of cancer therapy.  
It involves the administration of radiation to a patient in a variety of potential ways.  
In certain instances radioactive isotopes have been conjugated to antibodies to 
maximise the efficacy of therapy (Juweid, 2002).  Radiotherapy works due to 
knowledge that upon exposure to radiation, DNA undergoes fragmentation and is 
severely damaged thereby resulting in apoptosis of the affected cell.  The hope is that 
by exposing tumour tissues to this environment, the resulting DNA damage will lead 
to their destruction.  This is further supported in the knowledge that radiation damage 
preferentially affects rapidly dividing cells of which tumour cells are a good example 
of. 
 
Radiotherapy remains a heavily utilised form of cancer therapy and is front-line 
treatment for certain malignancies for example head and neck carcinomas, where it 
has demonstrated a high success rate (Mittal et al., 1983; Bailet et al., 1992; 
Ikushima, 2010).  Furthermore, it is used as part of standard therapy regimen for non-
small lung cell carcinoma, oesophageal, cervical and prostate carcinomas along with 
lymphoma (Ikushima, 2010; Katz et al., 2010; Nakano et al., 2010).  
 
The majority of radiotherapy is performed by external beam technology, employing a 
focused beam of radiation that is fired from an external source into the area where the 
tumour resides (Nakano et al., 2005; Nakano et al., 2010).  Initially, this principle 
relied on the use of X-rays and CT scans to ‘guide’ a clinician on the location of the 
tumour and where to direct the beam of radiation.  There are obvious drawbacks with 
this such as missing the tumour entirely, so radiotherapy has undergone rapid 
sophistication and is now a very precise practice.  Currently used methods include 
stereotactic irradiation, which uses multiple beams that can attack tumour masses 
from various angles and image-modulated radiation therapy (IMRT) (Ikushima, 
2010).  These advancements themselves have evolved to overcome shortfalls, evident 
from the use of the highly sophisticated Cyberknife® system (Gibbs, 2006, Coppa et 
al., 2009; Vahdat et al., 2010) and development of image-guided radiation therapy 
(IGRT) (Ikushima, 2010).   
   
Like chemotherapy, detailed below, the reasons why radiotherapy is so successful are 
also the reasons why it has so many disadvantages.  While radiation can be focused 
onto a particular region or group of cells, especially with the assistance of advanced 
tumour imaging, in essence there is still a risk of radio beams affecting healthy 
tissues.  Perhaps the most sinister aspect of radiotherapy comes from the notion that 
while it is very effective, radiation is one of the most powerful of the known 
carcinogens.  For example, it has been shown that the use of ionising radiation on 
glioblastoma cell lines can in fact activate the highly potent AKT signalling pathway 
(Li et al., 2009b).  This finding entails that in a clinical setting the use of radiotherapy 
has the potential to contribute to increasing resistance to the very therapy being used 
to treat malignant cells.  While the benefits of radiotherapy far outweigh the risks, 
there is still a chance that this type of treatment can actually initiate the development 
of further tumours, effectively causing the very disease it is supposed to treat.  
1.5.3 Chemotherapy 
 
Chemotherapy remains the most heavily employed frontline form of treatment for 
cancer.  Even though anti-malignant drugs have evolved to a point where they are 
extremely targeted and precise, the use of chemical poisons to destroy tumour cells 
remains popular.  A vast array of different drugs can be administered orally, 
intravenously or intra-spinally to combat virtually every known form of cancer.   
 
This form of treatment acts in a similar manner to radiotherapy in that chemotherapy 
acts to damage the DNA of tumour cells.  Cytarabine, for example, is a purine 
analogue, so-called due to its ability to substitute purine bases in target cell DNA, 
thereby disrupting the cell’s genome, ultimately leading to apoptosis of the cell 
(Galmarini et al., 2002).  Other drugs may attack tumour cells by inhibiting the 
actions of proteins central to DNA metabolism, for instance shown by the action of 
etoposide on topoisomerase II (Montecucco and Biamonti, 2007).  Alkylating agents 
such as cisplatin are first-line therapy for a wide array of different cancers and 
function not only to disrupt the DNA pattern of cells, but also attacks the 
cytoskeleton, which destroys cellular integrity (Siddik, 2003).   
 
Chemotherapy is also as well known for its drawbacks as it is for its effectiveness.  It 
is most effective against rapidly dividing cells, such as tumour cells.  This is because 
it is during cell division where DNA is most vulnerable to nucleotide substitution and 
attack against proteins used to maintain genomic integrity.  However, chemotherapy 
is completely indiscriminate and as a result, it kills other cells in the body capable of 
rapid cell division.  These include keratinocytes in the hair, leucocytes and gastric 
cells.  The death of these cells results in the stereotypical side-effects seen in 
oncology/haematology patients such as hair loss, neutropaenia and nausea 
(Antonarakis and Hain, 2004; Caggio et al., 2005; Mols et al., 2009).  The former can 
be distressing to patients undergoing chemotherapy, while the latter two require 
particular attention, as it renders a patient susceptible to infection or dramatic weight 
loss thanks to loss of appetite respectively.  In addition to this, chemotherapeutic 
drugs can cause nephron toxicity, resulting in renal damage (Hanigan and Devarajan, 
2003).  All of these side effects mean that the use of drugs requires very strict, careful 
monitoring and guidelines towards their use and management of supportive therapy 
(Aapro et al., 2006).   
 
Another drawback of chemotherapy comes in the form of the resistance that can be 
demonstrated by tumours towards these drugs.  Even though they are extremely 
potent, it is known that tumours are able to withstand their effects.  This is mainly a 
characteristic of highly aggressive or late stage tumours, but nonetheless it remains a 
concern that cells are able to form resistance against even the most harmful of 
poisons.   
 
The mechanisms that underlie this response are to date very unclear.  Resistance to 
platinum-based drug compounds such as cisplatin and carboplatin has been well 
documented (Siddik, 2003; Stewart, 2007) and could represent a good model to 
examine chemotherapy resistance.  Cancerous cells could reduce their uptake of the 
compounds or use efflux pumps to withstand effects of chemotherapy (Siddik, 2003; 
Stewart, 2007).  Alternatively, DNA repair mechanisms could be utilised by 
malignant cells to reduce the impact of damage induced by drugs (Martin et al., 
2008).  Expression of specific molecules could additionally aid resistance, including 
AKT or up-regulation of inhibitors of apoptosis (IAP) (LaCasse et al., 1998; Gagnon 
et al., 2004).  To overcome this, combinational chemotherapy regimens may be 
employed, where certain drugs are used in association with each other.  A well known 
example is the use of ICE (Ifosfamide, carboplatin, etoposide) and CHOP 
(Cyclophoshamide, doxorubicin, vincristine, prednisone) therapy used to treat 
haematological tumours such as lymphoma (Zelenetz et al., 2003; Hertzberg et al., 
2006; Pfreundshuh et al., 2006). Not only does this reduce the risk of a malignancy 
becoming resistant to any one of the drugs used, but it can maximise their effects, 
thereby giving more chance of success for the patient.   
 
1.5.4 Specific Therapies and the Evolution of the Single Agent Treatment 
  
Knowing that both radio- and chemotherapy, while effective, are non-selective and in 
themselves can represent a threat to patient wellbeing, there was obvious scope to 
design drugs that could have the same impact as the older forms, but reduce patient 
risk.  Increased understanding of cancer molecular biology has made it possible to 
now explicitly recognise the precise genes and proteins that are responsible for certain 
cancer types.  Concurrent improved pharmacological/pharmokinetic techniques has 
resulted in better drug design.  This has led to the development of a new generation of 
cancer drugs that now seek to specifically inhibit target molecules that act to promote 
tumorigenesis or have a key role within a cancer cell. 
 
1.5.4.1 Oncogene Addiction and Synthetic Lethality 
 
The evolution of NGS analysis has now made it possible to begin examining the 
genome of cancer cells in far greater detail and in much shorter time than has been 
imaginable in the past (Stratton et al., 2009; Pleasance et al., 2010a; Pleasance et al., 
2010b).  This work has already been able to highlight the huge number of mutations 
that are present in certain tumours.  Cancer is a disease characterised not just by 
mutation, but also by the aberrant up- and down-regulation of a whole host of 
different genes that may contribute to the malignant phenotype.  Nevertheless, 
speculation exists as to the number and identity of the genes whose expression are 
fundamental to the development of tumour cells.  Over-expression of certain genes 
may confer the majority of characteristics required for the malignant phenotype.  
Alternatively, due to the loss of both alleles of certain genes (e.g. TSG) cancer cells 
depend on particular genes (Kaelin Jr., 2009).  As such, expression of these genes is 
vital for tumour cells, creating a situation dubbed ‘oncogene addiction’ (Sharma and 
Settleman, 2007; Weinstein and Joe, 2008).   
 
This theory was initially proposed by Weinstein, citing evidence from cell line culture 
experiments, murine models and patient studies as the foundation for this argument.  
Induction of the c-MYC gene in haematopoietic progenitor cells in mice has been 
shown to bring about myeloid and T lymphocyte leukaemias.  Interestingly, inhibition 
of this gene subsequently resulted in these cells exhibiting healthy characteristics 
(Felsher and Bishop, 1999; Weinstein and Joe, 2008).  One can recognise addictive 
genes in specific cancers, for example RAS, B-RAF, BCR-ABL and HER2 amongst 
others (Weinstein and Joe, 2008).   
 
It is thought that if the products of these genes can be inhibited or the genes 
themselves inactivated, then tumour cells will die.  The premise behind this is that 
since a malignant cell could be so dependent on a gene in order to survive, then 
targeting this molecule would leave the cell unable to cope and undergo apoptotic 
death as a result of ‘oncogenic shock’.  While this theory goes a long way to account 
for the action and dependence of oncogenes in cancerous cells, it does not explain 
why their inhibition leads to differentiation in certain instances or the possible 
existence of CSC (Weinstein and Joe, 2008).    A counter argument to Weinstein’s 
oncogene addiction theory is that of ‘oncogene amnesia’ proposed by Felsher.   This 
proposes the existence of almost induced ignorance of malignant events within and 
outside cells, which brings about the same phenomena as oncogene addiction but also 
attempts to answer the other issues (Felsher, 2008; Weinstein and Joe, 2008). 
 
Due to this apparent dependence, gene addiction is closely linked to synthetic 
lethality.  The principle behind this comes from the idea that certain mutations/events 
lead to loss of specific gene expression and because of this, cells become dependent 
on other genes in order to survive and these could be targeted to induce death.  This 
notion is being employed with great promise with the PARP inhibitor Olaparib.  
BRCA- deficient breast and ovarian carcinomas depend on BER DNA repair in order 
to survive.  Work by Ashworth and colleagues was able to identify the molecule, 
poly-ADP ribose polymerase-1 (PARP-1), as being central to BER in BRCA-
deficient cells, hence PARP-1 is addictive.  The drug has been highly effective and 
recently completed a Phase II clinical trial (Ashworth et al., NCRI Conference, 2009).  
Olaparib specifically targets PARP-1 in both healthy and malignant cells.  However, 
healthy cells still possess HR DNA repair and will therefore survive (Fong et al., 
2009; Fong et al., 2010; Sandhu et al., 2010).  Other PARP-1 inhibitors exist and are 
part of clinical trials for numerous tumour types (Sandhu et al., 2010).   
 
1.5.4.2 Monoclonal Antibody Therapy 
 
One of the more popular methods of targeted cancer treatment can be found in the 
form of monoclonal antibody (mAb) therapy.  The use of Ig molecules for use against 
specific tumour antigens has shown significant success with various different tumour 
types.  mAb treatment is a specific variation of immunotherapy in that its goal is to 
try and induce immune reactivity against tumour cells that express particular antigens.  
Ig molecules utilised in mAb therapy can be found in different forms, depending on 
the method utilised to generate them.   
 
The administration of mAb aims to mimic the action of the natural order of Ig 
reactions within the body, yet modified to the extent that only malignant cells are 
targeted.  Ig binding to specific antigens present on tumour cells can attract NK cells 
to the region and promote the actions of both ADCC and other mechanisms to destroy 
these cells.  Since NK cells are potent producers of various cytokines including 
interferon- (IFN-) (Cooper et al., 2001; Moretta et al., 2002; Zamai et al., 2007), 
there is the potential for them to provoke an adaptive reaction from CTL. 
 
It stands to reason that in order for these specific uses of mAb to be of any use to 
patients, the target molecules must be either unique or significantly over-expressed by 
cancer cells. Likewise, the patient must actually express the molecule on their 
tumours in order to be considered for the use of this therapy.   There are well known 
and successful mAb therapies that have been employed for different malignancies.  
Some began their use as immunosuppressive drugs for ablative therapy prior to 
transplants.  This can be seen with alemtuzumab (CAMPATH 1-H®), an anti-CD52 
mAb used for stem cell transplant (SCT) which has now been re-employed for 
patients with haematological tumours or tumours where myeloid cells are implicated 
in specific aspects of tumour phenotype (Tibes et al., 2006; Alinari et al., 2007; 
Pulaski et al., 2009).   
 
Perhaps the best publicised is the drug trastuzumab (Herceptin®) which is used to 
target the HER-2 molecule over-expressed in breast carcinomas and acts to inhibit the 
action of signalling pathways that can be initiated by EGF members.  This has shown 
impressive results in clinical trials, achieving therapy response rates of up to 35% 
when used alone and has shown to slow the rate of disease progression and increase 
patient survival when combined with chemotherapy agents such as paclitaxel and 
docetaxel (Slamon et al., 2001; Esteva et al., 2002; Nahta et al., 2009; Redana et al., 
2010). 
 
Another drug, rituximab has been highly successful in the treatment of B cell non-
Hodgkin’s lymphoma (NHL) and is considered to be one of the most accomplished 
forms of tumour immunotherapy (van Meerten and Hagenbeek, 2009).  This is a 
chimeric antibody raised against the CD20 antigen present on B cells, which due to 
its potency is incorporated into first-line chemotherapy for patients with mantle zone, 
follicular and diffuse large B cell (DLBCL) lymphomas (Coiffier et al., 2002; van 
Meertenn and Hagenbeek, 2009).  Retrospective studies into the use of rituximab 
have shown that it can considerably improve the survival of DLBCL patients 
(Rodenburg et al., 2009).  Upon recognising its effectiveness, there has been 
development of next generation anti-CD20 mAb therapies that have either been 
approved for patient use or are undergoing clinical trial (Lim et al., 2010). 
 
However, like all cancer therapies to date, there are issues with mAb treatments.  
While initial impressions of trastuzumab are impressive, there are some quite 
fundamental flaws with its use as a single agent.  The first comes from the recognition 
that only 25-30% of patients with metastatic breast carcinoma over-express the HER-
2 oncogene (Nahta et al., 2009).  Additionally, it has been shown that a large number 
of patients whose tumours express the antigen do not respond.  Likewise, the same 
studies that show the benefits of combined trastuzumab/chemotherapy regimens have 
highlighted following single treatment, time taken to develop resistance and go on to 
progress is made shorter.  Such disadvantages have now led to the development and 
use of other drugs such as lapatinib for HER-2 positive tumours (Nahta et al., 2009). 
 
For rituximab, issues include the development of resistance to the antibody following 
prolonged periods of application.  Though the reasons for this refraction still remain 
unclear, there are suggestions that it may be a result of tumour resistance 
mechanisms.  These include antigen (CD20) down-regulation, promotion of anti-
complement mechanisms and activation of survival mechanisms (Meerten and 
Hagenbeek, 2009; Borgerding et al., 2010).  It has been shown that its effectiveness 
as part of salvage therapy for relapsed DLBCL patients is quite limited, hinting at its 
use being confined to newly diagnosed patients (Borgerding et al., 2010).  This 
limitation is compounded by the recognition that rituximab is incorporated alongside 
combinational chemotherapy regimens such as CHOP (R-CHOP) and ICE (R-ICE) 
(Pfreundshuh et al., 2006; Griffen et al., 2009).  Although rituximab is very 
successful in this setting, such employment brings its use as single therapy into 
question, much like trastuzumab. 
 
Therefore, mAb therapy regimens, though extremely promising and in certain cases 
highly effective, still suffer from the same problems as the more traditional methods 
of treatment.  It has to be said that as a therapy, the use of mAb has made significant 
improvements to the treatment of cancer patients.  It has been noted though that this 
improvement has been relatively slow and as yet requires even more improvements 
and modifications in order to optimise it fully (Yan et al., 2009).  As a result, it is 
necessary to find other types of treatment applications. 
 
1.5.4.3 Tyrosine Kinase Inhibitors 
 
Cancer exerts its effects in cells through the manipulation of a large number of 
different cell signalling cascades.  By doing this, it can bring about the prominent 
hallmarks that are representative of the malignant phenotype.  While many effector 
molecules such as RAS, PTEN and AKT are corrupted in order to cause this, the 
receptor molecules that make use of these effectors can also be modified in cancer, 
with perhaps the most recognisable being the receptor tyrosine kinases (RTK).  This 
group of surface receptors span the membrane of cells to transmit stimuli brought 
about by ligand binding, which they then propagate through the cell.  More 
specifically, they communicate the action of growth factors including epidermal 
growth factor (EGF), FGF, IGF and PDGF amongst others.   
 
Receptors to these mitogens may be over-expressed or rather subject to increased 
binding caused by autocrine signalling that is common in tumour cells; in either case, 
the result is similar.  Since RTK are receptors for growth factor ligands, then they 
bring about pro-proliferative, anti-apoptotic signalling in cells, thereby increasing 
cellular populations.  This is of obvious use to malignant cells and can allow them to 
grow efficiently. Well known examples of RTK subverted in cancer include HER-2, a 
member of the EGF receptor (EGFR) family and BCR-ABL in CML (Parsons and 
Parsons, 2004; Arighi et al., 2005).  What is noticeable about some of the molecules 
that bind to these receptors is that aside from proliferation, they act in processes such 
as angiogenesis and metastasis.  Therefore, there is obvious scope to inhibit such 
molecules and in more recent years, therapies have been developed, referred to 
collectively as tyrosine kinase inhibitors (TKI). 
 
One of the best examples of this type of therapy comes in the form of Imatinib 
(Gleevec), a TKI that was designed to inhibit BCR-ABL in CML.  As already 
mentioned, this new genetic sequence is due to a reciprocal translocation that takes 
place between chromosomes 9 and 22 within haemopoietic stem cells.  This 
translocation causes the formation of a smaller version of chromosome 22 known as 
the Philadelphia (Ph) chromosome with all cells harbouring this being referred to as 
Ph-positive.  The result of this modification is a fusion gene that combines the ABL-1 
proto-oncogene and placed next to the active BCR promoter region (Deininger et al., 
2000; Kabarowski and Witte, 2000).  This translocation is responsible for 
approximately 95% of all cases of CML and is present in the cells of 20% of adult 
acute lymphoblastic leukaemia (ALL) patients (Druker et al., 2001b).  The protein 
product of this gene is a highly active RTK that impels the malignant characteristics 
exhibited by the cell clone derived from the stem cell affected by this translocation.  
The BCR-ABL protein itself can be found in different molecular weight forms, either 
190, 210 and 230 kDa (p190, p210 and p230 respectively).  The p210 form is most 
common in CML, while p190 predominates in Ph-positive ALL (Chopra et al., 1999; 
Deninger et al., 2000a).  
 
Imatinib, the drug designed to combat BCR-ABL, was the original TKI to be 
accepted for clinical use and arguably remains the most effective example of it.  It 
works by acting as a competitive inhibitor of the ATP binding site within the BCR-
ABL protein.  The attachment of Imatinib to this region stops the function of the 
protein and therefore signalling from it cannot proceed and the cell dies through 
apoptosis due to the attenuation of a pathway upon which it depends (Deininger et al., 
2000b).   
 
The use/discovery of Imatinib revolutionised treatment for CML (Druker et al., 
2001a; Druker et al., 2001b). Until its acceptance, standard therapy was through the 
use of interferon-alpha (IFN-), which was the only way to induce lost lasting 
remission along with allogenic SCT (Goldman, 2009).  However, since its inception, 
the use of Imatinib has meant that 70-90% of patients in chronic phase (CP) can 
achieve a complete cytogenic response, whereby their bone marrow does not contain 
detectable Ph-positive cells.  In blast-crisis (BC) patients, this reaction is found in up 
to 60% (Palandri et al., 2007; Hehlmann et al., 2007).  Further to this, 84% of patients 
have been able to remain disease-free for five years. Patients who relapse following 
SCT are also treated with this drug (Druker et al., 2006; Hehlmann et al., 2007).   
 
Though its effectiveness cannot be doubted, Imatinib, as with all cancer therapy, 
suffers from flaws.  In this case, it comes in the form of resistance, rendering the 
treatment ineffective against malignant cells.  It is thought that up to 30% of patients 
may form resistance against Imatinib (Quintás-Cardama et al., 2009).  For the former, 
resistance is thought to be due to specific mutant variants of the BCR-ABL gene 
created during the Ph translocation.  Conversely for BC patients, the consideration is 
that the amalgamation of mutations gained during their disease course produces 
resistance (Bixby and Talpaz, 2009; Quintás-Cardama et al., 2009).  Formation of 
Imatinib resistance led to the production of second generation TKI against BCR-
ABL.  These are Nilotinib, Dasatinib and Borotinib, all of which have displayed 
significant effectiveness for use in treatment (Kantarjian et al., 2006; Fava et al., 
2008; Aguilera and Tsimberidou, 2009; Ramchandren and Schiffer, 2009; Swords et 
al., 2009). 
 
One of the more recent members to be part of TKI therapy is Masatinib, a drug that is 
capable of inhibiting the action of c-KIT (Stem cell factor (SCF)/CD117), a receptor 
involved in cell production (such as erythropoiesis and gametogenesis) (Roskoski Jr., 
2005).  This is a proto-oncogene that due to modification achieves gain of function 
constitutive activation in various tumour types including the acute leukaemias, 
melanoma and gastrointestinal stromal tumours (GIST) (Lennartsson et al., 2005; 
Dubreuil et al., 2009).  Masatinib was designed to combat the actions of this receptor 
and was initially shown to be successful in pre-clinical models against both the 
murine and human forms of c-KIT as well as specific gain of function mutant of the 
protein.  It can also inhibit the de-granulation of mast cells thereby reducing 
inflammatory episodes, for which c-KIT is a potent driver (Dubreuil et al., 2009).  
Combined with the chemotherapeutic agent gemcitibine, Masatinib is effective 
against human pancreatic cancer cell lines in vitro and within a murine host model, 
which shadowed a Phase II clinical trial involving the same regimen on patients with 
pancreatic carcinoma (Humbert et al., 2010; Mitry et al., 2010).  Therefore, the 
effectiveness of this drug appears to show the potential of TKI in therapy and how 
this follows on from the promise made by Imatinib.   
 
Though they are highly effective at inducing remission and reducing disease burden, 
TKI remain unable to cure their target tumours.  SCT still remains the only true way 
of curing haematological tumours such as CML and ALL, while it remains unclear if 
Masatinib will be an effective single.  Even though problems remain, the creation of 
such drugs signals progress towards finally identifying a regimen that can target and 
potentially cure specific cancers.  Having said that, there remain aspects of therapy 
that need to be explored in order to achieve this goal. 
 
1.5.4.4 Immunotherapy 
 
For many years, the goal of both cancer researchers and clinicians has been to create a 
therapy that can generate long lasting effects against tumours within patients.  The 
perception that the body’s immune repertoire can react towards malignant cells 
allowed the establishment of immunotherapy and it was believed that this could 
address the ultimate goal of cancer therapy.  By manipulating a patient’s own 
immunity to limit the growth of their tumour or even to destroy it entails that it may 
be possible to avoid the harsh side effects that blight both radio- and chemotherapy.  
Seminal work was performed by Baldwin and co-workers, using various immune-
based therapies in studies.   This concept has been built and expanded upon to 
promote such treatment and has made the principle of immunotherapy a realistic 
prospect for combating tumours.  (Baldwin and Pimm, 1973; Rees et al., 1975; Shah 
et al., 1976; Greager and Baldwin, 1978; Robins et al., 1979).   
 
Since its inception, virtually every facet of the immune system has been manipulated 
in an attempt to induce anti-tumour immunity (Borghaei et al., 2009).  As previously 
described, the use of mAb such as rituximab exemplifies the use of immunotherapy as 
front-line cancer treatment for various cancers.  In this setting, immunotherapy has 
been successful, however it is flawed.  One of the aims of immunotherapy is to try 
and create immune memory to ensure long lasting resistance against a tumour.  One 
of the issues with mAb treatment is it does not induce immunological memory, so 
there is always the possibility of patient relapse.   
 
Aside from this, many other concepts have been used to activate the immune system, 
with increasing emphasis being placed on the use of vaccines.  Immune activation can 
be achieved in either non-specific or specific methods.  Non-specific immune 
stimulation includes the use of cytokines.  Due to the fact that a large number of these 
proteins are highly capable of activating immune cells in acute situations, they 
represent an inviting proposition for this type of treatment.  IL-2 bolus injection has 
been used as part of trial of a large number of patients with metastatic melanoma, in 
which 16% of patients responded, 6% displaying complete remission (Atkins et al., 
1999).  This trial was able to significantly prolong patient survival for more than 30 
months (Atkins et al., 2000).  Other cytokines, such as IFN have been shown to 
activate NK cells that can go on to inhibit the proliferation of cells transformed by a 
carcinogenic virus (Fresa and Murasko, 1986).  Furthermore IFN- combined with 
the chemotherapy drug vinblastine was shown to prolong the survival of renal cell 
carcinoma patients better than vinblastine alone (Pyrhönen et al., 1999). 
 
The alternative to the broad-spectrum approach of using cytokines can be found 
through the employment of more specific forms of immunotherapy, which involves 
the more targeted utilisation of immune components.  Specific immunotherapy can be 
targeted due to the fact that tumour cells possess antigens that can be recognised by 
the immune system, known as tumour associated antigen (TAA).  Such antigens are 
varied in their expression patterns and composition (Boon and van der Bruggen, 
1996; Kawakami and Rosenberg, 1997; Novellino et al., 2005); therefore meaning 
that one should use caution when designing therapy against them.  A list of well 
known TAA is shown in Table 1.1 and they are discussed briefly below. 
 
Over-expressed Antigens: 
 
These antigens are derived from molecules expressed by a wide range of tissues.  
Members include the HER-2 antigen found in breast carcinoma (Peoples et al., 1995), 
MUC-1 in breast and ovarian carcinoma (Brossart et al., 1999) and Wilm’s tumour-1 
(WT-1) in a variety of tumours such as gastric, lung, ovarian, uterine and hepatic 
carcinomas as well as leukaemias (Ohminami et al., 2000; Azuma et al., 2002).    
Expression of these TAA is higher in malignant tissue compared to healthy cells; 
however expression does not seem to be higher in any one particular cancer (Boon 
and van der Bruggen, 1996; Kawakami and Rosenberg, 1997; Novellino et al., 2005). 
   
Differentiation/ Lineage Specific Antigens 
 
This group of antigens are tissue specific, being found in both the healthy and 
malignant cells of that particular tissue.  The majority of differentiation antigens 
isolated to date are derived from melanoma, including gp100, Melan-A/MART-1, 
tyrosinase and gp75 (Brichard et al., 1993; Bakker et al., 1994; Kawakami et al., 
1994; Wang et al., 1995; Boon and van der Bruggen, 1997).  Other than melanoma-
based antigens, this group contains prostate-specific antigen (PSA) and 
mammaglobin-A in prostate and breast carcinoma respectively (Corman et al., 1998; 
Jaramillo et al., 2002).  Some of these antigens have been used as part of clinical 
trials in an attempt to utilise them as part of immunotherapy, as seen with gp100 and 
Melan-A/MART-1 for melanoma patients (Di Pucchio et al., 2006; Yuan et al., 
2009).   
 
Virally-derived Antigens 
 
Those proteins that are responsible for the neoplastic transformation of cells 
following viral infection are well characterised.  Viral proteins such as E6 and E7 
products of HPV, EBNA from EBV and TAX produced by HTLV infection are 
responsible for the production of malignant phenotype in affected cells.  Due to the 
importance of these proteins in tumorigenic transformation, there is the belief these 
proteins are necessary for maintenance of this situation and thus act as highly inviting 
targets for therapy (Hung et al., 2008).  Such promise has led to various work 
investigating the use of possible immunotherapy against such antigens (Taylor et al., 
2004; Demachi-Okamura et al., 2008; Hung et al., 2008; Uozumi, 2010).  
Investigations into targeting viral TAA led to the development of prophylactic 
vaccines for immunisation against HPV (Harper, 2008) 
 
Onco-foetal Antigens 
 
Some genes which are normally inactivated following birth can become re-expressed 
in tumours.  For example, proteins that promote proliferation and reduce apoptosis, a 
situation required during foetal development, should become redundant in neo-natal 
life.  However, as shown by carcioembryonic antigen (CEA) in colorectal carcinoma 
(Novellino et al., 2005) and alpha-foetal protein (AFP) in HCC, these genes become 
expressed again and result in malignant changes in adult cells (Ribas et al., 2003).  A 
similar situation can be found with the cancer/testis antigens, discussed in greater 
detail later on. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
One of the original methods of specific immunotherapy which is still being used as 
part of clinical trial is adoptive T cell therapy (ACT).  ACT exploits the observation 
that a patient’s tumour contains lymphocytes that have trafficked to the lesion: 
purported tumour infiltrating lymphocytes (TIL).  The notion that these cells can 
ColorectalCEA
HCCAFP
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Cervical, head and neckE6/E7
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specific
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Table 1.1: A list of the major classes of tumour associated antigen (TAA) found in cancer, 
along with common examples and types of malignancy in which they can be found. 
References detailing these TAA are found in the main test.
migrate into malignant tissue suggests some form of immune reactivity.  The 
principle behind ACT is to isolate TIL from tumour lesions, which are treated in vitro 
with a cytokine cocktail including IL-2 that allows the clonal expansion of these cells.  
During this time, patients undergo conditioning therapy using drugs such as 
cytarabine and fludarabine to ablate lymphocytes, total body irradiation (TBI) to 
bring about general marrow ablation and cytokine therapy to remove all other 
immune cells.  Once the patient is completely immuno-suppressed, then the modified 
TIL are infused back into their peripheral blood, allowing them to re-traffic to the 
tumour and attack cells within it (Dudley et al., 2003; Rosenberg and Dudley, 2009).   
 
ACT therapy has been employed by Rosenberg and colleagues for a number of years 
against late-stage melanoma patients in several clinical trials.  It has been able to 
achieve highly significant results in these studies, to the point where extremely large 
lesions showed complete regression (Dudley et al., 2008; Rosenberg et al., 2008; 
Rosenberg and Dudley, 2009).  Furthermore some of these TIL were shown to be able 
to recognise specific antigens prevalent in melanoma (Panelli et al., 2000; Seiter et 
al., 2002).    ACT does seem to highlight the extent of immune down-regulation 
taking place in tumours, due to the vigorous conditioning therapy required for TIL to 
help in eliminating lesions.  The necessity of traditional therapy also implies that 
immunotherapy may be less potent as a single agent.  Other issues one must take into 
account include the principle of T cell affinity and avidity discussed earlier (McKee 
et al., 2005).  Extent of T cell priming and the strength of interaction between TIL 
and antigen presented to them would all impact on the success of ACT.   
 
However, while ACT has been successful for melanoma, there has been limited 
impact on other tumours.  Indeed, retrieving TIL from tumour types other than 
melanoma has proved problematic, though evidence exists for their extraction from 
bladder and lung carcinoma (Weynants et al., 1999; Heidecker et al., 2000).  
Difficulty in extracting TIL from lesions other than melanoma may be due, at least in 
part, to the relative ease of access to tumours.  Nonetheless, the use of specific 
immunotherapy in the form of ACT has provided hope that immune based medicine 
other than mAb can be used successfully against tumours.   
 
One of the aspects of specific immunotherapy that has become more focused upon in 
recent years is the development of therapeutic vaccines that could potentially be used 
to initiate immune reactivity against malignant cells (Jäger et al., 2003).  This 
concentration has come about thanks to the discovery of the cancer/testis antigens that 
are discussed in detail further below (van der Bruggen et al., 1991; Rosenberg, 1999).  
The formulation of vaccines that could lead to the elimination of tumour spread 
would satisfy the goal of a therapy that could be used to target cancer and spare 
healthy tissue.  Following the formation of this concept, nearly every single 
conceivable form of vaccine has been utilised against a whole host of different TAA 
ranging from irradiated autologous tumour cells to gene therapy involving viruses 
(Ribas et al., 2003).  One of the most widely used approaches includes the use of 
DNA vaccines, whereby plasmids containing targeted genome material are 
administered using gene gun or direct injection.  This has been utilised with DNA for 
both TAA and immune ligands (Ribas et al., 2003; Zhou et al., 2005) with the 
intention of increasing recognition of tumour targets or stimulating immunity 
respectively.  Likewise, dendritic cells (DC) have been at the centre of research into 
vaccination against tumours due to their pivotal role in immunity (Melief, 2008).  
Their use in immunotherapy has involved either the ex vivo treatment of autologous 
patient DC using peptides and other material or the design of modified immune 
ligands that could stimulate in situ DC within the patient to act against tumours 
(Hanks et al., 2005) .  The aim is to reintroduce these DC into patients and allow 
them to traffic to lymphatic tissue where they can interact with T cells and activate 
immunity against malignant cells. 
 
So far tumour vaccination has had extremely limited success, certainly in a 
therapeutic setting, where only a minority of patients have exhibited actual tumour 
regression (Rosenberg et al., 2004).  However, there is more promise with vaccines in 
the realm of prophylactic prevention of cancer.  This can be seen with Cervarix, a 
DNA vaccine used via needle injection that has undergone large scale trials for 
immunisation of women to reduce the risk of cervical cancer induced by HPV 
infection (Harper, 2008).  Very recently initial evidence has emerged of a 
prophylactic therapy against breast carcinoma that has shown great promise in murine 
studies (Jaini et al., 2010).  For vaccination to work as a therapy against established 
tumours however, it may be that our knowledge of the relationship that exists 
between tumours and the immune system remains insufficient. 
 
1.6 Cell Signalling in Tumour Cells 
 
1.6.1 Significance of Cellular Signalling 
 
All actions performed by cells are controlled by extremely complex molecular 
communication networks.  Everything from proliferation, DNA repair, trafficking 
through to apoptosis are subject to the machinations of signalling cascades found in 
the intracellular environment.  These are initiated and inhibited by the actions of both 
external influences such as ligand-receptor interactions and internal factors including 
genomic damage.  The actions of these stimuli are mediated by vast numbers of genes 
and proteins that interact with each other in order to bring about a phenotypical 
action.  Signalling cascades are subject to intense levels of control present to maintain 
strict levels of homeostasis. This entails that in a healthy environment, cells respond 
to initiation and inhibitory stimuli when required, thus maintaining a stable 
population of cells. 
 
1.6.2 Consequences of Abnormal Cellular Signalling 
 
While signalling within cells is subject to stringent levels of control, it is very 
possible that this can be corrupted with significant consequences.  Cancer is a disease 
occurring when signalling homeostasis is undermined.  Cellular signalling is a very 
finely balanced process that involves both pro- and anti-communication systems.  
Every molecule shown to undergo mutation or modification in malignancy more 
often than not is central or at least has a key role in signal transduction.  This tips the 
balance of a particular cell process in favour of tumorigenic behaviour and results in 
the formation of the hallmarks exhibited by tumour cells. 
   
 
 
 
 
1.6.3 Major Pathways Subverted in Tumours 
 
1.6.3.1 The Magnitude of the RAS Proto-oncogene  
 
Perhaps one of the most recognisable molecules to be affected in cancer is that of 
RAS.  This is a group of human genes initially discovered as homologues of viral 
genes capable of initiating tumours in mouse cell lines, the first members to be 
discovered being Harvey rat sarcoma viral gene homologue (H-RAS) and the Kirsten 
rat sarcoma homologue (K-RAS) (Der et al., 1982).  These two alongside N-RAS, the 
third member to be discovered in neuroblastoma (Shimizu et al., 1983), represent the 
three major species of this gene that are present in human cells (Downward, 2003).  
To understand the importance of RAS in signalling and more pertinently to what 
impact this has in cancer, then one must appreciate the function of the molecule and 
the diversity of other molecules it effects. 
 
RAS belongs to a family of small-GTP binding proteins present in the cytoplasm of 
cells, with a molecular weight of 21kDa (p21RAS) (Wennerberg et al., 2005).  It acts 
to communicate pro-proliferative signals from receptors on the cell surface to a 
diverse number of different cascades in the cytoplasm.  It can be activated by a 
number of different receptors including RTK and G-protein coupled receptors 
(GPCR) (Mitin et al., 2005).  Following receptor-ligand binding, RAS is recruited to 
the membrane where it too can be made active.  The RAS protein is constantly bound 
to guanine phosphate and it is the extent of this molecule’s phosphorylation that 
determines its state of activation.  When bound to GDP, RAS is inactive and in order 
to undergo activation, this is swapped for GTP in a reaction catalysed by guanine 
exchange factors (GEF), which include the son-of-sevenless (SOS) proteins.  RAS 
itself possesses an intrinsic GTPase ability that breaks down GTP as a form of self-
regulation towards ensuring it can be made inactive.  This however, is relatively slow 
and inactivation is vastly potentiated by proteins that convert the GTP to GDP, 
referred to as GTPase activating proteins (GAP) such as p120RASGAP (Downward, 
2003; Mitin et al., 2005; Schubbert et al., 2007).  An overview of this is shown in 
Figure 1.3.   
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Figure 1.3: Basic overview of the steps involved in activation of RAS.  Stimuli to cell receptors 
leads to guanine exchange factors (GEF) transferring GDP to GTP on RAS, thereby activating it.  
RAS activity is stopped by GTP-ase activating proteins (GAP) catalysing the hydrolisis of GTP to 
GDP.  RAS frequently undergoes mutations occurring at codons 12, 13 or 61, leading to resistance 
to the actions of GAP, thus making it constitutively active in affected tumour cells.  Adapted from 
Cox and Der, 2002.  
When present in a GTP-bound form, RAS is extremely efficient in its role as a 
mediator of signal transduction.  Its actions lead to a large number of molecular 
changes in the cell to induce a wide range of different behaviour by cells (Campbell 
et al., 1998; Shields et al., 2000).  The reason for having roles with such a diverse 
range of cell functions comes from its position in signal pathways and recognising the 
sheer number of molecules that are influenced by RAS as a result.  It is because of 
this that RAS represents one of the most important molecules in cancer.   
 
The major reason for its importance comes from the recognition that RAS is subject 
to point mutations that most commonly occur at codons 12, 13 and 61 of its genetic 
sequence (Bos, 1989; Downward, 2003).  The effect of these mutations is a change to 
the amino acid sequence of the protein product, which results in RAS becoming 
resistant to the GTPase action of GAP members (Bos, 1989).  Lack of inhibition 
entails the constitutive action of a highly potent promoter of proliferation and 
inhibitor of apoptosis.  RAS mutations are thought to be present in up to 30% of all 
human cancers, underlining its importance and effect in cells (Bos, 1988).  The extent 
of this is made clearer when one examines the array of different molecules that make 
up the signalling cascades controlled by RAS.  Due to the fact that RAS controls 
molecules that can induce proliferation, cell survival, production of ROS and 
angiogenesis along with metastasis, then its constant activation is a significant event 
in tumour cells. 
 
1.6.3.2 The PI3-Kinase Pathway and the Importance of AKT and PTEN 
 
Some signalling pathways present in cells can be highly beneficial tumours once they 
become corrupted. One of the more notable involves phophotidylinositol-3-kinases 
(PI3K), a series of heterodimeric lipid kinases situated within the cytoplasm close to 
the cellular membrane.  PI3K proteins consist of a regulatory and catalytic subunit 
(p85 and p110 respectively in the case of class I PI3K) and may be activated by 
different types of cell surface receptors (Cantley, 2002; Vara et al., 2004).  For 
example, the class I subtype IA is activated by RTK while IB responds to signals 
from GPCR (Vara et al., 2004; Calhoub and Baker, 2009).  Activation can take place 
following direct interaction with the phosphorylated SH2 regions of activated 
receptors or via the activation of upstream regulators that include RAS.  The action of 
PI3K is to initiate signal relay from growth factor receptors following mitogen-
receptor binding by phosphorylating the D3/3'OH region of inositol lipids to bring 
about pro-survival signalling in cells (Vara et al., 2004).  Activation of these lipids in 
this manner leads to increased production of phosphotidylinositol-tri-phosphate 
(PIP3), a compound that specifically binds to pleckstrin homology (PH) domains of 
target proteins (Calhoub and Baker, 2009).     
 
One such example of these targets is AKT (Protein kinase B/PKB), the human 
homologue of the v-AKT viral oncogene (Staal, 1987; Nicholson and Anderson, 
2002).  The importance of this molecule in tumour cells is evident following the 
understanding the sheer number of signalling events that are controlled by it.  AKT is 
used to promote proliferation, survival, angiogenesis and motility amongst other 
actions (Datta et al., 1997; Vara et al., 2004).  To do this, it is recruited to the 
membrane following the stimulation of upstream molecules, where it becomes 
activated either by phosphorylation of its PH region or via residue phosphorylation by 
PDK or mTOR (Nicholson and Anderson, 2002; Calhoub and Baker, 2009).  A brief 
overview of PI3K/AKT signalling is shown in Figure 1.4.   
 
PI3K/AKT signalling is significantly subverted in cancer.  PIK3CA, the gene that 
encodes the p110 catalytic subunit of PI3K undergoes amplification in a wide range 
of tumours including head and neck, lung, ovarian and breast carcinoma (Isakoff et 
al., 2005; Calhoub and Baker, 2009).  This gene is subject to point mutations, as seen 
in a wide range of different tumours, most commonly in prostate carcinoma, but also 
in breast, endometrial and colonic carcinoma (Calhoub and Baker, 2009).  The effect 
of both of these alterations is the constitutive activation of PI3K which in turn leads 
to the continuous activation of AKT.  Knowing that PI3K is stimulated by RAS 
(Pacold et al., 2000; Shields et al., 2000), then obviously over-
expression/amplification and mutations of these respectively can result in increased 
signalling from this pathway.  Mutations may additionally take place in the AKT 
genes (Staal, 1987; Calhoub and Baker, 2009).  
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Figure 1.4: Basic overview of the PI3K/AKT signal cascade.  Signalling stimuli from 
receptor-ligand binding or the actions of RAS leads to activation of PI3K.  Action of PI3K 
can result in AKT recruitment and activation resulting in numerous downstream effects.  
These include direct interactions with proteins or acting on transcription factors to 
promote survival of a cell and induce proliferation.  Adapted from Downward, 2003.
The consequence of excessive AKT activity from theses changes is the development 
of an ideal setting for tumorigenesis.  AKT can create such an environment by acting 
on transcription factors that may promote apoptosis for example the Forkhead 
proteins that are used to transcribe BAD, BIM and Pro-caspase-9 (Brunet et al., 1999; 
Dijkers et al., 2000; Nicholson and Anderson, 2002).  It can additionally directly 
phosphorylate target proteins to induce the same effect.  In this manner, AKT inhibits 
the action of BAD and through that promotes survival (Datta et al., 1997; Calhoub 
and Baker, 2009).  Likewise, it renders GSK-3 inactive, thus promoting survival, 
cell cycle progression and -catenin proliferative signalling (Calhoub and Baker, 
2009).  The interaction with GSK-3 is also thought to promote metastatic 
development through the increased maintenance of SNAIL (Qiao et al., 2008) 
 
Since it is implicated in such a range of different aspects of pro-tumorigenic biology, 
increased AKT activation or mutation is considered to be a poor prognostic factor in 
cancer.  Evidence suggests that its activity can lead to increased radiotherapeutic 
resistance in head and neck carcinoma patients (Bussink et al., 2008).  Moreover, as 
previously mentioned, there are indications that AKT may be induced by exposure to 
radiotherapy (Li et al., 2009), therefore implying a potential risk of using this form of 
treatment for cancer. 
 
Under normal physiological conditions, the action of AKT is repressed by the 
phosphatase and tensin homologue deleted on chromosome 10 (PTEN) protein (Li et 
al.,. 1997; Steck et al., 1997; Dahia, 2000).  PTEN does this by converting PIP3 to its 
bis-phosphate form (PIP2) (Maehama and Dixon, 1998; Chow and Baker, 2006), 
thereby reducing stimulation of AKT by PI3K as it cannot migrate to the membrane 
to be acted upon (Vara et al., 2004).  In this sense, PTEN is an example of a highly 
potent TSG and is therefore in turn highly important in preventing tumorigenic 
transformation.  It is also of note that evidence has shown that PTEN is also required 
to maintain the integrity of chromosomes (Puc et al., 2005; Shen et al., 2007; 
Calhoub and Baker, 2009) and may play an active role in the HR DNA repair 
(Mendes-Pereira et al., 2009).   Ironically, in spite of its great potency, PTEN is 
frequently affected, causing loss of PTEN function, whether that is due to deletion, 
mutation or reduction in protein activity (Li et al., 1997; Steck et al., 1997; Dahia, 
2000; Chow and Baker, 2006; Calhoub and Baker, 2009).  Without such a barrier in 
place, then PI3K signalling through AKT is unrestricted, thus promoting tumour 
development and progression (Vara et al., 2004; Chow and Baker, 2006; Calhoub and 
Baker, 2009).  The PI3K/AKT/PTEN pathway is an excellent example of a cellular 
network involving the oncogenic activation of specific molecules that takes place 
alongside the inhibition of TSG. 
 
1.6.3.3 The MAPK Pathway 
 
The mitogen activated protein kinase (MAPK) signalling network represents another 
cascade that has been shown to be vastly modified in tumour cells.  Much like the 
PI3K pathway, MAPK is involved in a series of cell behaviour ranging from 
proliferation through to differentiation, apoptosis, migration and cell transformation 
(Huang et al., 2004; Kim and Choi, 2010).  Whereas PI3K is a single line of 
communication, MAPK consists of a series of different pathways that interact with 
one another to bring about their action.   
 
Broadly, they are organised into a three-level system that leads from stimulus brought 
about by ligand-receptor binding and is carried through to a response by a series of 
intermediary kinases (Schaeffer and Weber, 1999; Kim and Choi, 2010).  These 
kinase effectors act upon each other to bring about activation by phosphorylation and, 
tracing upstream to downstream, are usually organised as a MAPK kinase-kinase 
(MAPKKK) that acts on a MAPK kinase (MAPKK) before finally initiating the 
action of a MAPK (Schaeffer and Weber, 1999).  From this point, MAPK can act on 
a series of genes or proteins that bring about the effect of this pathway, as shown by 
Figure 1.5.  MAPK signalling abnormalities have been shown to be present in a 
variety of different human pathological conditions.  This is not simply restricted to 
cancer and includes neurodegenerative lesions such as Parkinson’s and Alzheimer’s 
diseases along with amyotrophic lateral sclerosis (Kim and Choi, 2010).   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As can be assumed thanks to the range of different MAPK networks, different 
pathways respond to different stimuli.  For example, the B-RAF/ERK pathway acts in 
response to growth factors to stimulate proliferation, as opposed to the p38 and JNK 
cascades, which act due to stress to stimulate inflammation, differentiation and 
apoptosis (Schaeffer and Weber, 1999; Weston and Davis, 2007; Feng et al., 2009).  
All of these pathways are capable of inducing cell migration (Huang et al., 2004).   
Since MAPK signalling involves a series of different communication pathways, there 
Figure 1.5: Representation of the MAPK signalling network.  This typically involves the 
action of a MAPKKK, which activates a MAPKK that in turn serves to promote MAPK 
function.  MAPK subsequently target their downstream targets to induce effect.  The 
pathway shown above details the nature of the RAF proliferation pathway, but the can 
involve JNK or p38 mediated cascades.  Adapted from Kim and Choi, 2010.
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are a wide variety of different molecules that act in specific capacities in each of the 
specific tiers of the cascades.  Aberrations in MAPK signalling has been implicated in 
numerous different tumour types, including breast carcinoma where alterations to the 
ERK-1/2 (Growth factor) cascade has been connected to disease progression (Whyte 
et al., 2009), and is also modified in AML (Zebisch et al., 2006). 
 
In cancer, the MAPK network is subject to various influences that can disrupt its 
normal way of functioning.  This can come from changes to external stimuli such as 
up-regulation of receptors or autocrine signalling caused by transformation, 
particularly with the ERK-1/2 path (Kim and Choi, 2010).  Stress and inflammation, 
environments that are common in tumour tissue, may bring changes to the JNK and 
p38 networks (Davis, 2000; Feng et al., 2009).  The role of these latter mediators is 
unusual and open to controversy in tumours.  JNK has been said to be involved in 
tumorigenesis, using evidence from cell lines to promote this idea (Ip and Davis, 
1998; Kennedy and Davis 2003; Weston and Davis, 2007).  There was also belief 
JNK was required for transformation mediated by RAS, however other evidence 
points to possibility of JNK actually suppressing RAS activity (Kennedy and Davis, 
2003).  On the other hand, certain p38 isoforms ( and ) can induce proliferation in 
cells and prevent apoptosis, while the other members ( and ) can promote cell death 
(Feng et al., 2009).  This conflicting data and variation in isoform-specific activity 
means the exact signalling properties of JNK and p38 in cancer remain unclear and 
may depend entirely on the balance of various signalling molecules. 
 
While all of these are changes taking place with molecules that control these 
pathways, significantly molecules that actually participate within them undergo 
manipulation, perhaps most recognisably with RAF.  This is a MAPKKK of three 
isoform members (A-RAF, B-RAF and C-RAF) mediating pro-proliferative 
signalling with the ultimate activation of the MAPK ERK-1/2 via the MAPKK MEK 
(Robinson and Cobb, 1997).  Much like RAS, a molecule that has control over RAF 
activation, RAF is also significantly mutated in tumours.  Though numerous 
mutations to RAF have been found, the most common occurs at position 600 of the 
amino acid chain of B-RAF, where valine is replaced with glutamic acid (RAFV600E) 
(Garnett and Marais, 2004; Nucera et al., 2009).  This mutated protein has a 500 
times greater activity rate, with obvious downstream effects to the RAF-MEK-ERK 
cascade (Wan et al., 2004).  Mutations to B and C-RAF have been shown in 
melanoma, lung, hepatic and colorectal carcinomas (Davies et al., 2002; Yuen et al., 
2002; Garnett and Marais, 2004). 
 
Attempts to tackle mutant RAF have shown limits, much like with RAS.  The kinase 
inhibitor Sorafenib has been used as part of clinical trials and has demonstrated 
promising results both in vitro and in animals (Tuveson et al., 2003; Sharma et al., 
2005).  However, it has yet to have a significant impact in patients, especially in 
melanoma, where B-RAF is the most commonly occurring mutation and is only 
licensed for use against renal cell (RCC) and hepatocellular carcinoma (HCC).  More 
advances have been seen using anti-MEK therapy, but this is only effective in the 
presence of particular RAF mutants.     
 
The knowledge that cancer cell phenotype is inextricably linked to cell 
communication networks and the interactions of the molecules involved means that 
other genes and proteins central to tumours can be investigated with the intention of 
developing therapy against them.  The success of Imatinib and the considerable 
promise of Olaparib also give hope that better understanding of certain cancer-related 
molecules could potentially result in the formulation of successful therapy against 
certain types of malignancy. 
 
1.7 The Cancer/Testis Antigens 
 
Whereas other classes of TAA discussed previously are over-expressed, lineage 
specific or mutated forms of ubiquitous cellular components (van den Eynde and van 
der Bruggen, 1997), their use in cancer therapy, especially immunotherapy, is limited 
because they are expressed by normal cells.  The risk of their inclusion in therapy is 
the destruction of healthy tissue as well as malignant and in the case of immune-based 
treatment, the potential threat of generating auto-immunity.  Conversely, another 
TAA group exists that has the promise of by-passing these issues.  The cancer/testis 
(CT) antigens are unique amongst TAA due to their expression being confined to 
cancerous cells, with very little or no expression found in healthy cells, with the 
exception of normal testis and placenta tissue (Scanlan et al., 2004; Simpson et al., 
2005).  Since these latter tissues lack expression of MHC, they are considered 
immune-privileged sites and cannot be targeted by the body’s immune system (Haas 
et al., 1988; Ribas et al., 2003).  This means that they have a great deal of promise for 
cancer therapy.    
  
1.7.1 Discovery 
 
The existence of CT antigens was initially recognised by van der Bruggen, who along 
with colleagues at the Ludwig Institute (Belgium), used a genetic technique of 
transfecting cDNA from tumour cells into cells that express MHC prior to 
interrogation by patient autologous TIL.  It was this work that led to the advent 
discovery of the melanoma antigen (MAGE) (van der Bruggen et al., 1991).  Since 
many cancers do not readily produce TIL, another technique, serological analysis of 
recombinant cDNA expression libraries (SEREX), came into being (Sahin et al., 
1995; Li et al., 2004).  This requires the existence of humoral immunity against TAA 
within patients.  Antibodies taken from cancer patients can be used to screen cDNA 
libraries to identify particular antigens.  This has been used to successfully identify 
the CT antigen SYCP-1 along with a number of TAA in a range of tumours and has 
even been shown to discover antigens that can be recognised by CD8+ T cells (Old 
and Chen, 1998; Türeci et al., 1998; Kawakami et al., 2004; Miles et al., 2007).  
Another method, representational difference analysis (RDA), which involves the 
comparison of simpler synthetic forms of genomes extracted from cancerous and 
normal tissue panels (Hubanks and Schatz, 1994), has led to the discovery of CT 
antigens including MAGE-C and MAGE-D (Lucas et al., 1998, Lucas et al., 1999). 
 
Collectively, the use of the above techniques has allowed the discovery of over 100 
antigens that are part of 44 separate families.  The vast majority of CT antigens are 
encoded by genes found on the X-chromosome (CT-X antigens), however an 
increasing number of these molecules are being found to be coded for by genes on 
other chromosomes (non-X-linked CT antigens) (Scanlan et al., 2004; Simpson et al., 
2005; Linley et al., 2009).  A list of CT antigens is shown in Table 1.2.  Though a 
large number of these antigens have been shown to exist, very little is known as to 
what function they perform. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.7.2 Involvement of CT Antigens in Cell Biology 
 
All of the molecules described so far have a known function in both a healthy 
environment as well as a malignant one.  CT antigens differ from this in that 
following their discovery, it has yet to be shown what role they have in tumour cells.  
Interestingly, certain non-X-linked antigens have had their function described in 
healthy cells.  For example, Sperm Protein 17 (Sp17) has been proposed to be 
involved in cell migration and adhesion that involves heparin and heparan sulphate 
and may act as a kinase in the binding of sperm with zona pellucida (Frayne and Hall, 
2002, Linley et al., 2010).  Likewise, CDCA-1 along with three other subunits form 
the Ndc80 complex that associates with the kinetochore of chromosomes and may 
stabilise microtubule attachment (Ciferri et al., 2005; Hayama et al., 2006; Linley et 
al., 2010).  Conversely, it is unknown what these antigens do in cancerous cells, 
whether they have the same role as in normal tissue and if so, what purpose they 
serve within a tumour cell.  Due to their expression pattern being confined to normal 
Genetic screen12p13.31CT23OY-TES-1
Genetic screen11q24.2CT22SP17
RDA6q12-q13CT13HAGE
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CTL cloning21p11.1CT2BAGE
Non-X-linked
SEREXXp22.11CT26CAGE
RDAXq26CT7MAGE-C
SEREXXq28CT6NY-ESO-1
CTL cloningXp11.23CT4GAGE
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Table 1.2: Examples of members of the cancer/testis (CT) family of TAA.  Antigens shown are 
listed according to their class (X-linked or non-X-linked), identifier, chromosomal location  and 
the technique used to recognise them in malignancies.
testis and placenta, it has previously been proposed these antigens may be involved in 
embryogenesis (Lucas et al., 1998).   
 
1.7.3 Progress in CT Antigen Therapy 
 
The discovery of MAGE by van der Bruggen and colleagues led to a resurgence in 
interest in cancer immunotherapy due to promise that CT antigens have with regards 
to this type of treatment.  Thanks to this, large numbers of different members of this 
class of TAA were found and treatments were designed against them, with emphasis 
placed firmly in the realm of tumour vaccination.  Virtually every known type of 
vaccination strategy has been employed against a wide variety of CT antigens (Ribas 
et al., 2003).  It could be argued that the development of these vaccines has 
significantly increased our knowledge as to how immunotherapy functions in the 
body.   
 
Certain CT antigens have been shown to be highly immunogenic and some of the 
therapies designed against them are highly effective against tumour cells expressing 
them both in vitro and within murine models.  This has been seen most prominently 
with the CT-X antigens MAGE and NY-ESO-1 (Marchand et al., 1999; Jäger et al., 
2000) and is becoming evident with the non-X-linked antigen Sp17 (Chiriva-Internati 
et al., 2002a; Chiriva-Internati et al., 2002b; Chiriva-Internati et al., 2003; Linley et 
al., 2009).  For this promise, some antigens have proceeded to clinical trial or, in the 
case of Sp17, are part of pre-clinical testing (Dadabeyev et al., 2005; 
www.clinicaltrials.gov).  
 
Specifically, Thierry Boon and colleagues from the Ludwig Institute (Belgium) have 
placed a large amount of focus attempting to use immunotherapy to target the 
immunogenic antigen MAGE in various tumours.  They employed peptide injection, 
peptide-pulsed DC, adjuvant therapy or viral vectors that code for the target antigen 
(Marchand et al., 1999; Marchand et al., 2003; van Baren et al., 2005; Carrasco et al., 
2008).  These vaccines have been able to induce tumour regression and this was 
strongly linked with anti-tumour immunity.  However, while tumour shrinkage was 
possible, the extent of complete or partial regression in the cohorts tested was low.  
This perhaps reflects on the issues with other immunotherapeutic techniques and 
concepts of immunity discussed earlier.   
 
To date however, clinical trials have displayed very limited impact within patients or 
are at such an early stage, it is difficult to estimate if they will be successful.  This 
means that despite having such a significant level of potential, using CT antigens as a 
target for therapy has not fulfilled this.  In part, this could be due to the fact that 
cancer is such a multifaceted disease and the immune system so complex, that the use 
of CT antigens for therapy remains a distant prospect. 
 
1.8 The Helicase Antigen (HAGE) and the Rationale for this Project 
 
1.8.1 HAGE 
 
As has been described so far, following the identification of MAGE, large numbers of 
CT antigens were isolated using a variety of techniques.  One such example of this is 
the helicase antigen (HAGE).  This was initially identified by Martelange and co-
workers along with the CT-X antigen SAGE (Sarcoma antigen) using RDA of a 
rhabdomyosarcoma cell line (Martelange et al., 2000).  HAGE, itself, is a non-X-
linked CT antigen (CT13) encoded by a gene located at chromosome 6q12-q13, 
which produces a putative protein of 648 amino acids.  This contains the sequence 
motif D (Asp), E (Glu), A (Ala), D (Glu) that is homologous to the DEAD-box family 
of ATP-dependant RNA helicases where HAGE is denoted DDX43 (Linder, 2006).  
The structure of HAGE is shown in Figure 1.6. 
 
DEAD-box proteins belong to a super-family of RNA helicases, which include the 
DEHD-box and Ski families, collectively termed the DExD/H-box family.  The 
function of RNA helicases centres around the unwinding of double stranded RNA, 
which can occur in cells in particular circumstances (Du et al., 2002; Linder, 2006; 
Marsden et al., 2006). They are believed to have a variety of roles in the metabolism 
of RNA, ranging from the splicing of mRNA, nuclear export, ribosome biogenesis, 
initiation of translation, RNA decay and interference (Silerman et al., 2003; Rocak 
and Linder, 2004; Cordin et al., 2006; Fuller-Pace, 2006; Linder, 2006).  Though 
different members of the DEAD-box family have had some of these functions 
assigned to them, it is unknown if a single member may have multiple different 
functions.  However, due to the nature of these functions and examples of this family, 
including translational initiators such as eIF4a/b, it could be speculated that they have 
some role in cellular proliferation (Linder, 2006).     
 
Different DEAD-box proteins have been implicated in cancer.  Notable examples 
include p68 (DDX5), which is over-expressed in both colorectal and prostate 
carcinomas (Causevic et al., 2001; Clark et al., 2008).  Since this has been linked to 
splicing of H-RAS, there is indeed a potential link with tumours (Liu, 2002; Guil et 
al., 2003; Camats et al., 2008).  Other examples include p54/RCK, which like p68 has 
been associated with colorectal carcinoma, where there may be some link with c-myc 
(Nakagawa et al., 1999; Hashimoto et al., 2001), but has been additionally found in a 
B-cell lymphoma cell line (Akao et al., 1995).  The cancer-associated antigen 
(CAGE/DDX53) is also a CT antigen that has been found in different tumour types 
(Cho et al., 2002; Iwata et al., 2005; Shim et al., 2006). 
 
Work into HAGE has predominantly concentrated on its mRNA expression in 
different cancers and a large amount of focus has been placed on expression in 
haematological tumours.  HAGE is expressed in both CML and AML cell lines and 
patient material (Adams et al., 2002; Roman-Gomez et al., 2007).  Specifically for 
CML, mRNA expression of HAGE has been found in more than 50% of CP-patients 
and over 70% of BC-patients.  Work performed by Roman-Gomez et al. (2007) 
indicated that as patients progress from chronic phase to blast crisis, there is 
significant hypomethylation of the HAGE gene promoter, meaning that its expression 
increases dramatically.  This notion would seem to agree with the work of Adams et 
al. (2002), suggesting that HAGE expression could be associated with more 
aggressive disease.  Such an idea has been previously alluded to in a review 
demonstrating a relationship between BCR-ABL and HAGE expression in patients 
who failed to respond to Imatinib (Riley et al., 2009).  Microarray analysis has found 
HAGE to be expressed in cells of patients with both MM and monoclonal 
gammopathy of unknown significance (MGUS) (Condomines et al., 2007).  This 
indicates that the gene is expressed by malignant lymphocytes as well as myeloid 
cells, though it is yet to be shown if HAGE is present in both chronic lymphocytic 
leukaemia (CLL) and ALL.  Aside from blood-borne cancers, it has been shown that 
HAGE gene expression is evident within both malignant and benign tumours of the 
salivary glands (Nagel et al., 2003).   
 
Though some work has been carried out into detecting HAGE expression, it has only 
focused on its mRNA expression.  This laboratory was the first to describe evidence 
that HAGE is actually translated within tumour cells.  It has been possible to 
demonstrate HAGE protein expression in both cell lines and patient material taken 
from an assortment of different tumour types (Mathieu et al., 2010).  Other work has 
identified that HAGE can act as a target for immunotherapy.  In the first instance 
immunogenic class I and II peptides derived from the protein were identified, which 
have been shown to be processed by immune cells and could therefore presented to T 
cells (Mathieu et al., 2007).  Secondly, the use of HAGE cDNA as part of therapeutic 
gene gun vaccination approach was able to bring about significant reduction in 
growth of a lymphoma cell line within an in vivo murine tumour model, thus 
indicating that HAGE has the potential to be utilised in this setting (Riley et al., 
2009).   
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Figure 1.6: Representation of the protein structure of the CT antigen and DEAD-box 
protein HAGE.  Each of the sequence motifs found in members of the DEAD-box family 
are indicated, with the homologous DEAD region highlighted (Red ring).  Regions which 
interact with ATP, needed for protein function and substrate (Double stranded RNA) are 
additionally noted.  Adapted from Rocak and Linder, 2004.
1.8.2 Rationale of this Study 
 
One of the major criticisms that could be levelled at the use of immunotherapy 
against CT antigens, is that relatively little progress has been made, especially if one 
considers the significant amount of investment placed in its research in terms of time, 
cost and effort.  This may well be as a result of the lack of knowledge into the exact 
role these molecules might have within tumour cells and the inability of current 
assays to predict patient response.  A comparison could be drawn with Olaparaib, 
which as a result of the in-depth knowledge of PARP-1 action in DNA repair, has 
made fast progress from basic research into Phase II clinical trial.  On the other hand, 
since discovery in 1991, no FDA approved drug against CT antigens is in use.  One 
may argue that better understanding of a specific molecule’s involvement in cancer 
may improve the design of therapy targeted against it. 
 
The establishment that HAGE exists as a protein and is both a CT antigen and a 
DEAD-box protein implies that it has a potential role in cancerous cells, possibly 
associated with cell proliferation.  If it were possible to discern what function this 
antigen has in cells, or identifying the processes it might be involved in, there is the 
potential to design and formulate a drug for use against HAGE-expressing cancers.  It 
could even be possible to redeploy currently existing therapy if this knowledge were 
to be attained.  Therefore, this study aims to use molecular screening and functional 
techniques to determine the possible role of HAGE in malignancy.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 2  
Materials and Methods 
2.1 Laboratory Consumables and Equipment 
 
2.1.1 Reagents used and list of producers 
All reagents were stored according to the manufacturer’s instructions and used within 
their expiry date. 
 
Culture Media       Supplier 
RPMI 1640       Lonza 
Reduced serum Opti-MEM (With L-glutamine  Invitrogen  
and HEPES) 
 
Culture Media Supplements     Supplier 
Foetal calf serum (FCS)      Bio Whittaker Europe 
L-glutamine        Lonza 
Geneticin (G418)      Promega 
 
Other Cell Culture Materials     Supplier 
Dimethyl sulfoxide (DMSO)     Sigma 
Dulbecco’s phosphate buffered saline (DPBS)   Lonza 
Trypan blue stain      Sigma 
Trypsin/Versene       Lonza 
 
Chemical Reagents      Supplier 
Acrylamide        Geneflow 
Ammonium persulphate (APS)     Geneflow 
Bovine serum albumin (BSA)     Sigma 
Chloroform       Sigma 
Deoxycholate       Sigma 
DilC12(3) fluorescent dye     SLS 
Dithiothreitol (DTT)      Sigma 
dNTP        Bioline 
Ethanol        BDH 
Ethyldiamine tetraacetic acid (EDTA)    Sigma 
Glycerol        Sigma 
Hydrochloric acid (HCl)     Fisher Scientific 
INTERFERin transfection reagent    Polyplus Transfection 
Isopropanol       Fisher Scientific 
Lipofectamine 2000      Invitrogen 
Marvel milk powder      Premier Brands 
Methanol       Fisher Scientific 
Microscint-O scintillation media    Perkin-Elmer 
PBS tablets       Sigma 
Phenol/chloroform/isomyl alcohol    Sigma 
Potassium acetate (KOAc)     Sigma 
RapidStep ECL Reagent      Calbiochem 
RNA-STAT-60       AMS Biotechnology 
Sodium azide (NaN3)      Sigma 
Sodium chloride (NaCl)      Fisher Scientific/ Sigma 
Sodium dodecyl sulphate (SDS)    Sigma 
Sodium fluoride       Sigma 
Sodium orthovanadate      Sigma 
Stacking gel buffer for SDS gels     Geneflow 
SYBR Green Supermix      BioRad  
TEMED        Geneflow  
Tris-base       Melford/Sigma 
Tween-20       Sigma 
Western-C Precision Plus molecular weight marker  BioRad 
 
Immunochemical Reagents     Supplier 
 
Mouse anti-human DDX43 (HAGE) monoclonal antibody Santa Cruz/Sigma     
Mouse anti-human FAK monoclonal antibody   Santa Cruz 
Mouse anti-human FAS-ligand (CD178) antibody  Sigma 
Mouse anti-human MMP-9 monoclonal antibody  Santa Cruz 
Mouse anti-human N-RAS monoclonal antibody  Sigma 
Mouse anti-human p21CIP1 monoclonal antibody  AbCam 
Mouse anti-human TIMP-4 monoclonal antibody  Santa Cruz 
Rabbit anti-human polyclonal HAGE antibody  Pacific Immunology 
Rabbit anti-human phospho-AKT (Ser 473) antibody Cell Signalling 
Technology 
Rabbit anti-human total AKT antibody Cell Signalling 
Technology 
Rabbit anti-human -actin antibody Cell Signalling 
Technology 
Rabbit anti-human phospho-GSK-3 (Ser9) antibody Cell Signalling 
Technology 
Rabbit anti-human total GSK-3 antibody Cell Signalling 
Technology 
Mouse IgG isotype negative control antibody   ABD Serotec 
Rabbit IgG isotype negative control antibody   Pierce Biotechnology 
Alexa-Fluor 448 fluorescent secondary antibody  Santa Cruz 
Alexa-Fluor 558 fluorescent secondary antibody  Santa Cruz 
Goat anti-mouse-HRP secondary antibody   Dako 
Steptavidin-HRP secondary antibody    BioRad 
Swine anti-rabbit-HRP secondary antibody   Dako 
 
Plasmids       Supplier 
 
pBudCE 4.1, pcDNA3.1      Invitrogen 
HAGE shRNA and negative control shRNA plasmids  S.A. Biosciences 
 
Small Inhibitory RNA (siRNA) Molecules   Supplier 
 
HAGE, H-RAS, K-RAS, N-RAS, negative control  EuroGentec 
 
 
 
 
Kits        Supplier 
Reverse Transcription: 
M-MLV reverse transcription kit    Promega 
 
Total Protein Assay: 
Total protein assay kit      BioRad 
 
Phospho-protein evaluation: 
Proteome Profiler MAPK array kit    R&D Systems 
 
Active Ras (Ras-GTP) detection: 
Active Ras Pull Down and Detection kit   Thermo 
 
RNA Extraction: 
RNA extraction kit      Ambion 
 
Caspase detection:  
Caspase-Glo 3/7 Assay      Promega 
 
Cell Invasion: 
Biocoat Matrigel Invasion System plate (8m pore)  BD 
Falcon FluoroBlok 24-Multiwell Insert System (8m pore) BD   
 
Apoptosis: 
Annexin/7-AAD staining kit for apoptosis detection  Beckman-Coulter 
 
2.1.2 Equipment 
Glassware 
 
Pyrex glassware was used.  All items were washed in dilute presept/ teepol and then 
rinsed twice in distilled water and autoclaved prior to use. 
 
 
Disposable equipment and plasticware   Supplier 
Bijou tubes (7ml)      Sterilin 
Coverslips       SLS 
Cryovials (1.5ml)      TPP 
Eppendorf tubes (0.5ml/1.5ml)     Sarstedt 
FACS tubes       Elkay 
Flat-bottom culture dishes (6 well/ 24 well)   Sarstedt 
Filter tips (20l/200l/1000l) Sarstedt/ Deuchter 
Scientific 
Hybond-P PVDF western blot membrane   G.E. Healthcare 
Pasteur pipettes       Sarstedt 
96-well round-bottom culture plates    Sarstedt 
Real-time qPCR tubes      Qiagen 
Scalpels        Swann Morton 
Scrapers        TPP 
Screw top tubes       Sarstedt 
Serological pipettes      Sarstedt 
Tips (20l/200l/1000l)     Sarstedt 
T25/T75/T175cm3 culture flasks    Sarstedt 
Unifilter 96-well filter plates     Perkin-Elmer 
20ml Universal tubes      Sterilin 
Western blot filter paper     Schleicher-Schwell 
0.2m filters       Sartorious  
 
 
Equipment       Supplier 
2100 Bioanalyser      Agilent Technologies 
Biofuge Pico 4oC micro-centrifuge    Heraeus 
CCD Camera       Fuji Systems 
4oC refrigerated centrifuge     Eppendorf 
Class II safety cabinet      Walker 
Confocal microscope      Leica 
Cryostat        Leica 
Cryostore       Forma Scientific 
Drying cabinet       SLS 
Electrophoresis gel tanks     Geneflow 
-80oC Freezer       Thermo Scientific 
Combined 4oC fridge/-20oC freezer    Premier 
Gallios flow cytometer      Beckman-Coulter 
PALM Laser-capture microdissector (LCM)   Carl Zeiss 
Microscope       Nikon 
Microwave       Matsui 
Mini-orbital shaker      Stuart 
Nanodrop 8000 spectrophotometer    Thermo Scientific 
pH meter       Mettler Toledo 
Plate reader       BioRad and Tecan 
Plate rocker       VWR 
96-well plate harvester      Packard 
PCR workstation cabinet     Grant-Bio 
Power packs       BioRad 
Real-time qPCR thermal cycler     Qiagen 
Sealing film       Bando Chemicals 
Transfer apparatus      Geneflow 
37oC/5%CO2 incubators     Forma Scientific 
Top count scintillation counter     Packard 
UNO-thermoblock      Biometra 
Vortex mixer       Scientific Industries 
Water baths       Grant 
 
 
 
 
 
 
 
 
 
2.1.3 Buffers 
Buffers used for cell culture: 
 
Trypan Blue for cell counts: 
0.1% (v/v) solution Trypan Blue in DPBS. 
 
Buffers used for western blot analysis: 
 
1X 10% Resolving SDS gel:   1X 15% Resolving SDS gel: 
1900l ddH2O     1100l ddH2O 
1700l Acrylamide    2500l Acrylamide 
1300l 1.5M Tris-HCl (pH 8.8)  1300l 1.5M Tris-HCl (pH 8.8) 
50l 10% (w/v) SDS    50l 10% (w/v) SDS 
50l 10% (w/v) APS    50l 10% (w/v) APS 
2l TEMED     2l TEMED 
 
1X 5% Stacking SDS gel:   Reducing sample buffer: 
 
1400l ddH2O     0.5M Tris-HCl (pH 6.8) 
330l Acrylamide    2% (w/v) SDS 
250l 1M Tris-HCL (pH 6.8)   10% (v/v) Glycerol 
20l 10% (w/v) SDS    1% DTT 
ddH2O to final volume  
Tris buffered saline+ Tween-20 (TBST): TBST+ Marvel blocking buffer: 
 
1.21g Tris base     100ml TBST 
22.33g NaCl     10% (w/v) Marvel milk powder 
pH made to 7.5 with HCl 
100mM sodium orthovanadate 
100mM sodium fluoride 
0.05% Tween-20 
 
5X SDS gel running buffer:   SDS gel transfer buffer: 
 
15.1g Tris-base     5.8g Tris-base 
94g Glycine     2.9g Glycine   
50ml 10% (w/v) SDS    0.37g SDS 
1L ddH2O     200ml Methanol 
Made to 1x for each use using ddH2O  800ml ddH2O 
 
Buffers used for flow cytometry (FACS) analysis: 
 
Fixation solution:    Permeablisation solution: 
1% (v/v) paraformaldehyde in DPBS  70% (v/v) Ethanol in DPBS 
 
FACS buffer: 
0.1% (w/v) BSA 
0.02% (w/v) NaN3 
1xDPBS 
 
Buffers used for immunohistochemistry: 
 
Primary antibody:    Secondary antibody: 
100g/ml rabbit anti-HAGE antibody  10g/ml goat anti-rabbit IgG-biotin 
5% (v/v) goat serum     1.5% (v/v) goat serum 
Made to final volume using PBS  Made to final volume using PBS 
ABC Reagent:     DAB Reagent: 
2.5ml PBS     2.5ml DDH2O 
1 drop Reagent A    1 drop buffer 
1 drop Reagent B    2 drops DAB 
       1 drop H2O2 
 
 
 
 
Buffers for Immunofluorescence 
PBST      Blocking solution 
1L ddH2O     1X PBST  
Buffered to pH 7.2 using PBS tablets  10% (w/v) BSA 
0.1% (v/v) Tween-20 
 
Buffers for LCM section staining 
Ethanol solutions     Cresyl Violet 
Diluted to strength using molecular  1% (w/v) solution in 50% (v/v) ethanol 
grade water.     Filtered before use 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1.4 Cell Lines and Growth Conditions 
All cells were grown cultured in incubators supplying a 37oC/5%CO2 atmosphere 
 
Table 2.1: List of tumour cell lines used in this study, describing their tumour 
histology, growth conditions as well as their source supplier 
 
 
 
Cell Line Description Media Source 
FM-3 Human melanoma 
RPMI 1640+10% (v/v) 
FCS+2mM L-glutamine 
Prof. D Schadendorff 
(Tuebingen University)
FM-6 Human melanoma 
RPMI 1640+10% (v/v) 
FCS+2mM L-glutamine 
Prof. D Schadendorff 
(Tuebingen University)
FM-82 Human melanoma 
RPMI 1640+10% (v/v) 
FCS+2mM L-glutamine 
Prof. D Schadendorff 
(Tuebingen University)
FM-3/-ve 
Human melanoma 
transfected with 
pcDNA3.1/-ve plasmid 
RPMI 1640+10% (v/v) 
FCS+2mM L-
glutamine+500g/ml G418 
Nottingham Trent 
University 
FM-3/HAGE 
Human melanoma 
transfected with 
pcDNA3.1/HAGE plasmid
RPMI 1640+10% (v/v) 
FCS+2mM L-
glutamine+500g/ml G418 
Nottingham Trent 
University 
FM-82/Ctrl 
Human melanoma 
transfected with control 
shRNA plasmid 
RPMI 1640+10% (v/v) 
FCS+2mM L-
glutamine+500g/ml G418 
Nottingham Trent 
University 
FM-82/ 
shRNA 
Human melanoma 
transfected with HAGE 
shRNA plasmid 
RPMI 1640+10% (v/v) 
FCS+2mM L-
glutamine+500g/ml G418 
Nottingham Trent 
University 
Jurkat Human T cell lymphoma 
RPMI 1640+10% (v/v) 
FCS+2mM L-glutamine 
ATCC 
PCI-13 
Human head and neck 
carcinoma 
RPMI 1640+10% (v/v) 
FCS+2mM L-glutamine 
Prof. E Tatour (Hôpital 
Européen George 
Pompidou) 
2.2 Methods and Procedures 
 
2.2.1 Examination of HAGE in Tumour Proliferation 
 
2.2.1.1 Transient HAGE cDNA Transfection to Induce HAGE Gene Expression 
Induction of HAGE gene expression was done transiently by transfecting the HAGE-
negative human melanoma cell line FM-3 with the pBud CE4.1/HAGE cDNA 
plasmid or control plasmid using Lipofectamine 2000 reagent.  Briefly, cells were 
plated in the wells of an 8 well chamber slide (for immune-staining) or a T25 flask 
(for RNA extraction and real-time qPCR) and allowed to grow normally overnight.  
The following day, cells underwent transfection.  In one tube, Opti-MEM media was 
combined with the plasmid.  In a separate tube, the same amount of Opti-MEM media 
was used to dilute Lipofectamine 2000 transfectant reagent. These tubes were agitated 
using a vortex mixer and allowed to incubate for five minutes at room temperature 
(RT).  Following this, the contents of both tubes were combined, mixed using a 
vortex and allowed to stand at RT for 20 minutes.  During this time, media was 
removed from the cells and replaced with RMPI 1640 media.  Following incubation, 
transfection mixtures were applied to all relevant cells.  To ensure even coverage of 
all cells, after incubation, plates/ flasks were agitated using a rocking platform while 
all materials were applied and plates were allowed to rock for five minutes post 
application. 
 
2.2.1.2 Transfection of Small Inhibitory RNA (siRNA) to Bring about Transient 
RNA Interference 
 
Transient silencing of HAGE and RAS members via RNA interference (RNAi) was 
brought about using a siRNA molecule that was specific for each gene, the sequences 
of which are shown in Table 2.2.  To transfect this material into the cells, 
INTERFERin transfection material (Polyplus) was used.  Briefly, cells were grown 
overnight in either 24-well plates or T25cm3 flasks.  Reagent mixtures were then 
made in Opti-MEM media.  40M of siRNA or a negative control siRNA was diluted 
into this media and placed briefly on a vortex mixer.  INTERFERin reagent was then 
added in a certain volume and vortex mixed again.  For in vitro proliferation studies, 
some cells were treated with Opti-MEM media laced with INTERFERin only or 
simply Opti-MEM media alone, to create further negative controls.  In all cases, these 
latter two control measures were prepared at the same time as those involving siRNA, 
only omitting inclusion of said molecule.  All reagents were added to appropriate 
cells while vessels were agitated on a rocking platform to ensure transfection and 
plates were allowed to rock for a further five minutes. 
 
Table 2.2: Sequences of sense and anti-sense strands of siRNA molecules used to     
knockdown expression of genes in specific cell lines. 
Gene siRNA Strand Sequence 
Sense 5΄ AUUAGAGAGGAAGGUUUGA 3΄ 
HAGE 
Anti-sense 5΄ UCAAACCUUUCCUCUCUAAU 3΄ 
Sense 5΄ CGUGAGAUCCGGCAGCACATT 3΄ 
H-RAS 
Anti-sense 5΄ UGUGCUGCCGGAUCUCACGTT 3΄ 
Sense 5΄ UCAAAGACAAAGUGUGUAATT 3΄ 
K-RAS 
Anti-sense 5΄ UUACACACUUUGUCUUUGATT 3΄ 
Sense 5΄ CAGCAGUGAUGAUGGGACUTT 3΄ 
N-RAS 
Anti-sense 5΄ AGUCCCAUCAUCACUGCUGTT 3΄ 
 
2.2.1.3 Generation of Human Melanoma Cells Stably Transfected with HAGE 
cDNA or shRNA 
 
To investigate the effect of induced expression/silencing of the HAGE gene over 
prolonged periods of time, it was necessary to create stable transfectant cell lines.  For 
stable cDNA transfection, the cell line FM-3, normally negative for HAGE 
expression was used, while the FM-82 cell line, which demonstrates high HAGE gene 
expression was utilised to induce stable knockdown. Both cell lines were grown 
overnight in eight wells each of two 24 well plates.  The following day, the cells of 
one plate were transfected using the gene-specific plasmid, with the other plate being 
treated with the control.  For the generation of a stable cell line with induced HAGE 
expression, the pcDNA.3.1/HAGE plasmid was employed, while the other was 
treated with the pcDNA.3.1/-ve plasmid, thus producing a negative control cell line.  
To create a cell line with stable knockdown of HAGE, one plate of FM-82 cells was 
treated with a HAGE-specific shRNA, while the other underwent treatment with the 
negative control plasmid.    
 
In both cases, cells underwent transfection using Lipofectamine 2000 reagent in the 
same manner as with the transient transfection of the pBud CE4.1 plasmid described 
above.  In this instance, the amount of media used was enough to ensure that there 
was 100l/well and enough plasmid for 1.2g/well. In the second tube, the same 
amount of Opti-MEM media was used to dilute Lipofectamine 2000 transfectant 
reagent for 2l/well.  During plasmid/Lipofectamine incubation, plated cells had their 
growth media removed and this was replaced with 500l/well of fresh complete 
RPMI 1640 media.    
 
48 hours following transfection, media was removed from all wells and cells were 
washed using DPBS before undergoing trypsinisation to remove them from the plate 
wells.  All of the cells were pooled into a tube containing complete RPMI media, 
therefore providing two tubes, which were then centrifuged to wash each cell line.  
Supernatant was discarded before cells were resuspended in complete RPMI media 
containing 500g/ml G418 selective antibiotic and transferred to flasks and allowed 
to grow.  Since all the plasmids used contain an antibiotic resistance gene, addition of 
G418 would potentially allow all cells that expressed the plasmid to continue 
growing, while eliminating all those that did not.  This way it was possible to 
maximise the number of transfected cells.  Cells were cultured for four passages prior 
to RNA extraction and real-time qPCR confirmation that HAGE was expressed by 
cells transfected with the HAGE containing plasmid and not those transfected with 
the empty vector.  This process of passaging and examination of HAGE gene 
expression was continued until 10 passages had been completed since initial 
transfection.         
 
2.2.1.4 Tritiated thymidine (3H) Incorporation Proliferation Assay 
 
To examine effect of HAGE expression on cell proliferation, FM-3, FM-6 and FM-82 
were grown and treated in 24-well plates as described above.  Stable transfectants 
were grown in 24-well plates as per normal growth conditions.  Proliferation readings 
were taken at three and seven days post plating/treatment for all cells except FM-3/-
ve and FM-3/HAGE, which due to extremely fast growth had to have the 
measurement times optimised to four and six days post plating.  In all cases, the day 
prior to measurement, cells had their media removed and replaced with media that 
had been laced with 3H.  Each well was treated with 200l of cell culture media 
containing 2l 3H and plates were incubated overnight at 37oC/5% CO2.  The day 
following 3H treatment, plates were removed from incubation and the media was 
extracted from all wells using a pipette.  Each well of the 24-well plate was then 
washed with 200l of ddH20 to allow cell lysis and release the incorporated 3H before 
this water was transferred to the well of a 96-well round bottom culture plate.  This 
process was repeated for all wells to be tested.  The contents of the plate were 
subsequently harvested onto a Unifilter 96-well plate using a Filtermate Harvester, 
which was allowed to dry using a drying cabinet.  Each test well was filled with 40l 
of Microscint-O media that would allow the 3H to be read.  Plate reading was carried 
out using a Top-Count NXT microplate scintillation counter.  
 
2.2.1.5 Examination into the in vivo Growth of HAGE stable transfectants 
To check extent of growth of HAGE-positive tumours in vivo, a malignant growth 
model was established.  Non obese diabetic/severe combined immunodeficiency 
(NOD/SCID) mice were acquired (Harlan Laboratories, U.K) and kept in accordance 
with U.K Home Office regulations.  Mice were kept in IVC cages supplied with 
laminar air flow along with autoclaved food and water taken ad libitum.  All work 
with these mice was performed in sterile conditions within a laminar flow hood.  Two 
sets of studies were carried out, the first comparing FM-3/-ve with FM-3/HAGE 
while the second involved a comparison between FM-82/Ctrl and FM-82/shRNA.  In 
both studies, two groups of mice were utilised, each being injected with one of the 
specific cell lines.  In all cases, mice were injected sub-cutaneously (s.c) into the right 
flank.  1x106 cells/100l were injected per mouse.  Tumour development was 
observed twice weekly using calliper measurement.  When required, mice were 
euthanised prior to tumours being excised, placed on cork boards, coated in OCT 
mounting media and snap frozen in liquid nitrogen-cooled isopentane and stored at-
80oC.  
Tumours were sectioned using a cryostat to produce 8m thick sections that were 
placed on sialinised microscope slides.  These were permeabilised using 4% (w/v) 
paraformaldehyde at RT for 10 minutes, washed in PBS, then fixed in 70% (v/v) 
ethanol for 10 minutes at RT, before a final PBS wash.  Slides were then placed in 
storage at -80oC. 
 
2.2.1.6 Detection of HAGE Protein in Human Melanoma Cell Lines Using 
Immunofluorescence Dual Staining. 
 
For examination of protein expression in cell lines, methanol washed coverslips were 
placed in to the wells of a flat-bottomed 24-well plate.  Cells were counted and 
diluted accordingly before cells were plated into wells at 5x104 cells/well and allowed 
to grow for 48 hours.  For staining, media was removed and cells were washed in 
PBST for 10 minutes.  Following washes, 4% paraformaldehyde was applied for one 
hour at RT to fix cells, after which cells were washed using PBST.  PBST was 
removed and replaced with 200l of blocking solution applied for two hours at RT 
while the plate was moving on a rocking platform.  Once the blocking period had 
ended, primary antibodies from different host species for proteins of interest or 
isotype controls were added to the blocking solution in relevant wells.  The plate was 
placed on a rocking platform and staining took place overnight at 4oC.   
The following day, blocking solution was removed and cells underwent three separate 
washes with PBST.  A cocktail of Alexa-Fluor 468 (Green) and 568 (Red) fluorescent 
secondary antibodies were diluted in blocking media and once the final wash had 
been completed, 200l of this was added to all relevant wells.  The plate was covered 
in foil to retain signal and placed on a rocking platform for one hour at RT after 
which cells were washed as above.  To individual microscope slides, a small amount 
of Vectashield containing DAPI stain was added.  The coverslips bearing the stained 
cells were then removed, inverted and placed coverslip face up on the slides.  These 
were viewed using a fluorescence microscope.   
 
2.2.1.7 Immunofluorescent Staining of Murine Tumours. 
Slides were removed from -80oC storage and treated with a 1-3% (v/v) H2O2 solution 
for 15 minutes at RT.  Slides were rinsed in PBS and placed in a PBS bath for five 
minutes to fully remove the prior reagents.  Dual immune staining was then 
performed.  In brief; a solution of 5% (w/v) human serum in PBS was applied to 
slides to act for 30 minutes at RT and washed in PBS.  Primary antibodies were 
diluted in a solution of PBS with 10% BSA and 0.1% (v/v) Tween-20.  The primary 
antibodies used were raised in two separate species (i.e. Rabbit and mouse) to ensure 
distinct separate staining.  This mixture was placed onto slides and allowed to act at 
RT for two hours.  Slides were rinsed with PBS before being placed in a PBS/0.1% 
(v/v) Tween-20 bath for five minutes.  This was repeated to ensure complete washing.  
Secondary antibodies specific to the primaries, were prepared in the same manner as 
the primary, applied to slides for 30 minutes at RT.  Slides were rinsed and washed as 
above ahead of slides being mounted using Vectashield+DAPI and a coverslip.   
Slides were incubated at 4oC overnight and the following day, were examined using a 
fluorescence microscope.   
 
2.2.1.8 Immunohistochemistry of Murine Tumours 
Slides were removed from -80oC storage and 0.03% (v/v) H2O2 diluted in 1X PBS 
was added to the tissue sections for five minutes before being washed with PBS. 
Sections were then blocked for 10 minutes with 10% (v/v) serum made from the 
species of the secondary antibody. In the case of HAGE, goat serum was used. 
Following incubation, the serum was removed and 100g/ml of the primary antibody, 
a mono-specific polyclonal antibody was added for overnight incubation at 4°C. 
Slides were then washed in 1X PBS and 10g/ml of the secondary antibody (biotin-
conjugated goat anti-rabbit IgG) was added. Slides were incubated for 30 minutes at 
RT and washed thoroughly with 1X PBS. The ABC reagent was laid onto the slides, 
left to react with secondary antibodies for 30 minutes at RT and washed off with PBS. 
The DAB reagent was added to the sections in order to react with the ABC reagent 
for 10 minutes at RT and washed off with ddH2O. Finally, frozen and paraffin-
embedded sections were counterstained in Gill’s and Harris’ staining, respectively, 
and fixed consecutively in graded ethanol (70%, 100%, 100% (v/v)) and in xylene. 
Slides were mounted, air-dried and observed under the microscope.  
 
 
 
2.2.1.9 PALM LCM and RNA Extraction of NOD/SCID Tumours 
 
PALM membrane slides were exposed to U.V. light in a sterile hood for 15 minutes 
to improve adherence of tissue.  NOD/SCID tumours were sectioned using a cryostat 
in the same manner as sections used for IHC.  Slides were placed on dry ice and 
stored at -80oC.  For fixation and staining, slides were treated in molecular grade 
solvents.  They were placed in 95% (v/v) ethanol for 40 seconds, 75% (v/v) ethanol 
for 30 seconds and 50% (v/v) ethanol for 30 seconds while agitating the slide on the 
final wash to remove OCT media.  300l filtered cresyl violet stain was added to each 
slide to inhibit the action of any RNase molecules present.  Slides were drained, 
placed in 50% (v/v) ethanol for 30 seconds, 75% (v/v) ethanol for 30 seconds, 95% 
(v/v) ethanol for 40 seconds before two separate washes in 100% (v/v) ethanol for 40 
seconds.  Slides were then rinsed xylene and then bathed in this solvent for five 
minutes.   
 
After fixation and staining was complete, LCM was performed immediately to 
maintain specimen quality.  Section was done using a PALM LCM instrument, using 
onboard software to isolate approximately 500 cells.  Cut sections were captured into 
the caps of LCM tubes and immediately 100l RNA lysis buffer was placed into the 
tube.  Tubes were sealed, vortex mixed and placed in storage at -20oC. 
RNA extraction of these sections was done using an RNAqueous Micro extraction kit 
as according to the manufacturer’s protocol, specifically the protocol for extraction of 
tissue taken by LCM.  The manufacturer’s advice for DNAse treatment was also 
adhered to.      
 
2.2.1.10 Cell Cycle Analysis 
 
Cells were starved overnight in serum free media to bring about synchronisation of 
their cell cycle.  The following day, cells were harvested and washed in FACS buffer.  
They were subsequently fixed using ice cold 70% (v/v) ethanol mixed using a vortex 
and incubated at 4oC for 30 minutes.  After this cells were pelleted by centrifugation 
at 2,000 rpm for five minutes ahead of two washes using FACS buffer.  50l of a 
100g/ml RNAase solution was applied to degrade RNA in the cells, followed by 
50l of a 25l/ml 7-AAD solution to stain DNA. Cells were analysed using a Gallios 
flow cytometer, collecting 25,000 events for each sample tested.  The percentage of 
cells in each phase of the cell cycle was determined using Kaluza® software 
(Beckman- Coulter).  
 
2.2.2 Examination of the Genetic Interactions of HAGE 
 
2.2.2.1 Extraction of RNA Using RNA-STAT-60  
 
Cells were grown as already stated and had their culture media removed before being 
carefully washed using DPBS.  Following the removal of DPBS, RNA-STAT- 60 was 
applied in either 500l (For 24-well plates and T25cm3 flasks) or 1ml (For T75cm3 
flasks) quantities.  The extraction of material was carried out as according to the 
manufacturer’s protocol.  RNA pellets retrieved from 24-well plates and T25cm3 
flasks were re-suspended in 10l ddH2O or in 20l ddH2O if the sample pellets came 
from cells grown in a T75cm3 flask.   
 
Quantity of RNA extracted was tested using a Nanodrop 8000 U.V. 
spectrophotometer after the instruments had been calibrated using a ddH2O blank.  
This allowed readings to be taken at 260nm and 280nm wavelengths, permitting a 
ratio to be given that could give a general reading of RNA quality.  Measurements 
with Nanodrop 8000 involved pipetting 1.5l of extracted RNA onto the 
measurement wells.  The concentration of RNA in g/l was calculated before each 
sample’s quantity was adjusted to 1g/l using ddH2O.  RNA samples were stored at 
-80oC for future use.  
 
2.2.2.2 Genechip® Oligonucleotide Microarray Analysis 
 
FM-82 cells were grown in T25cm3 flasks and treated with either control or HAGE-
specific siRNA.  RNA from test and control flasks was extracted using RNA-STAT-
60 as mentioned above.  All experiments were performed in triplicate, therefore 
providing six samples.  Since high quality RNA is required for microarray analysis, in 
the first instance, quality was checked using Nanodrop spectrophotometry as 
mentioned above.  Once this was satisfactory, RNA was supplied to NASC 
Affymetrix Service based at University of Nottingham, where microarray testing was 
carried out. Prior to testing, quality was assessed again through the use of Agilent 
Bioanalysis.  Microarray analysis was performed using the Affymetrix Genechip® 
microarray platform with Human U133 Plus 2.0 arrays. Data provided from these 
experiments was subsequently supplied back to this laboratory. 
 
2.2.2.3 Data Analysis of Genechip® data 
 
Genechip® report data was checked using Genespring software (Version 9.0) (Agilent 
Technologies) at University of Nottingham by Dr Neil Graham.  This checked the 
noise level, extent of RNA hybridisation and housekeeping gene expression for every 
Genechip® tested.  All of this data was satisfactory for analysis to continue.  Analysis 
was performed in association with Dr Morgan Mathieu and Dr Graham Ball using 
differential and regression analysis of the data.  For both experiments, the averaged 
values for those cells that expressed HAGE were compared to the averaged values of 
samples taken from control cells from the same experiment.  This provided ratios of 
relative expression for all genes and generated a list of genes that were up/down-
regulated when HAGE was silenced.   
 
2.2.2.4 Literature Searches 
 
From the list of genes generated from microarray testing, those with a change of 
expression ratio of 2.5 fold or greater were isolated for further study.  The function of 
these genes was researched using both Entrez Nucleotide and Online Mendelian 
Inheritance in Man (OMIM) online database searches (www.ncbi.nlm.nih.gov).  Both 
of these databases allowed the definition of each gene’s possible role in tumour-
modified events and could allow the possibility of having further work carried out on 
them.  
 
 
 
 
 
2.2.3 Gene Expression Analysis 
 
2.2.3.1 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
cDNA was synthesised using the RNA extracted from the cells used in different 
experiments.  cDNA was generated using reagents obtained from Promega and used 
according to the manufacturer’s protocol.  Briefly, 2g sample RNA was mixed in an 
Eppendorf tube with 1l oligo-dT primers and diluted to 15l with ddH2O.  This was 
repeated for all samples to be tested.  The primers were allowed to anneal to the RNA 
by heating all tubes to 70oC for five minutes using a UNO-Thermoblock.  During 
incubation, a reverse transcriptase mix was produced by combining Muloney murine 
leukaemia virus (M-MLV) 5X buffer, dNTPs, RNasin RNase inhibitor, M-MLV-
reverse transcriptase and ddH2O.  This mix was made to allow 10l to be added to 
each sample, thus bringing the total volume of each sample to 25l.  Following the 
addition of RT mix to all samples, tubes were placed in a water-bath pre-heated to 
39.2oC for 80 minutes to allow cDNA synthesis to take place.  Once this was 
complete, tubes were removed from water-bath incubation and were again placed in a 
UNO-Thermoblock and heated to 95oC for five minutes to stop the reaction.  Finally, 
all tubes were placed in a -20oC freezer for future use.   
 
2.2.3.2 Real Time qPCR 
cDNA generated as described above was used to act as a template in real-time RT-
PCR with the reagents shown below: 
 6.25l iQ Sybr Green  
 0.5l Gene specific sense primer 
 0.5l Gene specific anti-sense primer 
 4.75l ddH2O 
 0.5l cDNA template 
These reagent mixtures were added to all tubes for a specific gene.  All samples were 
tested in duplicate alongside negative controls that contained the same reagent 
mixture, omitting sample cDNA, to act as a non-template control (NTC).  Real-time 
qPCR was carried out using the Rotogene 6000 real-time qPCR analyser (Qiagen) to 
test the expression of genes of interest.  The expression of the housekeeping genes 
GAPDH, TBP-1 and HPRT-1 was used to calculate relative gene expression using 
2CT calculations.   Real-time qPCR was carried out using the following protocols: 
 
 
 
 
 
 
 
 
 
 
χ refers to the annealing temperature used to allow the annealing of gene specific 
primers to template cDNA, shown in Table 2.3 while y refers to extension times 
shown in Table 2.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
15 minutesχ*-95oCN/AMelt
y seconds*72oC3 (Extension)
30 secondsχoC2 (Annealing) 40
30 seconds95oC1 (Denaturation)
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15 minutes95oCN/AHold
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R: 5' GCCTCGTTGTTGTGAAGGGTT 3'
1060
F: 5' TCCTGCTCAGAAGGTTCCTA 3'
WNT-1
R: 5' TGGCCCCAGTCACTTAATC 3'
1059
F: 5' AAATTCCTGGAGCAGCTTCA 3'
STAT-1
R: 5' GAAGTGGTGGCTGAGGTTGT 3'
1060
F: 5' ATCTCTGTGCCAGCGAGTTT 3'
SFRP-1
R: 5' CCCTGAGTCCCATCATCACT 3'
1060
F: 5' AAACCTCAGCCAAGACCAGA 3'
NRAS
R: 5' TCCTGAGCCTGTTTTGTGTCT 3'
1060
F: 5' TACAGTGCAATGAGGGACCA 3'
KRAS
R: 5' ATCTCACGCACCAACGTGTA 3'
1058
F: 5' TGCCATCAACAACACCAAGT 3'
HRAS
R: 5' TGGGCTGTGTTGAAATGTGT 3'
1059
F: 5' CAAGCTCAAGAGCCTCATCC 3'
OAS-1
R: 5' GCTAGCCTCTGGATTTGACG 3'
1061
F: 5' ACCAGGACCAGAGGAAACCT 3'
PTEN
R: 5' TAAGGGGGCTGGATCTCTTT 3'
1060
F: 5' TGAAGGGGAGGATGAAGATG 3'
PKC-1
R: 5' CTCAGGTTCGCGTAGACAGG 3'
1060
F: 5' GCCCTGGAGGATTTACACAA 3'
JUN-D
R: 5' ACTTTGCAACTGGGGTGAAC 3'
1058
F: 5' ATTTTGGGCTGTTTCAGTGC 3'
IL-15
R: 5' TGCAGCAATTTTCTCCCTCT 3'
1058
F: 5' CGGTTTGACCTGACTGGAAT 3'
HSP-70
R: 5' GTCACCTCGTCTGGGGTAAAA 3'
1060
F: 5' CGAGTACGAATTTGCCAACC 3'
HSP-27
R: 5' CAAGATTGACCCCGGAAGTA 3'
1060
F: 5' GGAAAGTGGCCCATTTAACA 3'
FAS-L
R: 5' TGTCCTCAGTCAGGTTGCTTG 3'
1060
F: 5' GGCCAAGAACAACATCCAGT 3'
E2F2
R: 5' AACTTGCTTCCCGTTCTTCA 3'
1061
F: 5' GTCCTGTCTCTGCTGTGCTG 3'
CXCL-6
R: 5' AGAAACTGTCCCGTCACCTG 3'
1060
F: 5' CTTAACGTGAAGGCCACCAT 3'
CIDE-A
R: 5' AATCAGGCAAAGGTGAAGGA 3'
1058
F: 5' CCCCAAGAAGCCCAGATAAT 3'
CCNE2
R: 5' CACATCACAGCTCCCCACCA 3'
1056
F: 5' TGCACAGGAGCCAAGAGTGAA 3'
TBP-1
R: 5'GGTCCTTTTCACCAGCAAGCT 3'
1055
F: 5' TGACACTGGCAAAACAATGCA 3'
HPRT-1
R: 5' CCATCCACAGTCTTCTGGGT 3' 
1058
F: 5' ACCACCCCCTGCTTAGCACC 3' 
GAPDH
R: 5' GGATTGGGGATAGGTCGTTT 3'
3064.5
F: 5' GGAGATCGGCCATTGATAGA 3'
HAGE
Extension Time
(Seconds)
Annealing 
Temperature 
(oC)
PrimerGene
Table 2.3: List of primers used in real-time qPCR experiments to examine expression of genes of 
interest following HAGE expression modification in various cell lines.  Sequences, annealing 
temperatures and extension times are detailed for each set of primers.
 2.2.4 HAGE in Tumour Modified Events 
 
2.2.4.1 Investigation into HAGE Influence over Cell Signalling 
 
Mitogen activated protein kinase (MAPK) Proteome Profiler kits were obtained from 
R&D systems.  These were used in conjunction with HAGE-stable shRNA 
transfectant lines.  These kits were used as according to the manufacturer’s protocol.  
Prior to testing, protein concentration of cells was assessed under manufacturer’s 
advice and carried out using the total protein assay protocol described below.  
Membranes were developed using the same technique as for immune blots also 
described below.  Spot densitometry to test intensity was carried out using Aida 
software.    
 
2.2.4.2 Total Protein Assay 
 
For the calculation of cell lysate protein concentration, total protein assay were 
carried out using BioRad Dc protein assay reagents according to the manufacturer’s 
protocol.  Standards were produced from a stock BSA solution (10mg/ml) to create a 
series of standard dilutions (2, 1.5, 1.0, 0.8, 0.5, 0.4, 0.2 and 0mg/ml).  Standards 
were tested in duplicate, while protein extracts were tested in triplicate.  All assays 
were carried out in 96-well round bottom plates.  25l of reagent A was applied to all 
samples followed by 200l reagent B.  Plates were covered in foil and left to incubate 
for one hour at RT.  Absorbance measurements for plates were read using a plate 
reader set to a 750nm wavelength.  Using these absorbance values, protein fraction 
concentrations were calculated.   
 
2.2.4.3 Development of Proteome Profiler Arrays 
 
After secondary antibody application, arrays were washed as stated in the protocol.  
ECL reagents were used to lightly wash each membrane.  Following this, membranes 
were placed into a CCD camera chamber cooled to -25oC for development prior to the 
image being captured. 
 
2.2.4.4 Western Blot Analysis of Protein 
 
Following culture, cells were counted and diluted to a 1x106 cells/ml concentration.  
1x106 cells were taken from this dilution, placed into a tube and pelleted by 
centrifugation at 1,500rpm for three minutes.  This pellet was resuspended in 1ml 
DPBS, transferred to a 1.5ml Eppendorf tube and centrifuged at 2,000rpm for one 
minute to remove residual media.  DPBS was removed and cells were resuspended in 
300l sample reducing buffer, breaking down disulphide bonds in the protein 
structure and transferred to a 500l Eppendorf tube.  These were placed into a 
thermoblock set to 95oC for 10 minutes to allow protein denaturation and either 
separated using SDS electrophoresis or stored at -20oC for future use.  
 
40l of sample was loaded into the wells of a SDS gel immersed in a tank containing 
1X tris-glycine-SDS running buffer.  All samples were run alongside a molecular 
weight marker.  When loaded, a 70V current was applied to allow proteins to pass 
through the 5% stacking gel and once this was achieved, the current was increased to 
90V to permit proteins to be separated in 10% resolving gel.  PVDF transfer 
membranes were prepared by washing with 100% methanol for five seconds, ddH2O 
for five minutes and transfer buffer for 10 minutes.  When proteins had run through 
the gel they were transferred to the PVDF membrane using ‘wet transfer’.  Briefly, a 
gel frame was immersed in cold transfer buffer.  To this, a buffer sponge soaked in 
transfer buffer was placed into the frame.  This was followed by one piece of filter 
card, then by the gel, PVDF membrane, another piece of filter card and finally a 
second buffer sponge soaked in transfer buffer.  The frame was sealed and placed into 
an ice-cooled transfer tank filled with cold transfer buffer.  A 100V current was 
applied for one hour to allow the transfer of the proteins. 
 
When complete, membranes were cut accordingly so they could be treated with 
different antibodies, placed in vessels and washed in a 10% (w/v) Marvel milk 
solution for one hour at RT to block non-specific binding sites.  The blocking solution 
was decanted; protein-specific antibody was diluted in 10% (w/v) Marvel solution 
and applied to the necessary membranes, which were agitated on a plate rocker 
overnight at 4oC.  The following day, membranes underwent three separate 10-minute 
washes using TBST, while vessels were agitated on a plate orbital shaker at RT.   
 
Once washing was completed, secondary antibody specific to the host species of the 
primary was diluted in 10% (w/v) Marvel and applied to the required membranes for 
one hour while being agitated at RT on an orbital shaker.  A streptavidin-HRP 
secondary antibody was also added to each membrane in order to stain the molecular 
weight marker present on each membrane. 
 
Following staining with secondary antibodies, washes were carried out as above and 
membranes were developed.  This was done by removing the membrane from its 
wash vessel and placing it in a clean tray, lightly washing it with ECL reagent and 
exposing it for a certain period of time using a CCD camera. 
 
2.2.4.5 Detection of Activated RAS Protein 
 
To determine if HAGE expression led to an increase in the levels of activated RAS 
(RAS-GTP) in tumour cells, a pull-down/detection kit was acquired (Thermo 
Scientific).  This employs an antibody specific for the RAS-binding domain (RBP) of 
the RAF protein which is specific for activated RAS protein to isolate the active 
protein.  Once extracted, this protein can be detected using western blotting with an 
anti-RAS antibody supplied with the kit.  This was carried out on shRNA stable 
transfectants and performed according to the manufacturer’s protocol, using 500g of 
cell lysate proteins.  In all cases, a positive control was created using GTPS.  All 
recommendations for modifications to in-house immune blot techniques were 
followed.  Membranes were developed using a CCD camera. 
 
2.2.4.6 Detection of Caspase 3/7 Following Apoptotic Drug Treatment 
 
The levels of caspase 3/7 in HAGE stable cDNA and shRNA transfectant cell lines 
were measured using a luminometer screening method (Promega).  Briefly, cells were 
cultured in six-well plates and treated with different concentrations of staurosporine 
and cisplatin to optimise the amount of drug required to induce cell death.  For 
screening, cells were plated at 1x104 cells/well into a 96-well plate and grown 
overnight.  The following day, media was removed from cells and replaced with 
100l media containing 0.3g/ml of staurosporine or cisplatin.  To determine 
background, media/drug mixture was added to wells containing no cells.  The plate 
was incubated at 37oC/5%CO2 for four hours prior to the addition of 100l caspase 
3/7 detection reagent and incubated at RT for one hour.  The plate was read using a 
luminometer and caspase levels were determined by normalising test values by 
subtracting background reading.   
 
2.2.4.7Analysis of Apoptosis in Response to Cisplatin Treatment 
 
To investigate if reduction of HAGE expression could leave tumour cells more 
susceptible to apoptosis induced by cisplatin, FACS analysis using Annexin-V-
FITC/7-AAD staining was carried out according to the manufacturer’s protocol.  In 
brief, shRNA stable transfectants and Jurkat cells (positive control) were grown in 
T25cm3 flasks in their normal culture conditions.  For stable knockdown cells, the 
day prior to testing, media was decanted and replaced containing 0.3g/ml cisplatin.  
For Jurkat cells, 100ng/ml of a CD95 agonist antibody was added to the media to 
initiate FAS induced apoptosis.  For each cell line, a flask that underwent no 
treatment was used to act as a comparison.  Cells were cultured for 24 hours.  On the 
day of testing, cells were divided into tubes and either stained using Annexin-V-
FITC/7-AAD or left unstained.  All cells underwent FACS testing using a Gallios 
flow cytometer and data gained was analysed using Kaluza® software. 
 
2.2.4.8 Detection of Surface Expression of FAS-Ligand 
 
In order to confirm up-regulation of FAS-ligand (FAS-L) in HAGE-expressing cells, 
FACS analysis was used to determine surface expression of the antigen.  cDNA and 
shRNA stable transfectants were cultured as normal before being divided into tubes.  
Following two washes in FACS buffer, cells were treated either with an antibody 
specific for FAS-L (CD178) or an isotype-specific negative control and incubated on 
ice for 30 minutes.  Two washes with FACS buffer were carried out prior to the 
addition of a species-specific FITC-conjugated secondary antibody.  Cells were 
incubated on ice in darkness for 30 minutes, washed twice in FACS buffer and finally 
resuspended in isoton.  FAS-L expression was screened by FACS testing using a 
Gallios flow cytometer and data was analysed used Kaluza® software.    
 
2.2.4.9 Screening of Invasive Capability of HAGE-Expressing Cells 
 
Invasive capability of HAGE-expressing cells was tested using a Matrigel-Invasion 
System and used in accordance with the manufacturer’s guidelines to achieve real-
time observation of cell migration.  Briefly, FM-82/Ctrl and FM-82/shRNA were 
grown overnight in their normal conditions.  On the say of testing, media was 
decanted and replaced with media containing 10g/ml DilC12(3) fluorescent dye and 
cells were incubated for one hour at 37oC/5%CO2.  Following incubation, cells were 
counted and diluted in serum-free media to 1x105 cells/ml.  Cells were seeded at 
5x104 cells/well of either a test plate with wells containing Matrigel or a negative 
control plate containing no barrier material prior to the addition of a chemo-attractant 
(Media containing 5% FCS) under the migration pore and were incubated at 
37oC/5%CO2.  Detection of stained cells passing through the pore was done using a 
fluorescent plate reader over a 25-hour period.  Percentage invasion at each time point 
was calculated by dividing reading for the test plate by the reading for the control 
plate and multiplying by 100.    
 
2.2.5 Statistical Analysis 
For various experiments performed in this study, statistical analysis was carried out to 
highlight their significance.  In the first instance, on studies where biological repeats 
were performed, the difference between repeats was determined using standard 
deviation, calculated from average values gained for the control or test measures used 
in each experiment.  In certain cases, the significance between values gained was 
examined.  On these occasions, the p value was calculated using a student’s t test, 
which would allow the recognition of differences that were significant (‘*’/p=<0.05), 
very significant (‘**’/p=<0.01) or highly significant (‘***’/p=<0.001). 
 
 
 
Chapter 3 
 
The Effect of HAGE Expression on Tumour Cell Proliferation 
 
3.1 Introduction 
 
The heightened ability of cancerous cells to proliferate is perhaps the best known 
characteristic of tumours (Hanahan and Weinberg, 2000).  Uncontrollable 
proliferation is the reason why a tumour is capable of rapid expansion in its site of 
origin.  Angiogenesis may also be initiated thanks to proliferation due to tumours 
reaching a certain size and requiring oxygen for survival.  Furthermore, this ability is 
essential for these cells that have metastasised to distant locales in order to generate 
additional malignant lesions. 
 
This high proliferative capability is due to the expression of molecules that enable 
proliferation and progression through the cell cycle and mitosis, while inhibiting 
those that act to prevent these actions and promote apoptosis.  To achieve this cancer 
cells either alter their communication with other cells or modify that affect their 
signalling pathways.  
 
Interestingly, under normal conditions cells themselves have a finite ability to 
proliferate.  This was first demonstrated in culture cells by Hayflick (Hayflick, 1997).  
Following every round of replication, the telomeres of chromosomes are ‘shortened’ 
by a loss of approximately 50 to 100 base pairs (Hanahan and Weinberg, 2000).  
Progressive deficit of genomic material ultimately leads to a cell undergoing 
apoptosis because it is unable to support further mitotic division.  Thus, cell division 
and proliferation are self-limiting processes that can regulate the extent that a cell is 
able to expand the population from itself.  However, in both established cell lines and 
malignant cells in culture and in vivo, there appears to be an infinite ability to 
proliferate with the acquisition of immortality, made possible by repair of telomeres 
after each mitotic division.  Tumour cells can continuously divide without ever being 
in danger of entering apoptosis.  In the vast majority of instances, they achieve this by 
the abnormal over-expression of telomerase, the enzyme that acts to maintain 
telomeres in stem cells (Shay and Bacchetti, 1997; Bryan and Cech, 1999).  
Alternatively, the alternative lengthening of telomeres (ALT) mechanism, a form of 
genomic recombination is employed to accomplish the same outcome (Bryan et al., 
1995; Henson and Reddel, 2010).  In addition to this other genetic abnormalities 
affecting external and internal signalling will eventually lead to uncontrollable 
proliferation. 
 
The former can be provided by tumour cells developing autocrine and paracrine 
secretion of growth factors such as EGF, FGF and PDGF, thus making them self-
sufficient (Zandi et al., 2007).  A similar condition can be achieved via abnormal 
over-expression of receptors for these growth factors on the surface of malignant 
cells.  Once ligand-receptor binding has taken place, initiation of pro-growth cascades 
occurs, involving molecules such as RAS, PI3K and AKT (Cox and Der, 2002; Vara 
et al., 2004; Yoeli-Lerner and Toker, 2006).  These activate the expression of various 
molecules that encourage cell cycle progression at the same time as inhibiting the 
molecules that inhibit growth.  A good example of this can be seen with the PI3K 
pathway (Vara et al., 2004).  In this setting, the molecules that communicate the 
signal are not mutated themselves, instead they are subverted and their actions 
manipulated as a result of increased stimulation to surface receptors.  
As opposed to cell to cell communication, modifications can take place within a cell 
itself, granting it heightened potential to proliferate.  This can come in the form of 
gain of function modifications occurring with the molecules implicated in 
encouraging proliferation or loss of action of those that act to prevent this behaviour.  
This is evident with the former with regards to the generation of oncogenes, for 
example the point mutations that occur in B-RAF that predominates in melanoma 
(Tuveson et al., 2003) and RAS species in numerous tumours (Downward, 2003).  
These are supplemented by translocations, for example BCR-ABL in CML and ALL 
(Druker et al., 2001b), and amplifications as found with MYC (Al-Kuraya et al., 
2007; Rodriguez-Pinilla et al., 2007).   
 
The level to which malignant cells can proliferate is important.  Increases in tumour 
mass can only be achieved if apoptosis is limited, therefore limiting the rate of cell 
turnover (Hanahan and Weinberg, 2000).  Loss of pro-apoptotic functionality is a 
common event in a malignant cell.  In some instances, this takes place as a result of 
increased pro-proliferative signalling.  In cells where there is amplified AKT 
signalling, for example from the loss of PTEN or mutations to RAS, there is a natural 
inhibition of certain genes or proteins that act to cause cell death.  Initiation of AKT 
function leads to inactivation of the pro-apoptotic proteins BAD and BIM along with 
the anti-proliferative GSK-3, thus allowing a cell to increase the rate at which it 
enters mitotic cell division (Kandel and Hay, 1999).  Events like these are 
compounded further by the inactivation of pro-apoptotic molecules through deletion, 
mutation or insensitivity to stimulation, for example as seen with p53 (Levine and 
Oren, 2009).  Once a cell can achieve this, then there is a raised chance to which it 
can proliferate. 
 
It is essential to emphasise the importance of TSG in the evolution of tumour 
proliferation.  Some of the best examples of these genes and their products are central 
to proliferation signalling or progression through the cell cycle, the two processes 
required for cells to increase their population.  This can be seen with PTEN, which 
undergoes deletion in many tumour types subsequently allowing continual signalling 
via AKT, a highly potent signalling mediator (Chalhoub and Baker, 2009).  A similar 
situation can be seen with the retinoblastoma (Rb) protein.  Rb undergoes inactivation 
by mutation, increased phosphorylation by cyclin-CDK complexes or the action of 
the E7 gene product of HPV (Dyson et al., 1989; Zuo et al., 1996; Hanahan and 
Weinberg, 2000).  The normal function of Rb is to regulate activity of E2F 
transcription factor family members by complexing with them.  Loss of Rb activity 
means that E2F are free to act to propel the cell from G1 to S phase of the cell cycle 
and from there to mitosis (Weinberg, 1995).  Alternatively, other molecules that serve 
to stimulate TSG activity may be inhibited in the same fashion or TSG become 
insensitive to them.  In the case of Rb, insensitivity to or loss of function of TGF- 
and p15INK means that it cannot be activated and in turn, this has a comparable effect 
to loss of this TSG itself (Fynan and Reiss, 1993; Hanahan and Weinberg, 2000).  
Collectively, these mechanisms guide a malignant cell to increase the size of the 
nascent tumour mass.  Despite knowing so much regarding this process, it still 
remains one of the most difficult to curtail, implying that other factors must exist 
within cell communication networks that cause this phenotype. 
 
Work previously performed by this laboratory has indicated that the expression of 
HAGE in a tumour cell line may promote proliferation (Unpublished data).  
Expression of the HAGE protein in tumour cell lines (Mathieu et al., 2010) means 
that it potentially has a viable role in cells.  Since other DEAD-box proteins and CT 
antigens have been linked to proliferation (Por et al., 2010), it is possible that HAGE 
could also share this involvement.  To that end, the initial stages of this study aimed 
to investigate if this antigen contributes to tumour proliferation. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.2 Results 
 
3.2.1 Effect of Transient Transfection on HAGE Expression in Cells 
 
In order to understand what role HAGE has in tumours, it was initially important to 
discern what impact its expression has in malignant cells.  Any study into 
functionality requires either inducing target gene expression in negative cell line or 
reducing expression in a cell line that is naturally positive.  For this study, both 
techniques were utilised, either in a transient capacity or in a stable manner. 
 
In the case of transient modification to expression, a human melanoma cell line 
naturally negative for HAGE expression (FM-3) was transfected with a HAGE 
bearing plasmid (pBudCE4.1/HAGE).  At the same time, a human melanoma cell line 
that naturally expresses the HAGE gene (FM-82) was treated with a gene-specific 
siRNA molecule.  To ensure that both transfections had their desired effects at the 
genetic level, RNA was extracted from treated cells and used to synthesise cDNA 
using RT-PCR.  This was carried out a number of days post-transfection (3, 5 and 7 
days) to find out how long the effects of each treatment lasted.  Screening of this 
DNA involving real-time qPCR with the use of HAGE-specific primers was able to 
show that transfection of cDNA and siRNA was successful at inducing and silencing 
HAGE expression respectively.  Figure 3.1 indicates that the gene was detected using 
PCR, therefore showing that cDNA had been able to enter and be utilised by the cells 
to create HAGE gene expression in a negative cell line.  Relative expression, 
calculated using CT values of both HAGE and housekeeping genes, point to the 
greatest level of expression being shown at 3 days post-transfection, with expression 
decreasing as time progressed.  In the case of gene knockdown, Figure 3.2 
demonstrates that it was possible to decrease the level of HAGE in FM-82 cells.  
Relative expression in this graph highlights that it was possible to achieve an 85% 
decrease in gene expression 72 hours following siRNA treatment which decreased to 
approximately 45% one week after transfection had been carried out.  Real-time PCR 
screening of the genes OAS-1 and STAT-1 was previously used to confirm that 
transfection of HAGE siRNA does not trigger an IFN- mediated cell death as can 
happen when using siRNA. 
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Figure 3.2: Relative gene expression of HAGE in FM-82 human melanoma cells following 
treatment with a specific siRNA molecule (n=4).  Expression determined from 2CT 
calculations derived from results of real-time qPCR of RNA extracted from these cells 3, 5 
and 7 days post treatment.
Figure 3.1: Relative HAGE gene expression in FM-3 human melanoma cells transiently 
transfected with the pBud CE4.1/HAGE cDNA plasmid (n=4).  Expression determined 
using 2CT calculations of real-time qPCR data of RNA taken 3, 5 and 7 days post-
transfection. 
The findings of genetic changes were mirrored by the alterations in protein expression 
in these cells.  Figure 3.3 and 3.4 illustrates both cDNA transfected FM-3 cells and 
FM-82 cells treated with siRNA in the same manner as with the genetic experiments.  
These underwent immune staining using a mono-specific polyclonal antibody specific 
for the HAGE protein.  In terms of cDNA transfection, Figure 3.3 shows that HAGE 
protein expression was greatest after three days, but decreased as time progressed.  It 
could be seen that three days following siRNA treatment, HAGE was still expressed 
as a protein in these cells, evident by the level of FITC (Green) staining present and 
that HAGE appears to be confined to the cytoplasm.  This could be compared to the 
same cells stained with an isotype control antibody, where only the nucleus was 
visible.  However, five days after treatment, there was a decrease in staining, 
implying a reduction in the protein level, indicating that the siRNA had successfully 
managed to silence HAGE in these cells not only at the gene level, but also at the 
protein level.  By seven days, protein expression appeared to increase again for FM-
82 cells, while FM-3 cells demonstrated very little protein expression. 
 
3.2.2 Creation of HAGE Stable Expression in Tumour Cells 
 
While it is important to examine the effects of a temporary change in HAGE genetic 
expression, it is necessary to investigate what effects long term modifications could 
have.  To do this, cells were stably transfected in order to bring about long lasting 
changes to HAGE expression.  To induce gene expression, FM-3 cells were subject to 
transfection using the pcDNA3.1/HAGE plasmid or empty plasmid vector.  For gene 
silencing, FM-82 underwent treatment with a HAGE-specific shRNA plasmid or 
negative control shRNA vector.  All four of these new cell lines were grown in media 
supplemented with G418 selective antibiotic.  Figures 3.5 and 3.6 show that the real-
time qPCR of cDNA generated from RNA extracted from these cells was able to 
confirm the change in HAGE expression that was hoped for.  For the cDNA 
transfectants, Figure 3.5 shows that with the test cell line (FM-3/HAGE), HAGE 
expression was nearly 200,000 times greater than the FM-3/-Ve control line 
(p=<0.001).  This obviously stands to reason since FM-3/-Ve was treated with a 
plasmid that bore no HAGE cDNA, however it demonstrates the extent to which 
HAGE had become over-expressed in FM-3/HAGE.   
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.3: Immunofluorescent staining of HAGE protein in FM-3 cells transiently 
transfected with the pBud CE4.1/-Ve empty plasmid or pBud CE4.1/HAGE cDNA 
plasmid (n=2).  Staining involved the use of a mono-specific polyclonal antibody 
against HAGE and counterstained with FITC -conjugated secondary antibody.  DAPI 
was used to stain the nucleus of cells.  Image magnification at x40.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: Immunofluorescent staining of HAGE protein in FM-82 cells transiently 
transfected with either control or HAGE-specific siRNA (n=2).  Cells were stained in 
the same manner as cDNA plasmid transfected cells.  Image magnification at x40.
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Figure 3.5: Relative gene expression of HAGE in FM-3 human melanoma cells gained 
from 2CT calculations of real-time qPCR data (n=4).  Cells were stably trasnfected
either with the pcDNA3.1/HAGE DNA vector to create the FM-3/HAGE stable line, or 
the pcDNA3.1 empty vector to form the FM-3/-Ve control cell line (p=<0.001).
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Figure 3.6: Extent of gene knockdown in FM-82 human melanoma cells stably 
transfected with shRNA (n=4).  Cells were treated with either a HAGE specific shRNA 
plasmid (FM-82/shRNA) or a negative control plasmid (FM-82/Ctrl).  Expression was 
determined using 2CT calculations of real-time qPCR data (p=<0.001)
On the other hand, Figure 3.6 shows the decrease in expression in the stably knocked-
down cell line.  The FM-82/shRNA test cell line demonstrated approximately 80% 
less expression of the HAGE gene than the control cell line FM-82/Ctrl.   
 
As with the transient treatments, the effect of transfection seen at the genetic level 
was confirmed additionally at the protein level.  Figure 3.7 (A) shows the difference 
in HAGE expression between FM-3/-Ve and FM-3/HAGE.  No protein was found to 
be expressed in FM-3/-Ve, demonstrated by only the DAPI staining of the nucleus of 
these cells being present.  Conversely, examination of FM-3/HAGE cells shows that 
not only the molecule, but the level of staining visible indicated the extent to which 
the antigen was expressed within these cells. 
 
For the shRNA cell lines, Figure 3.7 (B) displays how the incorporation of the 
HAGE-specific molecule was able to significantly reduce the level of protein 
generated in FM-82/shRNA.  Interestingly, it is notable that HAGE is still expressed 
by the test cell line, however to a much lesser extent than FM-82/Ctrl.  This is 
reassuring, since shRNA treatment is an RNAi technique and does not involve gene 
knockout.  As a result, it means that HAGE was still expressed by FM-82/shRNA, but 
to a much lower concentration.  This would appear to agree with the relative gene 
expression calculated from real-time qPCR described earlier. 
 
Importantly, it must be noted that for FM-3/HAGE, expression of the protein was 
confined to the cytoplasm.  This matches what was found with the transient cDNA 
and also agrees with the localisation of HAGE in FM-82 which naturally expresses 
the protein.  This indicated that further work on these cells could potentially match 
what may be taking place in a naturally occurring cell line. 
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Figure 3.7: Immunofluorescent staining of HAGE protein in stable transfectant cell lines 
(n=2).  (A) cDNA stable transfectants stained with rabbit anti-HAGE mono-specific 
polyclonal primary antibody and with Alexa-468 (Green) secondary antibody staining.  (B) 
shRNA stable transfectants stained with mouse anti-HAGE monoclonal antibody and Alexa-
568 (Red) secondary antibody.  Cell nuclei stanied with DAPI. 
3.2.3 Effect of HAGE Expression on Tumour Cell Proliferation in vitro 
 
Work performed by this laboratory in the past has shown that the transient 
transfection of HAGE cDNA into the FM-3 results in a significant increase in the 
proliferation level of these cells in vitro (Unpublished data).  To confirm these 
findings, a reciprocal experiment was performed to discern if reduction of HAGE 
expression leads to reduced proliferative capacity.  This involved the use of FM-82 
cells treated with HAGE-specific siRNA in 3H incorporation proliferation assays.     
 
Figure 3.8(A) shows that three days following siRNA treatment, there was a 
significant decrease in the ability of those treated with HAGE-specific siRNA to 
proliferate in comparison to cells treated with control siRNA, transfection material 
alone or when growing naturally (p=<0.05).  Conversely, Figure 3.8(A) also shows 
that seven days following treatment, the pattern is not repeated and there is no 
reduction in proliferation of HAGE-siRNA treated FM-82 cells compared to control 
treatments.   
 
To investigate if the same finding could be repeated in another HAGE-expressing cell 
line, the human melanoma cell line FM-6 underwent the same technique, shown in 
Figure 3.8(B).  As can be seen in this instance, cells demonstrated the same reaction 
in response to HAGE knockdown as FM-82.   Three days after transfection, there was 
a reduction in the number of cells treated with HAGE siRNA compared to control 
cells.  This could be supported by the result gained for cells treated with 
INTERFERin reagent alone, where the number of cells was considerably lower than 
cells grown in their natural state.   
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Figure 3.8: Readings from in vitro 3H incorporation proliferation assays to assess the effect of 
HAGE siRNA treatment on three human melanoma cell lines; (A) FM-82, (B) FM-6 and (C) FM-
3 (n=3).  Measurements were taken 3 days (Green bars) and 7 days (Yellow bars) post siRNA
transfection (*=p=<0.05; **=p=<0.01).
In order to ensure that these findings were due to a reduction in HAGE expression 
and not a consequence of the transfection procedure used, HAGE-negative FM-3 cells 
were subject to the same experimental conditions.  This was done to act as a true 
negative control, as FM-3 does not express HAGE, specific siRNA should have no 
effect on this cell line.  Figure 3.8(C) shows that there was no significant difference 
between the treatments used at both times of measurement.   
 
All of the above had been performed on cells that had undergone transient 
transfection.  To confirm that long term modified HAGE expression has the same 
effect on cell proliferation, both sets of stable transfectant cell lines were used for 3H 
proliferation assays.  Figure 3.9(A) shows that following stable induction of HAGE 
gene expression, there was significant increase in the proliferation four days after 
they had been plated however there was no difference at day 6.  Findings for Day 4 
with  this cell line further agrees with previous proliferation assays in that once 
HAGE had begun to be expressed by these cells, then their level of proliferation was 
made more potent compared to the control cell line.  To corroborate the above, stable 
knockdown of HAGE in FM-82, shown in Figure 3.9(B), matched the pattern of 
results.  This was evident from reduction of HAGE gene expression by specific 
shRNA leading to a significant loss of proliferation as opposed to the cells transfected 
with control shRNA.  This effect was even more pronounced at Day 7, possibly 
implying that prolonged reduction in this gene’s expression resulted in an even 
greater reduction in cell proliferation. 
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Figure 3.9: In vitro 3H incorporation proliferation assay readings (n=3) gained for human 
melanoma cells stably transfected with (A) HAGE cDNA or (B) HAGE shRNA compared to 
control cell lines.  Readings were taken at 3 or 4 days (Green Bars) or 6 or 7 days (Yellow bars) 
(**=p=<0.01; ***=p=<0.001).
3.2.4 Effect of HAGE Expression in Tumour Cell Proliferation in vivo 
 
While it was of importance to discern the effect that HAGE had on in vitro 
proliferation, if this molecule is to be considered a realistic target for cancer therapy, 
then the same findings must be recognised in vivo.  To this end, FM-3/-Ve and FM-
3/HAGE cells were injected into two groups of NOD/SCID mice to investigate if 
HAGE expression could lead to increased tumour growth in an in vivo setting.  This 
strain of mice was used since they lack adaptive immunity as well as NK cell activity 
and as such, represents a suitable model to allow tumour growth to be monitored with 
the smallest risk of interference from the immune system of the host.   
 
As Figure 3.10(A) highlights, from approximately Day 12 onwards, mice that had 
been injected with FM-3/HAGE bore tumours that were greater in size on average 
when compared to the group of mice that had been inoculated with FM-3/-Ve.  
Moreover readings taken after Day 28 found that HAGE-positive tumours were 
significantly larger than the control tumours.  Subsequently, this would appear to 
point towards HAGE being associated with increased proliferation of malignant cells.  
The significant difference between the two groups (p=0.05; p=<0.01), of mice 
suggests a possibility that HAGE could have more of an impact on cell biology over a 
protracted length of time.   
 
To ratify these findings, the experimental conditions were reciprocated using FM-
82/Ctrl and FM-82/shRNA.  On this occasion, as shown by Figure 3.10(B), the mice 
injected with FM-82/shRNA developed tumours at a significantly slower rate than the 
control group (p=<0.05), complementing the findings of the previous experiment.  As 
expression of this gene was the only variable for these two experiments, it could be 
suggested that HAGE is able to promote increased proliferation in an in vivo 
environment.  This furthers the evidence of HAGE and proliferation and goes further 
to support that this antigen not only has a role in vitro but within an in vivo setting as 
well.   
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Figure 3.10: Size of tumours that developed in NOD/SCID mice following the injection of  either 
(A) HAGE cDNA stable transfectant and control cell lines or (B) HAGE shRNA and control cell 
lines (n=1).  Readings were taken bi-weekly using calliper measurement (*=p=<0.05; 
**=p=<0.01).
3.2.5 Verification of HAGE Expression in NOD/SCID Tumours 
 
By way of performing complete ratification of HAGE expression in these tumours at 
all levels, extra sections were taken, stained using cresyl violet and underwent laser-
capture microdissection (LCM).  The cell islets removed from these sections 
underwent RNA extraction and this was used to generate cDNA for analysis of 
HAGE gene expression using real-time qPCR.  The levels of relative expression are 
displayed in Figure 3.11.  Here, it could be recognised that three out of three FM-3/-
Ve cell islets tested demonstrated no HAGE mRNA, as could be expected.  For FM-
3/HAGE cells, two out of three islets expressed the mRNA to a relatively high 
degree.  Through the use of LCM, it had been possible to identify HAGE gene 
expression in these tumours, even from a very small number of cells and in turn, this 
was able to confirm the presence of the antigen in these cells and connect its presence 
with the increase proliferation in these tumours.  
  
In order to confirm increase tumour growth in vivo could be due to the expression 
HAGE, work was performed on these tumours to ratify the molecular expression of 
HAGE.  Mice were euthanized and their tumours removed and snap frozen in liquid 
nitrogen-cooled isopentane.  Sections taken from these tumours were used for 
immunohistochemical staining of HAGE and viewed using a microscope, the images 
taken from this illustrated in Figure 3.12.  No positive staining was evident in FM-3/-
Ve tumours, however widespread brown HRP was noticed in FM-3/HAGE based 
masses displaying a relatively high concentration of the HAGE protein in these cells.  
As can been seen, no brown from HRP staining was gained using the isotype control 
primary antibody. 
 
To further validate the presence of increased proliferation within these tumours, 
immune staining was performed on them to detect both HAGE and Ki-67, a protein 
marker that is produced by cells going through proliferation.  As can be seen in 
Figure 3.13, when stained for both proteins, FM-3/HAGE was found to express both, 
as did FM-82/Ctrl.  On the other hand, in both FM-3/-Ve and FM-82-shRNA there 
was none or decreased HAGE expression respectively and a reduced level of staining 
for Ki-67.  This hints that HAGE-bearing tumours were actively proliferating as a 
result of HAGE protein expression in cells.   
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Figure 3.11: Relative expression of HAGE mRNA expression in NOD/SCID HAGE cDNA 
tumours isolated by LCM.  Extracted tumours were grown from either (A) cDNA stable 
transfectants (p=<0.001) or (B) shRNA stable transfectants (p=<0.05).  Expression was 
determined using 2CT calculations of CT values derived from real-time qPCR (n=4).  
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Figure 3.12: Images taken from LCM viewing of tumours grown in NOD/SCID mice
following sectioning and immunohistochemistry staining of HAGE (n=2).  Tumours were 
either (A) HAGE cDNA stable transfectants or (B) HAGE shRNA transfectants.  Images 
taken when viewed at x20 magnification.
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Figure 3.13: Dual immunofluorescent staining of HAGE (Green) and the Ki-67 cell proliferation 
marker (Red) in NOD/SCID tumours (n=2).  Cells were stained with either (A) Primary antibodies 
against both proteins; (B) HAGE primary antibody and the isotype control against the primary for Ki-
67 or (C) Ki-67 primary antibody and the isotype control against the primary for HAGE.  Images 
taken when viewed at X40 magnification.
3.2.6 HAGE and Progression through the Cell Cycle 
 
If HAGE-positive cells have higher levels of proliferation, then it is possible that they 
have undergone modifications to permit increased progression through the cell cycle 
and through this, enter mitosis quicker.  Both cDNA and shRNA stable transfectants 
underwent serum starvation in order to synchronise cells to the same stage of the cell 
cycle.  Once completed, serum was replaced in the media and subsequently cells were 
analysed using FACS following staining using the 7-AAD genetic stain.  Data 
retrieved from this testing was analysed using the Kaluza® software package 
(Beckman Coulter).  This suggested that expression of HAGE permitted cells to 
advance through the cell cycle at a faster rate (Figure 3.14).  Examination of peaks 
gained from FACS analysis showed that there appeared to be more HAGE-positive 
cells in S phase once serum was replaced when compared to cells negative for the 
antigen. For example, for FM-3/HAGE, 35% of cells were found to be in S phase as 
opposed to 13% with FM-3/-Ve, a very significant difference.  This was 
complemented with data gained for FM-82/Ctrl cells, where 8% cells were at S phase, 
whereas 4% of FM-82/shRNA cells were at this stage.  While this latter difference 
was not as significant as seen with the cDNA transfectants, it was still considered to 
be significant.   
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Figure 3.14: Proportion of cDNA or shRNA stable transfectant cells in different stages of 
the cell cycle (n=2).  This was determined once cells had been synchronised by serum 
starvation and subsequent replenishment of serum in media.  Proportion of cells was 
calculated using FACS data analysed using Kaluza® software (*=p=<0.05; **=p=<0.01).
3.3 Discussion 
 
The initial aim of this study was to investigate the hypothesis that HAGE could have 
an association with tumour cell proliferation.  Genetic manipulation of HAGE, either 
in the form of cDNA, siRNA or shRNA transfection was employed to activate or 
reduce genetic expression.  It was initially possible to show that HAGE expression 
could be manipulated as required in a successful manner.  It was interesting to note 
that in both sets of experiments, optimal changes to expression were seen 72 hours 
following introduction of cDNA and siRNA.  Likewise, in both cases, after this point, 
there was a steady reversal back to each cell line’s natural genotypic pattern for 
HAGE.  In the case of both cDNA transfection and siRNA treatment, following the 
supplementation of cell media with these molecules and transfection lipids, they 
would be taken up by cells, and incorporated into the genome for DNA, while siRNA 
would initiate RNAi activity in the cells.  Data shown here implies that both these 
events require approximately the same amount of time to exert their effects on the 
gene.   
 
The reversal in gene expression over time can be explained in two ways.  For cDNA, 
not all cells in culture will take up the plasmid.  This means that unless one treats 
media with selective antibiotics to kill non-transfected cells as with stable 
transfection, then it means that there is a relatively more heterogeneous population in 
culture.  Non-affected cells will continue to proliferate, thereby diluting the level of 
target gene expression.  In the case of siRNA, the same applies.  Therefore when the 
cell divides by mitosis, the daughter cells do not contain a template for the DICER 
complex to carry out RNAi, thus these new cells will express genes in their natural 
fashion (Pushparaj et al., 2008).  Hence over time, target gene expression returns to 
its natural state.  
 
siRNA treatment was shown to optimally affect gene expression by 72 hours, but five 
days were needed before the protein level changed.  This suggests that until this point, 
translation of HAGE was still being carried out by the cells and by Day 5, this was 
not possible due to the degradation of HAGE mRNA being carried out as part of 
RNAi.  It appeared that protein expression was returning to its natural level after 
seven days, with a certain amount of FITC staining being visible.  Such a result 
would appear to suggest that once gene silencing has begun to diminish, then there 
could be a rapid re-initiation of the translation of target mRNA, quite possibly as part 
of a compensation mechanism in the cell after a certain time of losing a certain gene’s 
expression. 
 
Inhibition of HAGE expression resulted in a significant reduction in the proliferative 
capacity of the tumour cells.  In the case of FM-82, a significant reduction (p=<0.05) 
was seen three days following siRNA treatment, but not at Day 7.  Therefore 
proliferation seemed to be affected at the same time siRNA had the greatest impact on 
HAGE gene and protein expression.  At Day 7 however, there was a resurgence in 
HAGE expression at both RNA and protein levels.  It could be due to the loss in 
effect of the siRNA and cells had regained the ability to proliferate at the capacity 
prior to transfection.  The increase in proliferation would seem to match the increase 
in HAGE molecular expression and loss of siRNA activity.  Transfection of siRNA 
duplexes into cells can induce cell death mediated by cytokines such as IFN- 
(Robbins et al., 2009).  Such a reaction could bring proliferation results into dispute 
as it would mean reduction in cell growth would be due to cytokine activated cell 
death and not inactivation of the gene of interest.  Activity of this pathway can be 
monitored by screening genes involved in this reaction, such as OAS-1 and STAT-1.  
This has been previously performed for HAGE siRNA and it was shown that these 
were not significantly increased therefore IFN- was not activated and responsible for 
the effect observed (Unpublished data).  
 
Similarly, the above effect was also observed in FM-6 cells, where at Day 3, there 
was a significant decrease (p=<0.05) in tumour cell proliferation once HAGE 
knockdown had taken place.  Interestingly, in contrast to FM-82, this effect was 
significant at Day 7 as well (p=<0.01).  It is difficult to assess why this was the case.  
Since HAGE is expressed as mRNA by FM-6 to a very high level (Data not shown), 
the effect of gene-specific silencing may have a more detrimental effect on this cell 
line.  Alternatively, it could be that FM-6 cells were more sensitive to the transfection 
procedure and by Day 7, cells had begun to die.  This notion could be supported by 
the evident difference in proliferation of cells grown naturally and treated with 
INTERFERin alone.  There was a large decrease in cells treated with the transfection 
reagent, hinting that this cell line was more sensitive to the action of transfection as 
compared to FM-82.  The findings gained for FM-3 cells treated in the same manner, 
where there appeared to be no decrease in cell proliferation after siRNA treatment, 
seemed to ratify the notion that HAGE may be linked to proliferation.  FM-3 cells are 
naturally negative for HAGE gene expression and treatment with a HAGE specific 
siRNA had no impact on the number of cells in culture.  This was in contrast to the 
other cell lines, which are HAGE positive and following knockdown of this gene, 
experienced significant decreases in cell number.   
 
The results derived from siRNA studies were repeated using cells that had undergone 
stable transfection.  Once HAGE was stably expressed by FM-3, their level of growth 
was significantly increased four days after plating compared to cells transfected with 
an empty plasmid vector (p=<0.01), suggesting there was a connection between the 
introduction of HAGE expression and the ability of a cell line to proliferate at a 
greater rate.  This antigen may bring about the same phenotypic reaction when 
expressed for a relatively longer period of time.  However by Day 6, there appeared 
to be little difference between the two cell lines.  As mentioned above, FM-3 cells 
naturally proliferate at a fast rate.  The introduction of HAGE seemed to increase this 
yet further and thus, it is quite possible that by this point, cells were beginning to die 
through being over-confluent, resulting in the observed outcome.  In contrast, cells 
that had undergone stable knockdown using shRNA displayed significant reduction in 
proliferation compared to the control cell line.   This reduction was found to be very 
significant at Day 3 (p=<0.01) and became highly significant by Day 7 (p=<0.001).  
The stable knockdown of HAGE in this cell line complemented the findings gained 
from transient knockdown.  It again promoted the idea that HAGE could play a role 
in the proliferation of the cells. 
 
In vivo studies of stable transfectant cell lines were able to demonstrate that HAGE 
expression led to larger tumour masses over the same time period.  Genetic and 
protein studies of the tumour tissues grown in this manner confirmed the expression 
of HAGE.  Immune staining of the protein showed that HAGE was confined to the 
cytoplasm as was observed  in in vitro cultures.  This was encouraging as it showed 
that it was possible to detect HAGE in the same cellular region in cells grown either 
in vitro or in vivo.  In terms of in vivo work, this was only carried out once for both 
sets of stable transfectants, meaning repetition of these studies is required to confirm 
the initial findings.  This implies that the expression of the antigen in these cells was 
able to contribute to the development of larger tumours.  In turn, this could mean that 
HAGE has a role within the in vivo environment.    
 
Dual staining for HAGE and the proliferation marker Ki-67 in these NOD/SCID 
tumours demonstrated some interesting findings.  It was shown that there was strong 
co-expression of both proteins in HAGE-expressing tumours, implying a possible link 
between HAGE and proliferation in vivo.  However in tumours derived from cells 
with reduced or no HAGE expression, staining of Ki-67 was still evident.  It could 
well be HAGE does not directly influence Ki-67 and both of these proteins are 
expressed at different stages of the proliferative cycle of cells.  If HAGE does act to 
promote proliferation, then it is possible it acts in a specific manner before Ki-67 
becomes expressed by other means.  Nonetheless, data gained from them is highly 
encouraging as it implies that HAGE could have a role in patient disease and is not an 
in vitro phenomenon.  
 
The final interesting point concerning HAGE and proliferation comes from the 
apparent links to cell cycle progression.  FACS analysis of synchronised cells 
indicated that a greater percentage of HAGE-expressing cells were in S phase than 
those with negative expression.  This way highly significant for cDNA transfectants 
(p=<0.001) and very significant for shRNA cell lines (p=<0.01).  This was 
complemented by the finding that more HAGE-negative cells were found to be at the 
G1 stage of the cycle.  Tumour cells are notorious for manipulation of the cell cycle 
to promote cell proliferation.  This can be seen with the manipulation of the E2F 
family, Rb and other TSG like p21CIP1 and p27KIP1 (Weinstein, 1995; Payton and 
Coats, 2002; Cam and Dynlacht, 2003; Coqueret, 2003).  Therefore, data from these 
analyses would propose that HAGE-expressing cells were passing through the cell 
cycle at a faster rate than their counterparts.  This could account for the other findings 
that are detailed above.  
 
Collectively, this means that a large volume of data now exists to associate HAGE 
with the ability to which tumour cells are able to proliferate.  This is the first time that 
such a link has been made with this molecule and would appear to confirm the 
original theory into what process it is associated with.  One of the first proposals for 
the possible role of CT antigens was that they could be involved in embryogenesis 
due to the pattern of their expression (Lucas et al., 1998).  The nature of 
embryogenesis would require cells to proliferate at a very fast rate and therefore 
would appear to link the antigen family to this required phenotype.  It has been 
implied that both MAGE-A1 and NY-ESO-1 are involved in the proliferation of both 
male and female germ cells (Gjerstorff et al., 2007).  This would seem to agree with 
the localisation of these antigens and go some way to begin confirming the initial 
notion put forward by Lucas and colleagues (1998).  Likewise, due to their numerous 
potential roles, there is an argued role for members of the DEAD-box family in cell 
proliferation.  Evidence for this has been shown with the protein p68 (DDX5) and its 
associate member p72 (DDX17) promoting proliferation and inhibiting apoptosis.  
The over-expression of these antigens in cancer has been suggested to promote these 
actions in malignant cells (Janknecht, 2010).  CT antigens are expressed in healthy 
tissues, being confined to testis and placenta (Simpson et al., 2005) where it would 
seem they contribute to proliferation.  Once they become re-expressed in tumour 
cells, it would seem appropriate that they reprise this role and increase the extent to 
which these cells can proliferate.   
 
Data is beginning to emerge confirming these notions.  The CT antigen CAGE 
(Cancer-associated antigen) is also a member of the DEAD-box family (DDX53).  It 
has been found to increase the proliferation of tumour cells by influencing cell cycle 
progression through the up-regulation of cyclin D1 (Por et al., 2010).  Due to its 
classification as a CT antigen and DEAD-box protein, CAGE serves as an interesting 
comparison to HAGE.  The initial data from this study would appear to have 
similarity to the evidence gained for CAGE.  Therefore, together there seems to be 
more confirmation of the role of CT antigens and DEAD-box proteins in this role in 
malignant cells.  
 
Proliferation comes about through complex interactions that take place between vast 
numbers of different molecules.  In cancer, these relationships are severely disrupted, 
either through the modification of key mediators or by the expression of certain 
molecules (Weinstein, 2000).  With the expression of HAGE being restricted to 
malignant cells and its classification as a DEAD-box protein, results suggest that this 
antigen may be involved in both.  Since HAGE is an RNA helicase and acts to 
unwind RNA (Linder, 2006), it is possible that it could have interactions with specific 
molecules that lead to this kind of activity in cells.  It would be important to 
investigate if HAGE has relationships with molecules that promote specific areas of 
the proliferative response, whether it is those that act at the highest part of signalling 
cascades or the cell cycle.  Likewise, it would be necessary to find out if HAGE leads 
to these molecules up or down regulation and whether this effect is via direct contact 
with HAGE or through a series of different mediators.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 4 
 
Tumour Cell Gene Expression in Response to HAGE  
 
4.1 Introduction 
 
As previously described, perhaps one of the most unusual aspects of CT antigens is 
the apparent lack of understanding into their role in malignant cells.  Large 
collections of work have been carried out describing their expression, 
immunogenicity and response to in vitro and murine drug models.  Clinical trials 
involving the most immunogenic or promising CT antigens have had limited success 
in patients and this has led to the current situation that no FDA-approved drug exists 
towards these molecules.  Increasingly, there seems to be more evidence to promote 
these molecules as biomarkers for disease progression for a number of different 
cancers. 
 
A feasible argument, connecting the lack of progress observed in CT antigen drug 
development and the lack of knowledge surrounding them, could be raised.  This is 
perhaps best shown by CT-X antigens such as MAGE, GAGE and NY-ESO-1 
amongst others.  Members of this group were some of the original antigens of this 
class to be discovered and are amongst the most immunogenic, especially MAGE-A3 
and NY-ESO-1 (Marchand et al., 1999; Jäger et al., 2000).  At the same time, very 
little is known of their biological function.  There is however mounting evidence that 
certain CT-X antigens are employed in spermatogenesis, as MAGE and NY-ESO are 
expressed by both spermatogonia and primary spermatocytes (Simpson et al., 2005; 
Gjerstorff et al., 2007).  Further to this, genetic and protein data have been collected 
to propose that MAGE-A and GAGE may have a role in the differentiation of the 
earliest forms of somatic cells (Gjerstorff et al., 2008).  For malignant cell biology, 
MAGE-A3 and MAGE-C1 have been shown to promote survival of tumour cells in 
MM (Atanackovic et al., 2010).  This means that more is being addressed to identify 
what processes CT-X antigens are involved in, not just in terms of malignant cells but 
also in healthy situations. 
 
What is noticeable is that those CT antigens to which most is known as far as function 
is concerned appear to be non-X-linked antigens. Sperm protein 9 and 17 (Sp9/Sp17), 
OY-TES-1 amongst others have had their proposed mode of action described in 
healthy cells, for example Sp17 involvement in binding of sperm to zona pellucida 
(Frayne and Hall, 2002).  In part, this could be due to some of these antigens being 
recognised as testis proteins initially, before being found to be re-expressed in tumour 
tissue, as with Sp17 (Frayne and Hall, 2002).  While this is the case, it is difficult to 
appreciate what purpose some of these functions such as conjugation to zona 
pellucida and heparin-heparan sulphate binding would play in a malignant 
environment.  It is possible that these antigens could be aberrantly re-expressed 
thanks to random promoter demethylation, possibly on account of modifications to 
other genes or proteins.  It would seem unlikely however that a tumour would express 
genes that it has no use for, particularly when functional redundancy is taken into 
account. 
 
Progress has been made more recently with the antigen CAGE, a CT antigen that like 
HAGE is a member of the DEAD-box family (DDX53).  It was originally discovered 
by SEREX technology to be expressed by a variety of different tumours (Cho et al., 
2002).  Unlike other members of this group of antigens however, work has been 
carried out to find out what purpose CAGE has and the impact its expression has on 
malignant cell biology.  It was initially suggested that the molecule had an impact on 
both proliferation and cell motility (Kim and Jeoung, 2008).  Evidence has since 
emerged that CAGE promotes metastasis by up-regulating both MMP-2 and FAK 
(Shim et al., 2006; Kim and Jeoung, 2009) and proliferation by influencing the 
expression of cyclin D and E (Por et al., 2010).   By investigating CAGE in this way, 
it has been possible to isolate the processes it is involved in.  This, in turn has allowed 
initial recognition of other molecules that could interact with the antigen to cause 
these effects.  Ultimately, it may be possible to pinpoint a particular part of these 
interactions with therapeutic intervention; therefore working to discern CT antigen 
function could improve the design of drugs against them. 
 
Cancer in general is a disease caused by alterations taking place in molecular 
pathways (Weinstein et al., 1997).  Changes can be found in physical modifications to 
the mediators of these pathways, loss of expression of them or the expression of other 
molecules that can influence pathways in terms of promotion or inhibition.  In 
tumours, CT antigens become re-expressed by random demethylation, yet the series 
of events leading to this remain unclear.  It stands to reason that the presence of these 
molecules in tissues where they are not normally expressed could have a significant 
impact on cell biology.  This is evident as seen for CAGE and also with the data 
presented in the previous chapter with HAGE.  It is important to examine what effect 
HAGE expression has on the expression pattern of other genes in tumour cells. 
 
Attempting to determine which genes are affected in response to tumorigenic changes 
has been common practice for a number of years.  The evolution of oligonucleotide 
microarray analysis has allowed gene expression profiling to perform on a much 
larger scale.  This is especially apparent with the Affymetrix Genechip® system 
analysis that allows the transcriptomic analysis of the entire human genome (Kim et 
al., 2004; Eszlinger et al., 2007).  Thus, it is possible to investigate the impact of a 
target across all known genes and gain as much information as possible.  Microarray 
has been used widely in cancer research for a number of years for different tumours 
to investigate all aspects of cancer such a drug response and methylation (Kim et al., 
2004; Eszlinger et al., 2007).  Combined with real-time PCR, it is a very useful tool 
to screen gene expression. 
 
More recently, this type of technology has evolved yet further with the arrival of Next 
Generation Sequencing (NGS).  This system screens the genetic sequence of a cell at 
such a rate that it is possible to screen the entire human genome in a relatively short 
period of time.  It is also possible to recognise mutated, duplicated and deleted gene 
regions, amongst other factors, that may be taking place in a cancerous cell.  The 
power of this technology has been recently utilised alongside other analysis systems 
to find the number of mutations present in both a lung carcinoma and melanoma 
patient (Pleasance et al., 2010a; Pleasance et al., 2010b).  Though in both cases this 
information was gained from the cells of an individual patient, it demonstrates the 
huge potential of NGS and the extent of data that can be discerned at the current time. 
 
The previous chapter detailed the effect that HAGE expression has on the 
proliferation of tumour cells.  There is an implication that there are various genetic 
interactions that are altered to induce this phenotype.  To that end, gene expression 
profiling was performed in an attempt to discover what genes are influenced in 
tumour cells as a result of HAGE gene expression.  
 
4.2 Results 
 
4.2.1 Genome wide Expression Analysis 
 
To examine the possible changes that occur to cancer cell genome expression in 
response to the presence of HAGE, expression profiling oligonucleotide microarray 
was performed.  FM-82 cells were treated with either control or HAGE-specific 
siRNA to recreate the environment used in the initial in vitro proliferation studies. 
This was carried out in triplicate to generate a suitable number of repeats to examine 
the effect of gene expression change.  RNA from these cells was extracted and 
supplied to the NASC service to undergo analysis.  Microarray testing requires the 
use of very high quality RNA and the material supplied was suitable for this purpose 
as determined by spectrophotometry and Agilent Bioanalysis.  RNA was hybridised 
to the Human U133 Plus 2.0 Genechip arrays which have transcripts for 
approximately 56,000 genes including the entire human genetic sequence, 
housekeeping genes and negative control genes.  These were used to investigate the 
impact of HAGE on the whole human genome. 
 
Once the report data had been validated using Genespring software, differential 
analysis of the gene data took place.  Figure 4.1 shows the volcano plot derived from 
Genespring showing all the genes analysed, their change in signal intensity and fold 
change in expression following HAGE knockdown.  Differential analysis involved 
initially averaging the signal data gained for all the genes from the chip from the 
triplicate samples.  Averaged signals from the test samples were then divided by the 
averaged signals from the control samples to gain a ratio of test versus control.  This 
gave a basic indication as to the change in expression of all tested genes in response 
to the knockdown of HAGE.  To ensure that this analysis had been successful, the 
data was searched for the ratio of HAGE.  It was found that the ratio of the gene was 
0.18, meaning that there had been an 82% decrease in expression after siRNA 
treatment.  This meant that a suitable level of HAGE knockdown had been achieved 
and implied that other results were reliable.  
  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Volcano plot derived from analysis of Genechip microarray data using Genespring 
software.  Points on the plot represent all genes screened using the arrays of choice.  The X-
axis shows the fold change in expression of these genes, while the Y-axis shows the significance 
(p value) of change.  Points coloured in red denote genes deemed to be the most significantly 
changed.   
Differential analysis generated a considerable collection of genes in which to search.  
To refine this, in the first instance a smaller list was created by isolating all genes that 
showed a 2.5 fold change in expression, either up or down-regulation.  From this list, 
identities and functions were assigned to each gene using Entrez Nucleotide and 
OMIM database searches.  When completed, a collection of genes was chosen based 
on the extent of their expression change and published role in processes that undergo 
modification in cancer cells, shown in Table 4.1.  Some of these genes are involved in 
events that a tumour would promote such as proliferation and cell cycle progression 
(E2F2, CCNE2, WNT-1), immune escape (FAS-L), and cell survival (HSP-27, HSP-
70).  There were also genes that a tumour would inhibit in order to progress such as 
immune reactivity (CXCL-6, IL-15), apoptosis (PKC-1, SFRP-1, CIDE-A) and 
inhibition of angiogenesis (JUN-D).  
 
4.2.2 Validation of Microarray Data 
 
To examine if the data from microarray analysis was correct, specific primer 
molecules for the genes listed in Table 4.1 were acquired.  The annealing 
temperatures for these primers were optimised by synthesising cDNA using RT-PCR 
and using gel electrophoresis to examine if the generated product was of the correct 
size (Data not shown).  When done, these primers were used in real-time qPCR to 
ratify microarray data analysis.  In the first instance, this involved RNA extracted 
from FM-82 cells treated with control or HAGE siRNA thus recreating the setting of 
the microarray testing.  Samples were run in duplicate and for each gene analysed a 
non-template control was run to act as a negative control.  Housekeeping genes 
GAPDH, TBP-1 and HPRT-1 were also analysed and the data from these was used to 
normalise test data.  Following 2CT calculations, relative expression of these genes 
was calculated by comparing the results of test to control.  These are shown in Figure 
4.2.   
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.1: List of genes isolated for further study following differential data analysis of 
microarray data and literature searches.  Selection was based around the extent of expression 
change following HAGE knockdown and the published roles of the gene in a process known to 
be altered in cancerous cells.
Tumour suppression
p21CIP1
Rb
Cell invasion/metastasis
FAK
MMP9
Memory T cell developmentIL-15
NRAS
Genes down-regulated when HAGE is expressed
Genes up-regulated when HAGE is expressed
TIMP4 Inhibition of MMPs
CXCL6
SFRP1
CIDEA Apoptosis
PKCb1
Inhibition of angiogenesisJUN-D
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Figure 4.2: Relative expression of genes of interest in FM-82 cells treated with either 
control siRNA (Green bars) or HAGE-specific siRNA (Yellow bars) as determined by real-
time qPCR (n=4).  CT readings were normalised using the housekeeping genes GAPDH, 
TBP-1 and HPRT-1 and used to calculate 2CT values.  
One can notice that HAGE gene expression decreased by 92%, therefore this 
followed the same pattern as the microarray analysis.  As can be seen, those genes 
which would be advantageous for a tumour to promote were decreased following 
HAGE knockdown, with CCNE2, E2F2 and FAS-L displaying the greatest change.  
This entails that when HAGE is expressed, expression of these genes increases.  
Similarly, the majority of genes that are involved in anti-tumour activities increased 
their expression once HAGE underwent interference, with JUN-D, PKC-1 and IL-15 
all showing large changes in expression.  This would go to suggest that in tumour 
cells, HAGE is acting to decrease their expression.  The only exception to this was 
CXCL-6, which demonstrated a decrease in expression.  This meant in total, out of 13 
genes tested including HAGE, 12 (92%) shared the same change in expression as was 
found with microarray testing.   
 
Since it was important to determine if these results were due to HAGE knockdown 
and not simply cell line-specific, the above was repeated using RNA extracted from 
the HAGE-positive FM-6 cell line treated in the same way as FM-82.  As displayed 
by Figure 4.3, the relative expression of the gene panel demonstrated a very similar 
pattern in this cell line compared to that of FM-82.  On this occasion, the genes 
suspected of being promoted by HAGE again all decreased in expression, going yet 
further to consolidate the proposed role of HAGE in cancer.  With the role of genes 
that are involved in anti-tumour processes, the majority matched the expression 
change seen with microarray, with PKC-1 and IL-15 demonstrating large increases 
in their expression.  CXCL-6 showed an increase expression after HAGE knockdown 
and matched the expression profiling but was in contrast to the expression found in 
FM-82.  Conversely, with FM-6 both CIDE-A and SFRP-1 actually decreased their 
expression in response to HAGE knockdown, seeming to contradict the other data.  
Despite this, 11/13 genes (85%) shared the pattern of expression discovered using 
microarray analysis. 
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Figure 4.3: Relative expression of genes of interest in FM-6 cells treated with either 
control siRNA (Green bars) or HAGE-specific siRNA (Yellow bars) as determined by real-
time qPCR (n=4).  Relative expression was determine in the same manner used for FM-
82.  
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Figure 4.4: Relative expression of genes of interest in HAGE cDNA stable transfectants 
determined by real-time qPCR (n=4).  Expression in cells transfected with the empty plasmid 
vector (Green bars) was compared to that in cells treated with pcDNA3.1/HAGE cDNA 
plasmid (Yellow bars).   Relative expression was determined in the same manner used for 
previously described results.
Confirmation had been attained using HAGE-positive cell lines that had undergone 
transient RNAi.  To establish if similar results could be gained from cells with long 
term modifications to HAGE expression, the same experiment was carried out with 
cDNA generated from the RNA extracted from both sets of stable transfectants.  
Figures 4.4 and 4.5 highlight that considerable differences to expression changes 
could be seen in these cells compared to that observed in transient knockdown.  In 
terms of the stable cDNA transfection (Figure 4.4), it was found that HAGE had 
indeed been successfully introduced to a high degree, with a relative expression 
increase of approximately 196,000-fold compared to the control cell line.  However, 
the majority of genes tested did not share the expression changes seen previously.  
Only FAS-L increased its expression in response to stable induction of HAGE, with a 
221-fold rise in expression.  Other genes expected to increase with stable HAGE 
expression such as CCNE2, E2F2 amongst others, actually decreased.  With the genes 
previously shown to decrease with HAGE expression, there were more promising 
findings.  PKC-1, CXCL-6 and IL-15, all showing reductions in their expression, 
thereby giving the reciprocate picture as would be hoped for.  
 
A similar series was found with the stable knockdown cells (Figure 4.5).  A 
considerable decrease in HAGE expression was achieved, being around 82%, 
matching that attained with siRNA for microarray analysis.  In spite of this, like the 
cDNA transfectants, changes to target gene expression varied to that seen with 
transient knockdown.  Only HSP-27 and 70 demonstrated a large decrease, while the 
remainder showed increases or a very small decrease in WNT-1.  Comparatively, the 
pro-apoptotic genes PKC-1, CIDE-A and SFRP-1 all increased, matching previous 
results but JUN-D, CXCL-6 and IL-15 all decreased.  Therefore there seems to be 
some discrepancies between the effects of transient and stable transfection, hinting 
towards possible effects of prolonged changes to gene expression. 
 
In order to confirm that the effects in gene expression were not lineage-specific, 
cDNA was synthesised from the RNA extracted from a HAGE-positive head and 
neck carcinoma cell line PCI-13.  This had been treated transiently with HAGE-
specific siRNA in the same manner utilised for FM-82 and FM-6.  As shown by 
Figure 4.6, in this instance, it was possible to reduce HAGE expression by 
approximately 66%.  However, not all genes matched the pattern exhibited by the 
melanoma cell lines.  This cell line did not appear to express either PKC-1 or SFRP-
1 as it was not possible to gain any signal from real-time qPCR.  For the remaining 
genes, FAS-L and the two HSP members demonstrated decreases to go alongside 
HAGE, while JUN-D and CXCL-6 increased, thereby supporting earlier impressions 
that HAGE seems to inhibit their expression.  So, it was possible to show that some 
genes are influenced by HAGE across malignancies.   
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Figure 4.6: Relative expression of genes of interest in the PCI-13 cell line following 
siRNA treatment, determined by real-time qPCR (n=4).  Comparison was made 
between those cells treated with control siRNA (Green bars) or HAGE specific siRNA
(Yellow bars)   Relative expression was determined in the same manner used for 
experiments involving melanoma cell lines.
Figure 4.5: Relative expression of genes of interest in HAGE shRNA stable 
transfectants as determined by real-time qPCR (n=4).  Expression in cells transfected 
with the control shRNA (Green bars) was compared to that in cells treated with a 
HAGE specific shRNA  (Yellow bars).   Relative expression was determined in the same 
manner used for previously described results.
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
No changeDown-regDown-regUp-regUp-regIL-15
Up-regDown-regDown-regUp-regDown-regCXCL-6
N/AUp-regUp-regDown-regUp-regSFRP-1
Down-regUp-regUp-regDown-regUp-regCIDE-A
N/AUp-regDown-regUp-regUp-regPKC-1
Up-regDown-regUp-regUp-regUp-regJUN-D
Down-regDown-regDown-regDown-regDown-regHSP-70
Down-regDown-regDown-regDown-regDown-regHSP-27
Down-regUp-regUp-regDown-regDown-regFAS-L
Up-regDown-regDown-regDown-regDown-regWNT-1
Up-regUp-regDown-regDown-regDown-regE2F2
Up-regUp-regDown-regDown-regDown-regCCNE2
Down-regDown-regUp-regDown-regDown-regHAGE
PCI-13/
siRNA
FM-82/
shRNA
FM-3/
HAGE
FM-6/
siRNA
FM-82/
siRNAGene
Cell Lines and Treatment
Table 4.2: Summary of expression change seen in genes of interest following modification 
to HAGE gene expression in melanoma or head and neck carcinoma cell lines using 
siRNA, shRNA or cDNA.  Changes displayed are those noted using expression analysis 
involving real-time qPCR.  
4.3 Discussion 
 
It has been shown on many occasions that the expression of particular genes in cancer 
leads to changes in behaviour of a transformed cell, whether it is just one particular 
aspect or several.  Changes to biology come about thanks to alterations in the 
molecular interactions that take place within the cell.  Previously, it was discussed 
how initial experiments found evidence to support the involvement of HAGE in 
increasing the ability of tumour cells to proliferate.  In order to establish what 
possible molecular relationships may exist to provide this phenotype, gene expression 
profiling in the form of oligonucleotide microarray analysis was performed.  
Specifically, this was carried out on a human melanoma cell line that had undergone 
transient HAGE knockdown using siRNA to discover what occurs to a cancer cell 
transcriptome following this event.  Since the entire transcriptome of these cells was 
screened using microarray, a large number of different genes could have been 
analysed.  Selection of those chosen for further study was based on the extent of 
expression change, which was chosen to be a 2.5 fold up/down-regulation, and genes 
generating a product with published involvement in a cell process modified in 
malignancy 
 
What was noticeable about the confirmation of the microarray data using qPCR was 
the similarity in the change in expression in target genes in both FM-82 and FM-6.  
Both showed very close correlation between the genes that were both up and down 
regulated in response to the knockdown in HAGE expression.  On the other hand, this 
was not shared by both sets of stable transfectants.  While some genes did match 
overall, it was relatively fewer than might have been first thought of, especially in 
light of the change of HAGE expression that was gained in each set.  For the cDNA 
transfectants, this may result from the stable incorporation of the plasmid into the 
cell’s genome.  Since this was not a promoter-specific induction of gene expression, it 
is difficult to know what impact the plasmid might be having on the genetic stability 
of the cell.  Evidence gained from proliferation assays showed that these cells 
matched the behaviour of cells that naturally express HAGE, but this phenotype 
might be brought about through different genetic changes.  This is made all the more 
possible when one considers that this was originally a HAGE-negative line in which a 
significant change to a particular gene has taken place. 
 The shRNA lines were more of a concern as they in essence followed the same 
biological pattern as cells treated with siRNA.  However, it is difficult to say what 
effect long-term knockdown of a specific gene has on a cell’s genomic make-up.  It 
may well be that prolonged exposure to RNAi caused by integration of shRNA 
specific to HAGE could cause genetic changes that were seen in this experiment. 
 
It would appear that HAGE does have genetic effects shared across different tumour 
types.  This could be seen with the expression of genes seen in the PCI-13 cell line.  
On the other hand, like the stable transfectants this was not universal across the entire 
gene panel.  This series of experiments was carried out to investigate if any similarity 
existed.  In that respect, it could be called successful, since certain genes do alter their 
expression in the same way.  It would be highly unusual if two completely different 
tumours shared the exact same genetic pattern.  This can be argued further when one 
considered that naturally, these cell lines would naturally have very different levels of 
expression of all of the genes tested.  Therefore silencing of HAGE allowed the 
recognition of genes that could be implicated across different forms of cancer.  
However, this was only performed in one head and neck carcinoma line compared to 
the two natural and two modified melanoma cell lines.  Therefore, to confirm the 
hypothesis further, the same studies need to be to be repeated in other cell lines 
derived from this malignancy.  In the future, it would be interesting to perform this 
type of expression analysis using a panel of cells taken from a variety of HAGE-
expressing tumour types to further establish the extent of gene expression change 
involving this antigen. 
 
Primary indications from the analysed microarray data provided evidence that HAGE 
gene expression affects genes involved in proliferation and cell cycle progression.  
This was shown with decreases expression of CCNE2, E2F2 and WNT-1 once HAGE 
was silenced, therefore implying that their expression would be up-regulated in the 
presence of HAGE.  WNT-1 belongs to a series of secreted signalling molecules used 
in epithelial homeostasis that act on frizzled receptors on the cell surface and activate 
proliferation through the -catenin pathway (Fodde and Brabletz, 2007; Suzuki et al., 
2008).  WNT itself is classed as being an oncogene and is implicated in tumorigenesis 
(Behrens and Lustig, 2004).  It has been shown that inhibition of WNT signalling in 
colorectal carcinoma can result in apoptosis of cells (He et al., 2005).  Aberrant WNT 
can be found in numerous different cancers, especially breast cancer, where there is 
evidence of autocrine signalling (Schlange et al., 2007; Oloumi et al., 2010).  Of note 
is the data that has been published indicating that WNT signalling is inhibited by 
SFRP-1 (Matsuda et al., 2009), a gene that according to this study’s data was found to 
be down-regulated by HAGE.  Increased expression of WNT by HAGE would seem 
to suggest that the cells are capable of autocrine production of a potent signalling 
protein, given previous work showing its secretion from cells.  As this is initial data 
based on gene expression, this would obviously require confirmation at the protein 
level.  If however, this is the case, then increase signalling by this molecule could 
provide an answer for how HAGE expressing cells are able to proliferate quicker.  
This is made all the more interesting by the proposed role of SFRP-1 in WNT 
blockade, suggesting some sort of molecular interaction involving HAGE. 
 
CCNE2 (Cyclin E2) and E2F2 are both involved in the cell cycle process.  The latter 
is a member of the E2F family of transcription factors and promotes the transition 
from G1 to S phase, therefore promoting proliferation of a cell.  In particular E2F1-3 
have been implicated in this role.  Normally, the action of E2F members is inhibited 
by the TSG retinoblastoma (Rb), which binds to them and prevents them from 
inducing target gene transcription (DeGregori, 2002).  In a healthy environment, 
E2F2 alongside its associate member E2F1 can promote either apoptosis or cell cycle 
progression (Cam and Dynlacht, 2003).  In the absence/inactivation of Rb, a situation 
found in tumours, this balance is tipped towards the latter and hence proliferation 
(Cam and Dynlacht, 2003).  E2F2 over-expression has been shown to activate hyper-
proliferation in a transgenic murine model (Scheijen et al., 2004).  Furthermore, there 
is evidence indicating that E2F2 is required by MYC, a gene amplified in cancer, to 
promote cell cycle progression and that its ablation stops this process (Leone et al., 
2001).   
 
Other work has suggested E2F2 might inhibit tumorigeneis, thereby contradicting 
previous work into the molecule (Zhu et al., 2001; Li et al., 2003; Scheijen et al., 
2004).  It is possible that certain members of the E2F family have both pro and anti-
tumorigenic properties, but which depends on the state of other molecules in the cell.  
It is possible that in HAGE expressing cells, E2F2 acts to promote proliferation and 
increased mRNA expression could result in increased protein that contributes to the 
apparent raised cell turnover.  As with WNT-1, evaluation of the protein level of 
E2F2 in HAGE expressing cells would be needed to corroborate this theory further.   
 
Interestingly, further evidence of increased cell cycle progression came in the form of 
increased CCNE2 mRNA expression in HAGE-positive cells.  Increased expression 
of this gene has been shown in tumours and over-expression of CCNE2 is connected 
with increased cell cycle progression and increases the number of cells in S phase 
(Payton and Coats, 2002).  It can also be induced by oncogenic proteins by viruses 
(Zariwala et al., 1998).  This immediately suggests that HAGE positive cells could be 
capable of increased progression due to the enhanced expression of CCNE2.  It is 
able to bring about passage into S phase by complexing with CDK-2 (Gudas et al, 
1999).  The ability of CCNE2 to reduce the time taken for the cell cycle to occur 
comes from it acting on the TSG Rb, repressing its activity (Ohtsubo et al., 1995; 
Sherr and Roberts, 1999; Payton and Coats, 2002).  This is intriguing, since it is 
known that Rb acts to inhibit the E2F family.  As such, a hypothesis could be stated 
that in HAGE expressing cells, inhibition of Rb by CCNE2 and evidently increased 
E2F2 expression could lead to an enhancement of proliferation.  In order to confirm 
this, activation of Rb would need to be checked, as would possible coupling of 
CCNE2 protein to CDK2.  As with other regulatory molecules in tumours, there is a 
paradox as to the relationship that CCNE2 has with proteins that regulate it.  Both 
p21CIP1 and p27KIP1 are known to inhibit CCNE2-CDK complexes (Harper and 
Elledge, 1996; Payton and Coats, 2002).  However other work also states that the 
former can interact with p27KIP1 to inhibit its function (Sheaff et al., 1997), meaning 
that there is a need to study further some of the regulators and effectors of CCNE2. 
 
Examination of the differential analysis results revealed that it was not just 
proliferation that seemed to be affected by HAGE expression, but other cell processes 
involved in cancer too.  Collectively, these data indicate that HAGE promotes 
survival mechanisms in cells that expressed it.  This came from the recognition that 
genes reported to promote apoptosis, PKC-1, CIDE-A and SFRP-1, increased their 
expression when HAGE was silenced.  At the same time, there was a decrease in the 
expression of both HSP-27 and 70.  This implies that HAGE may be able to reduce 
and up-regulate these two groups of genes respectively.   
 
In terms of the former group, PKC-1 is one of two splice variants of the PKC- gene 
(Martiny-Baron and Fabbro, 2007).  It has been shown that this specific variant can 
contribute towards activating apoptosis.  This occurs during oxidative stress through 
the influence of ROS, where it contributes to the expression of p66.  This proteins 
acts to disrupt the mitochondrial membrane and through that activate apoptosis in 
response to oxygen related injury (Pinton et al., 2007).  It is possible then that HAGE 
expression leads to a reduction in pro-apoptotic molecules.  On the other hand, PKC-
2 has been shown to be involved in driving various tumorigenic events (Gökeman-
Polar et al., 2001; Martiny-Baron and Fabbro, 2007).  Elevation in levels has been 
linked to the development of colorectal carcinoma and expression.  The expression of 
PKC- in general is associated with uncontrollable proliferation and associated with 
poor prognosis in DLBCL (Martiny-Baron and Fabbro, 2007).  However there is 
evidence of this loss in expression in melanoma (Martiny-Baron and Fabbro, 2007).  
This is thought to be part of the differentiation process and could explain what was 
seen in the result gained.  On the other hand, this does not explain why reduction in 
HAGE results in reduced expression of PKC-1, hinting to a possible link with 
apoptosis. 
 
The gene CIDE-A (Cell death- inducing DNA fragmentation factor-a-like effector A) 
was first recognised in mice as being related to DNA fragmentation factor (DFF) 
family.  These are responsible for the break-up of DNA to cause apoptosis (Inohara et 
al., 1998).  To date, this molecule is predominantly linked to a role in adipocytes and 
loss of expression has been associated with obesity (Lin and Li, 2004; Nordström et 
al., 2005).  There have been two converse links with CIDE-A and cancer.  On the one 
hand, there has been an association with over expression of CIDE-A and cachexia, 
the weight loss that takes place in later-stage cancer patients (Laurencikiene et al., 
2008).  On the other hand other work has shown that the gene undergoes methylation 
and thus silencing (Hill et al., 2010; Huang et al., 2010), possibly to stop its potential 
role in apoptosis.  Results from this study indicated the latter and would appear to fit 
with the hypothesis that HAGE is involved in increasing tumour cell proliferation.  
 One of the most interesting molecules that HAGE seems to inhibit is SFRP-1 
(Secreted frizzled-related protein-1).  This belongs to a group of five glycoproteins 
that have been proposed to act as inhibitors of WNT (Jones and Jomary, 2002; 
Sogabe et al., 2008).  Work performed on cervical, colorectal and hepatocellular 
carcinoma (HCC) has shown that expression of SFRP-1 antagonises WNT signalling, 
while its loss has the opposite effect (Suzuki et al., 2004; Shih et al., 2007; Chung et 
al., 2009).  Additionally, loss or silencing of the gene has been found in bladder, 
breast, prostate and non-small cell lung carcinoma (NSCLC) (Stoehr et al., 2004; 
Fukui et al., 2005; Lodygin et al., 2005; Lo et al., 2006).  Both microarray and PCR 
data hinted at the decreased expression of this gene when HAGE was present in cells.  
As described above, WNT-1 was up-regulated in the same situation.  Therefore, there 
seemed to be some sort of agreement with previously published findings as to the 
relationship between WNT and SFRP-1 with the results displayed here.  The change 
in these genes’ expression following HAGE knockdown also insinuates that the 
demonstration of HAGE in cells could influence their expression.  Moreover, these 
findings act as another example of how HAGE expression has an effect on the 
relationship of genes that have involvement in cancer. 
 
Aside from affecting genes that could induce apoptosis and repress signalling, the 
data collected showed that genes promoting survival such as HSP-27 and 70 were 
also affected.  The heat shock proteins (HSP) are a group of chaperone molecules 
which serve to protect cells from death during stress events (Garrido et al., 2006).  An 
example of this is raised levels of both HSP-27 and 70 following the reoxygenation of 
cells, stopping cell death by oxidative injury (Kabakov et al., 2003).  HSP-27 and 70 
act by inhibiting the action of various prominent apoptotic mediators.  HSP-70 can 
inhibit the actions of BID and BAX, the JNK signal cascade and can prevent the 
actions of caspase 3, 7 and 9.  It is also capable of reversing apoptosis, even in its 
latter stages (Jolly and Morimoto, 2000; Garrido et al., 2006).  The necessity of HSP-
70 is exemplified by its down-regulation resulting in apoptotic cell death (Nylansted 
et al., 2000).  HSP-27, like 70 also inhibits caspases; in this case, it directly inhibits 
the actions of caspase 3.  It is also capable of inhibiting the activation of caspase 9 by 
preventing the action of cytochrome c (Garrido et al., 1999; Paul et al., 2002).  
Caspase independent cell death may also be stopped by HSP-27 through an apparent 
inhibition of the pro-apoptotic molecule DAXX (Charette et al., 2000; Garrido et al., 
2006; Schmitt et al., 2007).  Of particular note, is the ability of HSP-27 to 
phosphorylate and therefore activate AKT (Schmitt et al., 2007).  This not only helps 
to halt apoptosis through the inactivation of BAD, but can also lead to proliferation.  
The TSG cell cycle inhibitor p27KIP1 is ubiquinylated and therefore degraded as a 
result of HSP-27 and through that promoting cell cycle progression (Garrido et al., 
2006; Parcellier et al., 2006).  
 
HSP molecules are known to be up-regulated in cancers (Soti and Csermely, 1998; 
Jolly and Morimoto, 2000).  Indeed, HSP-27 is linked to drug resistance in tumours 
(Garrido et al., 1997; Choi et al., 2007).  This would again link HAGE to 
proliferation and prevention of apoptosis, particularly the possible relationship 
between HSP-27 and the pro-proliferative AKT molecule.  More to the point, this acts 
as evidence that HAGE may cause tumour cells to survive.  Up-regulation of HSP-27, 
a molecule known to create chemo-resistance, suggests that HAGE may be promoting 
a more aggressive phenotype in tumours.  On top of this is the connection that HSP-
27 has with the inhibition of p27KIP1.  This latter protein inactivates CCNE2-CDK2 
complexes, meaning that there is yet more possibility that HAGE is influencing 
various cellular interactions. 
 
A rather paradoxical change in expression came in the form of JUN-D.  This belongs 
to the JUN family of genes that have been associated with cancer in the past (Hirai et 
al., 1989; Ryder et al., 1989).  This member, like its other counterparts, has been 
classified as being an oncogene.  It has been described that expression of JUN-D 
promotes cell survival against oxidative stress (Gerald et al., 2004).  So, there appears 
to be a paradox in the results obtained, showing that JUN-D would be down-regulated 
when HAGE is expressed by malignant cells.  However, the same work that showed 
JUN-D protects against ROS described that angiogenesis is inhibited by this gene 
through this antagonism of the oncogene RAS (Gerald et al., 2004).  One could 
therefore argue that in a HAGE expressing cell, while JUN-D does protect a cell, it 
does so at the cost of a less aggressive phenotype.  Since it was possible to show 
evidence of other survival genes being up-regulated by HAGE, there is a theory that 
JUN-D is inhibited in order to promote RAS activation of angiogenesis and through 
that encourage a more aggressive disease state.    
 
Aside from the hallmarks of cancer detailed above that HAGE seems to have an 
effect on, gene data collected in this study indicated that HAGE expression could aid 
in tumour immune escape.  This came from the recognition that once HAGE 
expression appeared to lead to a decrease in the expression of both CXCL-6 and IL-
15.  The former is a chemokine connected with IL-8 and acts as ligand for innate 
immune cells.  It has been shown to both bring about innate immune reactions while 
also being increased during hypoxic conditions (Zhu et al., 2006; Mittal et al., 2008).  
So in this instance, it is possible that HAGE could allow tumour cells to protect 
themselves from attack from innate immune cells.  The finding that CXCL-6 is 
greater in hypoxia seems to give another link between HAGE and stress that 
reoccurred through the gene data gained. 
 
IL-15 on the other hand is an important cytokine used in the homeostasis of T cells.  
It stimulates continued proliferation of activated T cells (Waldmann, 2003), and 
contributes to both NK cell survival and maturation (Carson et al., 1997; Cooper et 
al., 2002; Cho and Campana, 2009), a factor has been demonstrated in vivo (Cooper 
et al., 2002).  Perhaps the most important aspect of IL-15 is its role in the generation 
and survival of memory T cells (Schluns et al., 2002; Surh and Sprent, 2008), which 
has been demonstrated in vivo (Zhang et al., 1998).  These are of great importance in 
immunity, especially in terms of tumour immunity as T cells capable of 
‘remembering’ tumour antigens are a powerful tool against malignancies.  This is one 
of the reasons why IL-15 is considered a potentially valuable tool in cancer 
immunotherapy (Cho and Campana, 2009).  This implies that a HAGE expressing 
tumour could have the potential to inhibit the actions to cause T cell memory and in 
turn grant itself a better chance of survival against immune reactivity.  Furthermore, 
the possible maturation of NK cells could be of threat to a tumour, due to the anti-
malignant activity of these cells.  Collectively, evidence for change in expression of 
this and CXCL-6 allows the impression that both aspects of immunity could 
potentially be altered by the expression of HAGE. 
 
Ultimately, it was shown that a number of different genes are affected by the 
expression of HAGE in tumour cells.  Aside from the initial confirmation that genes 
involved in cell proliferation and the cell cycle appeared to be affected as was hoped, 
there seemed to other processes that could be manipulated by HAGE.  While these 
findings were very promising, it must be stressed that this was genetic data and 
therefore must be confirmed at the protein level before any further conclusions could 
be made.  It did however appear to validate the use of the combined use of microarray 
and qPCR as an effective tool for achieving more insight into the possible role of a 
gene in cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 5 
 
 
Expression of HAGE and its Impact on Cell Signalling Pathways in 
Cancer 
 
5.1 Introduction 
 
Cancer is a disease which comes about through a disruption in the signalling 
networks that control cell behaviour.  Every behavioural facet of a cell is governed by 
communication cascades that induce them to perform a given action at all stages of 
their life.  This is brought about through the action of different proteins that either 
interact and influence other proteins, or act as transcription factors to provoke 
expression of specific genes.  Cellular signalling is such a highly complex subject that 
it cannot be covered comprehensively here, but the basic principles will be outlined.   
 
There are numerous different networks within cells, involving a huge number of 
different molecules.  They may consist of a single cascade or multiple pathways that 
connect together but bear the potential to act autonomously.  Furthermore, a cascade 
may well be controlled by its most upstream molecule but can also be influenced by 
other mediators that lie even further upstream than this, adding yet more complexity 
to the subject.  Good examples of this can be found with the PI3K pathways, which 
can act alone, reacting to ligand-receptor binding, or be activated through the actions 
of RAS members, which lies further upstream (Rodriguez-Viciana et al., 1994; 
Krasilnikov, 2000; Pacold et al., 2000).  Due to the extremely complicated nature of 
signalling, it is often portrayed as a situation where one pathway/network is active at 
a particular moment.  This is especially true in the case of explaining proliferation 
versus apoptosis signalling.  It would be naïve to believe that this is the case in vivo.  
A cell may well be constantly exposed to various simultaneous stimuli, that both 
encourage a cell expand its population or to inhibit it, senesce or die.  The key is the 
balance of these signals, which comes from homeostasis, which promotes specific 
cascades. 
 
In cancer, this balance is tipped in favour of promoting the acquisition of hallmarks 
described by Hanahan and Weinberg (2000).  For this to take place, there must be a 
situation where molecules, which can cause this phenotype, are promoted and others 
with the potential to inhibit are lost or down-regulated.  It is at this point that the 
modifications that occur to the proto-oncogenes and TSG become more apparent and 
their significance made more noticeable.  These alterations can take place not just at 
the genetic level, but also affect post-translational modification of protein products.  
Different alterations can affect molecules in different ways.  Point mutations in RAS 
and B-RAF significantly increase their activity and can cause increased proliferation 
of cells through either the PI3K or MAPK pathway (Bos, 1989; Davies et al., 2002).  
Conversely, the same change to p53 causes abnormal function, reducing the 
capability of affected cells to cause cell cycle arrest and apoptosis, contributing to 
proliferation (Levine and Oren, 2009).  Chromosomal translocation can also lead to 
increased proliferation of cells, seen following the formation of BCR-ABL in CML 
and ALL (Druker et al., 2001b).  At the same time, loss of PTEN through deletion 
allows continual signalling through the PI3K pathway (Blanco-Aparicio et al., 2007).  
Post-translational modifications that affect protein activity are most frequently seen in 
terms of phosphorylation.  AKT can experience this as a result of PTEN loss, which 
leads to more production of PIP3 that modifies AKT (Maehama and Dixon, 1998; 
Chow and Baker, 2006).  In this state, the molecule is more active and can cause 
increased proliferation by causing the transcription of various genes and inhibits 
apoptosis by inhibiting other proteins like BAD Datta et al., 1997).   
 
Phosphorylation is just one of the numerous different ways that proteins can be 
modified following translation.  Others include glycosylation, sumolysation (PML) 
(Dohmen, 2004), farnesylation and palmitoylation (both RAS) (Roy et al., 2005; 
Wright and Philips, 2006).  This diversity of modifications adds to the complexity of 
tumour signalling and targeting molecules involved.  This is especially true with 
RAS.  Upon translation of RAS isoforms, it was originally believed that they must be 
subject to farnesylation by farnesyl transferases in order to truly active and be capable 
of trafficking to the cell membrane (Downward, 2003; Omerovic et al., 2007).  This 
led to the development of various different inhibitors against farnesyl transferases as 
anti-RAS cancer therapy, which have had very limited effect to date (Downward, 
2003).  In part, this is due to the discovery that both K-RAS isoforms and N-RAS can 
still undergo prenylation by the geranylgeranyl transferase enzyme (Whyte et al., 
1997).  The other issue is that farnesyl transferase inhibitors are most effective against 
H-RAS, mutations of which occur in less than 1% of human tumours with oncogenic 
RAS (Bos, 1989; Downward, 2003; Omerovic et al., 2007). 
 
Cell signalling disruption is integral to the concept of Weinstein’s “oncogene 
addiction” theory and Felsher’s “oncogene amnesia” hypothesis (Felsher, 2008; 
Weinstein and Joe, 2008).  Both suggest evident reliance of tumour cells on certain 
gene products for their development.  This would seem to come about two ways.  The 
first could be from loss of genes leading to dependence on specific genes to maintain 
particular signalling pathways to maintain survival.  This can be seen with the 
reliance on PARP-1 for DNA repair signalling following the loss of BRCA (McCabe 
et al., 2006).  Alternatively, it could be that signalling involving specific oncogenes 
are so profitable to tumour cells, they become increasingly reliant upon that pathway.  
Moreover, it could be argued that a tumour cell moves to down-regulate other 
cascades that are not as efficient as the transformed ones so only this latter pathway is 
active.  Evidence for this can be found in the success of Imatinib in CML.  Use of this 
TKI causes signal attenuation via the BCR-ABL protein, leading to the death of Ph-
positive malignant white cells through apoptosis (Deininger et al., 2000b).  If other 
proliferative pathways were readily available to those cells, one would assume it 
would be possible to use them.  However, it would seem that loss of BCR-ABL 
signalling changes the signal environment and in the time taken for other cascades to 
be re-established, signalling homeostasis is tipped in favour of apoptosis and death 
occurs.  Therefore, oncogene addiction/amnesia and synthetic lethality are closely 
bound to signalling within tumour cells. 
 
Knowledge about tumour cell signalling has come from extensive research 
investigating how normal signals become corrupted.  This has involved combinations 
of genetic, proteomic and bioinformatic approaches over the years to piece together 
pathways and networks and changes to them.  Understanding of malignant cell 
signalling in general is currently highly extensive, with knowledge of certain 
pathways and the molecules involved being in-depth.  Paradoxically, in spite of this 
vast level of awareness, efforts to curtail signalling in malignant cells have been very 
limited.  Molecules that lie the furthest upstream are fewer in numbers and have 
proven very difficult to treat, as with RAS.  On the other hand, trying to target further 
downstream is arguably more testing due to the sheer number of effectors present.  
This is compounded by the possibility that signalling could be diverted by the tumour 
cell, rendering treatment useless.  Limitation in curtailing malignant signalling 
networks implies that there are molecules present in these pathways that currently 
remain unclear.  This would certainly account for difficulties being present in the face 
of apparently well developed understanding.  Therefore, other entities must exist that 
have influence over signalling that are yet to be discovered or are known molecules 
with extra abilities that are currently unclear.   
 
The data gained previously highlights a possible involvement of HAGE in tumour 
proliferation.  These also indicate that various genes concerned with various cell 
processes undergo expression change in response to HAGE being present in cells.  
Therefore work was carried out to investigate if this antigen has some form of 
influence over signalling networks in cancerous cells to cause the observed 
phenotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5.2 Results 
 
5.2.1 HAGE Expression and Alterations to PI3K Signal Molecule 
Phosphorylation 
 
To determine if signalling pathways, known to be altered in cancer, were affected by 
HAGE expression, the phosphorylation status of proteins involved in some of these 
paths were examined.  This was done using MAPK proteome arrays (R & D Systems) 
specific for the MAPK and PI3K pathways.  These can be used to determine the 
relative levels of phosphorylated forms of specific signalling proteins involved in 
these cascades.  Arrays were used in conjunction with protein lysates extracted from 
the shRNA stable transfectant cell lines.  Cells transfected in this manner represented 
the ideal way of further investigating HAGE as they represented the effect of long-
term knockdown in a line naturally positive for the antigen.  While the cDNA 
transfected cell line appeared to cause the same phenotype, it could be that this may 
be brought about through a different pathway.  To this end, the stable shRNA cell 
lines were used in preference. 
 
A representative image of arrays used with these lysates is shown in Figure 5.1(A).  
Every two spots seen in the image represents a specific signalling protein and its 
repeat.  Both the positive and negative controls for each array are highlighted.  Once 
images were gained for control and test lysates, densitometry was carried out to 
compare the levels of phospho-proteins following each treatment.  The average of 
these readings is shown in Figure 5.1(B).  As highlighted here, there appeared to be a 
difference in the levels of certain phospho-proteins known to be altered in tumours.  
Specifically, it seemed that once HAGE was reduced, there was a decrease in the 
levels of both AKT-1 and GSK-3 proteins involved in the PI3K signal pathway.  
Conversely, it could be noted that there was an increase in the level of phosphorylated 
ERK-2 in the same conditions.  For the former two proteins, this would appear to 
suggest that if HAGE is expressed by tumours, then there would be an increase in the 
level of their phosphorylation, suggesting possible post-translational modification 
resulting from HAGE expression.   
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Figure 5.2: MAPK Proteome Profiler array data obtained from lysates taken from shRNA
stable knockdown cells (n=2).  An image of the arrays used for densitometry is shown by 
(A).  Each two spots represents the capture region for a specific signalling protein and its 
repeat.  Positive controls are highlighted in green and negative controls in red.  
Densitometry readings of these arrays are shown in (B).
 5.2.2 Confirmation of Changes to Signal Protein Phosphorylation 
 
In order to confirm changes in phosphorylation status of AKT and GSK-3 hinted to 
by the proteome arrays, antibodies were obtained against these proteins for western 
blotting.  These would detect the phosphorylation at the same residues as detected by 
the MAPK arrays.  Antibodies against the total form of both these proteins were also 
acquired to assess whether changes observed are due to changes in the overall 
concentration of the protein.  Western blotting involved the initial separation of 
protein lysates derived from both FM-82/Ctrl and FM-82/shRNA.  These were then 
exposed to overnight staining for using these antibodies along with those against the 
housekeeping protein -actin.  Detected protein bands following membrane 
development are shown in Figure 5.2.  Bands detected by western blotting shared the 
same pattern that was noted with the Proteome Profiler arrays.  It was found that both 
AKT and GSK-3 total proteins were increased when HAGE was silenced yet with 
the phosphorylated forms of both proteins, it was found when HAGE was stably 
knocked-down using shRNA; there was marked decrease in their level.   
   
 
Densitometry was performed on these bands in order to calculate the difference in 
ratio of phosphorylated AKT and GSK-3 between FM-82/Ctrl and FM-82/shRNA.  
Readings for the test bands were normalised using the readings gained for -actin 
bands.  The ratio was then calculated by dividing the normalised reading for FM-
82/shRNA by the reading for the control cell line.  This was used to determine the 
proportion of phosphorylated protein in relation to total protein in each group of cells.  
For p-AKT (Ser473), the ratio gained for FM-82/Ctrl was 1.82 compared to 0.49 for 
FM-82/shRNA.  Though the visual difference between the bands was stark and the 
bars shown for this protein showed a difference, this was not considered to be 
statistically significant, implying more biological significance.  There was a similar 
pattern with p-GSK-3.  On this occasion, the ratio in FM-82/Ctrl was 0.69, which 
was greater than the 0.36 calculated for FM-82/shRNA.  Once again, though there 
was a recognisable difference between the levels of p-GSK-3 in each cell line, this 
was not seen as being statistically significant, suggesting biological significance.   
Thus, there seemed to be a connection between HAGE expression and the 
phosphorylation status of these two proteins.  In turn, this suggests HAGE could have 
some influence over molecules involved the PI3K signalling pathway.  If these 
modifications were a result of changes to gene expression or possible post-
translational modifications, the data from microarray analysis was referred back to.  
This showed that there was no significant change in the mRNA levels of both AKT 
and GSK-3 following HAGE gene knock down (Data not shown).  This implied that 
changes occurring to these proteins were a result of post-translational modification. 
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Figure 5.2: Confirmation of (A) AKT and (B) GSK-3 expression in HAGE stable knockdown cell 
lines.  Protein bands gained from western blotting (n=2) for total and phosphorylated proteins are 
shown along with averaged densitometry ratios used to determine the difference of p-AKT and p-
GSK-3 in each cell line.  Proteins were stained overnight with antibodies optimised to 1/500 for T-
AKT, T-GSK-3, p-GSK-3 and -actin.  Antibody for p-AKT was optimised to 1/250.   Ratios were 
calculated by normalising readings for test proteins using -actin readings and dividing the 
modified readings for the phosphorylated protein by that of the total, to represent the proportion of 
phospho-protein in that cell line. 
5.2.3 Effect of HAGE Expression on Molecules Associated with Cell Cycle 
Progression 
 
Increased phosphorylation of the PI3K effectors AKT and GSK-3 has links to 
increased proliferation of cells.  Therefore it was necessary to check the impact of 
HAGE expression on proteins involved in cell cycle progression.  To investigate this, 
an antibody against the CDK inhibitor p21CIP1, a downstream target of AKT, were 
obtained and used in western blotting using protein lysates from shRNA stable 
transfectants.  An image of these can be seen in Figure 5.3.  It was found that in FM-
82/shRNA cells, visually there appeared to be more p21CIP1 present than in control 
cell line.  This implied that in HAGE expressing cells, there would be a lower 
concentration of this CDK inhibitor.  Densitometry of the western blotting bands was 
performed to compare the level of the protein in each cell line, also shown in Figure 
5.3.  This was calculated by dividing the reading for the test band by its respective 
reading for -actin.  The averages of these were taken for each cell line and compared 
to one another.  The slight increased visually recognised in the protein bands was 
reflected in the ratios between the two lines, however this was deemed not to be 
statistically significant, suggesting that the difference was more biological. 
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Figure 5.3: Expression of the CDK inhibitor and AKT target substrate p21CIP1 in HAGE 
stable knockdown cells (n=2).  Proteins bands detected using a specific antibody are 
shown along with densitometry analysis of bands.  Proteins were separated using a 10% 
acrylamide SDS gel and stained overnight with antibody optimised to a 1/250 
concentration.  -actin antibody was optimised to 1/500.  Densitometry ratios were 
calculated by dividing readings for test band by reading for respective -actin, then 
averaging these readings.
FM-82/Ctrl FM-82/shRNA
-actin
p21CIP1
5.2.4 Impact of HAGE on the Expression of the N-RAS Oncogene 
 
Due to the apparent changes to the phosphorylated forms of both AKT and GSK-3, 
it was important to determine if the expression of HAGE had any impact on other 
aspects of signalling pathways.  In the first instance, a retrospective study of the 
microarray data analysis was performed to see if there were changes to molecules 
upstream of AKT and GSK-3 or more commonly modified downstream molecules.  
This review found that the oncogene N-RAS, which exists upstream of AKT and 
controls the PI3K cascade demonstrated a 70% decrease in expression following 
HAGE knockdown.  This implied HAGE would act to up-regulate this gene in 
tumour cells. 
 
Since RAS members are highly homologous, it was necessary to check if changes 
took place to K-RAS and H-RAS.  Examination of microarray analysis data indicated 
that there was no significant change in these latter two molecules, hinting that the 
effect of HAGE was confined to N-RAS.  To confirm this, primers specific for all 
three RAS members were obtained and used in real-time qPCR.  This initially 
involved cDNA generated from RNA extracted from FM-82 cells treated with siRNA 
to ratify the microarray findings.  Subsequently, cDNA synthesised from RNA 
extracted from shRNA stable transfected cells was used.  The relative expression of 
the three RAS genes in both instances is shown in Figure 5.4.  Figure 5.4(A) shows 
that following transient HAGE knockdown, there was a marked decrease in the 
mRNA expression of N-RAS.  Conversely, this change was not shown by either K-
RAS or H-RAS mRNA.  So in this instance, real-time qPCR was able to confirm the 
findings of microarray expression analysis.  When the same experiment was 
performed using stable knockdown RNA the pattern was reversed, highlighted in 
Figure 5.4(B).  Here, it could be seen that in response to prolonged reduction in 
HAGE expression, there was no change to the expression of N-RAS but a reduction 
to both K-and H-RAS gene mRNA expression.   
 
 
 
 
  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0
0.2
0.4
0.6
0.8
1
1.2
1.4
1.6
1.8
N-RAS H-RAS K-RAS
RAS Member
R
el
at
iv
e 
G
en
e 
E
xp
re
sio
n
Ctrl siRNA HAGE siRNA
A
**
R
el
at
iv
e 
G
en
e 
E
xp
re
sio
n
R
el
at
iv
e 
G
en
e 
E
xp
re
sio
n
B * *
0
0.2
0.4
0.6
0.8
1
1.2
N-RAS H-RAS K-RAS
RAS Member
R
el
at
iv
e 
G
en
e 
Ex
pr
es
si
on
FM-82/Ctrl FM-82/shRNA
R
el
at
iv
e 
G
en
e 
Ex
pr
es
si
on
Figure 5.4: Relative expression of RAS member expression determined by real-time qPCR
in response to HAGE silencing (n=4).  cDNA used for PCR was generated from RNA 
taken from either (A) FM-82 cells transfected transiently with siRNA (p=<0.01) or (B) 
FM-82 shRNA stable trasnfectants (p=<0.05).  Relative expression was calculated as 
previously described.
Though there seemed to be discrepancy between changes to N-RAS expression 
depending on the nature of HAGE knockdown, the implication was the oncogene’s 
mRNA expression was modified due to the presence of HAGE.  To gain more insight 
into this possible relationship, a siRNA duplex specific to N-RAS was obtained.  This 
was used to silence the FM-82 cell line, which is naturally positive for HAGE, to 
investigate if reduction in N-RAS expression resulted in a decrease in HAGE mRNA 
expression.  RAS gene expression was knocked down in the same manner used for 
HAGE.  Expression was detected using real-time qPCR and gene expression 
calculated using 2CT of PCR CT values normalised using the housekeeping genes 
GAPDH, TBP-1 and HPRT-1.  Due to the aforementioned homology that exists 
between RAS members, siRNA molecules unique for K-RAS and H-RAS were 
obtained and used in the same way as above.  In all cases, ‘BLAST’ nucleotide 
searches were performed on the designed siRNA sequence to ensure that they were 
unique to their target gene.    Following the knockdown of these genes, expression of 
OAS-1 and STAT-1 was checked using real-time qPCR to ensure that addition of 
siRNA would not lead to apoptosis mediated by the IFN- pathway, as done with 
HAGE in the past.  It was found for all siRNA molecules used that there was no 
significant increase in the expression of OAS-1 and STAT-1 (Data not shown), 
indicating that RAS siRNA did not induce the IFN- pathway. 
 
The relative expression for RAS and HAGE are shown in Figure 5.5.  As shown, 
transfection of siRNA into FM-82 cells was able to bring about reduced mRNA 
expression of specific RAS members.  Additionally, it was found that decreasing the 
expression of each RAS member did not lead to a simultaneous reduction in the 
expression of HAGE mRNA.  If one focuses on N-RAS, the specific RAS member of 
interest, Figure 5.5(A) shows that it was possible to achieve a marked reduction in the 
expression of the gene, reaching approximately 80%.  Conversely, though there was a 
decrease in HAGE, it was not as dramatic.  This begins to imply that HAGE may act 
upstream of N-RAS.  
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Figure 5.5: Relative gene expression of RAS members and HAGE in FM-82 following 
specific RAS siRNA transfection (n=4).  Expression was determined by real-time qPCR
analysis of cDNA synthesised from RNA extracted from cells treated with (A) N-RAS siRNA, 
(B) H-RAS siRNA or (C) K-RAS siRNA.  Relative expression was calculated from 2CT 
equations of PCR CT values following normalisation using GAPDH, TBP-1 and HPRT-1 
housekeeping genes (p=<0.001).
If HAGE does act to promote N-RAS, it was important to examine if this up-
regulation was noticeable at the protein level or confined to mRNA.  An antibody 
specific for N-RAS was obtained and used for western blotting of protein extracted 
from both FM-82/Ctrl and FM-82/shRNA.  An image of the detected bands along 
with -actin can be seen in Figure 5.6(A).  It could be noticed that following stable 
knockdown of HAGE expression in cells, there was a distinct decrease in the 
expression of the N-RAS protein.  This was in contrast to the mRNA of N-RAS in 
this situation, where there was no change following stable HAGE knockdown.  The 
decrease in protein was reflected in the densitometry ratio shown in Figure 5.6(A).  
From this, it could be argued that HAGE appears to promote N-RAS expression at the 
protein level. 
 
Since there seemed to be an increase in the protein level in HAGE expressing cells, 
there was the potential for an increase in the level of RAS-GTP, the active form of 
RAS proteins.  Should this be the case, there would be the possibility of HAGE 
interacting with GEF and/or GAP molecules that activate and inactivate RAS proteins 
respectively.  To that end, a pull-down method was used to isolate active RAS from 
FM-82/Ctrl and FM-82/shRNA and detected using western blotting.  For each cell 
line, part of the extracted lysate was supplemented with GTPS, thereby creating a 
positive control lysate to compare each test lysate.  The image taken for this is shown 
in Figure 5.6(B).  Here, it could be seen that there was no evident decrease in RAS 
activity following the stable knockdown of HAGE.  This meant that it did not seem 
HAGE had any influence over the direct activation or inactivation of RAS in cells. 
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Figure 5.6: Western blotting images of N-RAS protein expression in HAGE shRNA 
stable transfectants (n=2).  (A) shows bands detected following SDS electrophoresis 
using a 15% acrylamide gel ahead of transfer to membrane and staining with an anti-
human antibody optimised to a 1/250 concentration. -actin antibody was used at 
1/500.  Densitometry is also shown, calculated in the same manner for p21CIP1.  (B) 
shows western blotting of lysates isolated using a RAS-GTP pull down kit to isolate 
active RAS and run alongside lysate treated with GTPS acting as a positive control 
(n=1).
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5.3 Discussion 
 
Signalling pathways that reside within cells are remarkably difficult to target.  
Therefore, it therefore stands to reason there are aspects to these pathways that remain 
unknown.  Additionally, it means the possible existence of factors, as yet 
undiscovered, that are gained or lost as a result of malignant transformation that bear 
the facility to modify the actions of effectors of signalling pathways.  HAGE may be 
one of these factors.  
 
Preliminary work into this involved a basic screening of the MAPK and PI3K 
pathways, both of which are commonly corrupted in tumours.  The arrays utilised as 
part of this work were capable of identifying levels of the phosphorylated forms of 
major effectors proteins that exist within these cascades.  When used to screen protein 
lysates extracted from stable knockdown cell lines, there seemed to be a change in the 
level of certain phospho-proteins.  In particular, there were particularly noticeable 
changes to the PI3K effectors, AKT and GSK-3.  It was found once HAGE 
expression had been decreased using shRNA the phosphorylated forms of these 
proteins experienced clear reductions according to densitometry analysis.  These were 
matched by reductions to both the total AKT pool (AKT pan) and both GSK isoforms 
(GSK-3/, providing further evidence that there were changes to these proteins.  
Aside from this, there were additional reductions to the p38 isoforms, components of 
the MAPK signalling network.     
 
The MAPK arrays were validated using western blotting and antibodies against the 
total and specific phosphorylated forms of AKT and GSK-3.  Examination of these 
bands using densitometry software allowed the determination of changes in protein 
following normalisation using readings for the control band -actin.  In terms of the 
ratio of p-AKT (Ser473) to total AKT in each cell line, densitometry analysis 
indicated that there was a higher ratio of the phospho-protein in FM-82/Ctrl compared 
to FM-82/shRNA.  While the results were not found to be statistically significant, the 
stark decrease in protein level visualised between the control and test cell line implies 
a strong biological significance.  The same could be said of the ratio of p-GSK-3 to 
total GSK-3 in each cell line.  The large error bars seen with densitometry can be 
explained by the difficulties in gaining protein bands of exactly the same intensity 
when carrying out western blotting, despite identical experimental conditions.  
Though the same pattern was found when performing these experiments, there was 
variation in the darkness of the protein bands, hence the extent of the standard 
deviation noted.  Interestingly, examination of gene microarray data showed that 
there was no significant change to the gene expression of both these molecules.  This 
means that there was potentially no more protein available that could be 
phosphorylated.  An argument could therefore be put forward that HAGE expression 
leads to some form of alteration to post-translational modification of these proteins. 
 
Both AKT and GSK-3 play significant roles within PI3K signalling.  AKT, also 
called protein kinase B (PKB), is made active in cells through phosphorylation of 
specific amino acid residues.  This can either be threonine at position 308 (Thr308) 
caused by PDK-1 or serine at position 473 (Ser473), currently thought to be mediated 
by the mTORC-2 protein (Mora et al., 2004; Sarbassov et al., 2005).  Indeed, there 
have been attempts to target this latter relationship for tumour therapy.  Data 
presented here focused on the latter, perhaps showing increased activity of mTORC-2 
encouraging this increase in activity, though this would require confirmation.  AKT 
perhaps represents the major effector of the PI3K pathway, inducing both cell 
survival and proliferation in cells.  It can do this by the direct interaction with target 
substrates, instigating the phosphorylation and subsequent inhibition of proteins that 
include BAD and pro-caspase 9, both of which promote apoptosis (Datta et al., 1997; 
Vara et al., 2004).  Evidence shows an interaction between HSP-27 and AKT, which 
can interact with each other to promote survival (Arya et al., 2007; Schmitt et al., 
2007; Havasi et al., 2008).  AKT can additionally act indirectly via the inhibition of 
transcription factors like FOXO, which stops the production of mRNA for pro-
apoptotic FAS-L, BIM and the cell cycle repressor p27KIP1 (Brunet et al., 1999; Liang 
and Slingerland, 2003; Vara et al., 2004; Calhoub and Baker, 2009).   
 
Therefore, the stark increase in p-AKT seen from western blotting could help to 
explain the phenotype shown by HAGE-expressing cells.  It could be that expression 
of HAGE is somehow increasing AKT phosphorylation, in turn causing cells to 
survive and proliferate to increase their population.  This would appear to correlate 
with the proliferation data presented in Chapter 3.  Heightened expression of HSP-27 
mRNA shown in Chapter 4 found by expression profiling could be seen as 
interesting, indeed if this mRNA undergoes translation, there could be more target 
material for AKT to act on and promote survival.  An unusual point is the knowledge 
that AKT activity reduced production of FAS-L through FOXO inhibition, which 
seemingly contradicts the increased mRNA expression of FAS-L recognised in 
Chapter 4.  FAS-L can also protect tumour cells and this point is discussed in greater 
detail in Chapter 6. 
 
One of the major downstream substrates for p-AKT is the molecule glycogen 
synthase kinase- (GSK-3 one of two isoforms of GSK.  GSK-3 is thought to be 
an important molecule in the metabolism of glucose and is linked with various 
pathological conditions other than cancer including diabetes and Alzheimer’s disease 
(Kaytor and Orr, 2002; Lee and Kim, 2007).  Its implication in malignancy comes 
from its function to inhibit the action of -catenin and through that inhibit canonical 
signalling through WNT.  Phosphorylation of the GSK-3 isoform at serine 9 (Ser9) 
is thought to inhibit the action of the protein and causes accumulation of -catenin 
(Stambolic and Woodgett, 1994; Kandel and Hay, 1999; Rayasam et al., 2009).  From 
this, WNT signalling can take place, increasing cell proliferation.  Hence, GSK-3 
inhibition is intrinsically connected to abnormal WNT communication, a mechanism 
shown in tumours (Luo et al., 2007).  Phospho-AKT acts as a kinase to GSK-3 and 
can bring about the phosphorylation that is required to stop its action.  So in HAGE-
expressing cells, as well as higher levels of p-AKT (Ser473), MAPK arrays and 
western blotting were able to show increased levels of GSK-3 (Ser9).  This would 
suggest that in these cells, there is an environment where AKT activation is promoted 
and through that, GSK-3 activity is restrained.  This situation could lead to increased 
WNT signalling through the abundance of free-catenin. Ultimately, these data 
strongly suggest that HAGE presence in tumour cells could lead to the manipulation 
of PI3K signalling to promote cell survival and proliferation.  
 
Cell cycle progression that could allow increased proliferation seemed to be 
confirmed by the recognition that the CDK inhibitor and downstream effector of 
AKT, p21CIP1, was affected.  HAGE shRNA transfected cells demonstrated higher 
levels of this protein, indicating a reduction when the gene is expressed, a 
phenomenon reported for AKT activity in tumours (Zhou et al., 2001).  Since this 
CDK inhibitor acts to stop cyclin E activity (Kandel and Hay, 1999), this data could 
have some relevance and connection to the gene data for CCNE2 described in 
Chapter 4.  This would entail that HAGE expressing cells have a lower presence of a 
potent inhibitor of the cell cycle, furthering its link to proliferation.  As seen with 
AKT and GSK-3, though the visual changes were matched by the densitometry 
readings, they were not significant at the statistical level; however, the difference in 
protein level could lead one to argue the biological importance of this change.  Again 
the large degree of error seen could be explained due to the issues of band intensity 
between western blots described for AKT and GSK-3.  These data would seem to be 
connected and it is very interesting that changes appeared to be associated with 
expression of HAGE.  It means that possible future work could include further 
examination of other cell cycle inhibitors affected by AKT such as p27KIP1.   
 
Since there was possible deregulation of post translational modification to AKT and 
GSK-3, this required further investigation. Increased GSK-3 phosphorylation could 
be explained by raised AKT function, but changes to the latter come about through 
actions of upstream mediators. Aside from autocrine growth factor signalling, 
increases to AKT activity can come from events such as mutation to the catalytic 
region of PI3K (p110), loss of the TSG PTEN or modifications that occur to RAS 
(Calhoub and Baker, 2009).  Due to the prolific nature of RAS in human cancer, the 
microarray data analysis was referred back to examine if any expression changes took 
place with RAS isoforms.  There was initial evidence to suggest that HAGE 
expression could be associated with up-regulation of mRNA for the N-RAS oncogene 
isoform.   
 
Microarray data showed a decrease of approximately 63% in N-RAS gene expression 
following transient knockdown of HAGE in FM-82 cells.  Real-time qPCR of cells 
using specific N-RAS primers against cells undergoing the same treatment seemed to 
confirm this notion with N-RAS being shown to have around an 80% reduction in 
relative expression (p=<0.01).  RAS genes are highly homologous, sharing 
approximately 85% of their amino acid sequence (Downward, 2003).  In view of this 
homology, expression change to H- and K-RAS was also checked.  Microarray data 
analysis of FM-82 cells treated with siRNA hinted at no significant change in the 
other RAS members upon HAGE knockdown.  This was confirmed further using 
real-time qPCR, which suggested that in terms of a temporary reduction in 
expression, HAGE was specifically linked to N-RAS.    
 
Paradoxically, the above data did not seem to be confirmed with shRNA stable 
transfectant cells.  Here, there was no change in N-RAS expression after HAGE was 
stably knocked down, whereas there was a significant decrease in both H- and K-RAS 
(p=<0.05).  This indicated a possible difference between transient and stable RNAi 
techniques.  It could be that short term exposure to siRNA caused a sharp decrease in 
N-RAS expression in response to the transfection.  The apparent lack in change in 
expression following prolonged RNAi points to either possible cellular compensation 
or the potential that HAGE may not act on N-RAS mRNA specifically.  The 
difference in expression changes that took place with the other RAS isoforms will 
require further investigation.  
 
A decrease in N-RAS expression following HAGE knockdown would thus hint 
towards a situation in tumours where expression of HAGE could lead to increased 
levels of a known oncogene being produced.  Knockdown of N-RAS in the HAGE-
positive cell line FM-82 using a specific siRNA was capable of reducing the RAS 
member’s relative expression by around 80%.  However, the mRNA expression of 
HAGE was not reduced and thus one could argue that HAGE acts upstream of N-
RAS.  It was also noted that using the same technique with siRNA specific for H- and 
K-RAS resulted in no change in HAGE expression, meaning that reduction in any of 
the RAS members has no impact on the expression of HAGE mRNA. 
 
Evidence gained using western blotting would suggest the notion that HAGE could 
act on N-RAS protein and not mRNA might occur.  It was found that FM-82/shRNA 
had a marked reduction in N-RAS protein levels compared to the FM-82/Ctrl cells.  
As such, the HAGE expressing line therefore possessed a raised level of N-RAS 
protein.  Once again, the difference in N-RAS protein level was not considered 
statistically important, but similarly to p-AKT, such a notable decrease recognised 
with the protein bands could lead to the argument of this reduction being biologically 
significant.  Thus, it may well be possible that HAGE expression does not result in an 
increase in N-RAS mRNA, but instead leads to accumulation of protein.  This entails 
that HAGE could have a potential role in the translation of N-RAS.  DEAD-box 
members have potential roles in the translation of proteins in cells (Linder, 2006) and 
therefore it is possible HAGE could act in this manner.  No results to date have 
associated a CT antigen with this function, meaning this could represent a highly 
novel finding for this family of molecules.  Extraction of active RAS (RAS-GTP) 
from shRNA stable transfectants revealed that there was no discernable difference 
between the test and control cell lines.  The lack of change seen implied no 
interaction between HAGE and the GEF and GAP molecules that regulate RAS 
function such as SOS-1/2 and NF-1 (Downward, 2003).  It must be noted that the 
technique used to extract RAS-GTP from cells did not discriminate between RAS 
isoforms since no kit is available to do this.  Subsequently, all active forms of RAS 
were examined, so it is impossible to say for certain at this point in time if there is 
increased N-RAS protein activity in HAGE expressing cells.         
 
RAS genes represent one of the most frequently mutated molecules in cancer.  
Approximately 30% of all human tumours bear a mutation to one the members of this 
group (Bos, 1988).  Genetic alteration comes in the form of point mutation that occurs 
most commonly at codons 12, 13 or 61 (Bos, 1989).  Modification causes 
insensitivity to GTP hydrolysis by GAP molecules, meaning that mutant RAS is 
constitutively active in affected cells.  Mutations to RAS are considered to be 
amongst the primary genetic events in tumours, thanks to recognition of them in pre-
malignant lesions (Kranenburg et al., 2004).  K-RAS signifies the most commonly 
mutated isoform, with 85% of mutations occurring to the gene.  This is followed by 
N-RAS with around 15% and lastly by H-RAS, making up less than 1% (Downward, 
2003).  N-RAS is the most common isoform mutant in melanoma, AML and 
myelodysplastic syndromes (MDS) (Downward, 2003).  So there is an interesting 
overlap between the most commonly altered RAS member in melanoma, of which the 
FM-82 cell line is derived from and HAGE.   
 
The significance of RAS mutation in tumours can be recognised from the sheer scale 
of its influence in cells.  RAS proteins act as molecular switches, relaying signals 
initiated from receptors located at the surface of cells to induce the required 
phenotype (Downward, 2003).  They control a multitude of different pathways and 
mutation to them has been implicated in proliferation, survival, angiogenesis and 
metastasis (Shields et al., 2000; Campbell and Der, 2004; Kranenburg et al., 2004).  
Therefore, the above data would seem to suggest that HAGE expression in tumours 
could lead to increased production of a protein that is associated with a wide range of 
tumorigenic behaviour.   
 
RAS mediates the actions of two major pathways.  One is the MAPK network while 
the other is the PI3K cascade.  This is intriguing because it could be possible to 
connect the findings that have been seen with N-RAS to those that were presented 
above with AKT and GSK-3.  It is especially interesting that subsequent steps in this 
pathway appear to be affected by HAGE expression.  In the first instance this would 
apparently further the idea of HAGE involvement with proliferation and survival.  
Furthermore, it potentially links HAGE expression with other, more aggressive 
cancer hallmarks.  Ultimately, strong evidence now exists to suggest a novel 
interaction that occurs between a CT antigen and DEAD-box protein with a notorious 
oncogene in N-RAS.  Due to the number of malignancies involving N-RAS mutation, 
this work gives potential for the possibility of targeting HAGE.  More work is needed 
to establish if HAGE is intrinsically linked to N-RAS or if there is involvement with 
H- and K-RAS.  Moreover, it needs to be established if HAGE can induce similar 
effects in tumours without RAS mutation.  At this point in time though, these data are 
promising. 
 
 
 
 
 
 
 
 
 
 
 
Chapter 6 
 
HAGE Expression and Aggressive Tumour Phenotype 
 
6.1 Introduction 
 
The rapid expansion of tumour mass is driven by malignant traits that include growth 
factor self-sufficiency, hyper-proliferation and de-regulation of apoptosis.  However, 
the most aggressive tumours bear other phenotypic traits that further their progression 
even more, ultimately allowing them to grow, evade and survive the body’s defences, 
and disseminate to other regions of the body (Hanahan and Weinberg, 2000).  Should 
a tumour gain the capability to do this, then a patient’s malignancy becomes more 
aggressive and significantly raises the threat it poses to them.   
 
6.1.1 Apoptosis  
 
Programmed cell death (Apoptosis) is a vital process in cellular homeostasis (Schultz 
and Harrington Jr., 2006; Elmore, 2007).  It is used to efficiently eliminate older or 
damaged cells from the population in order to be replaced by new daughter cells 
generated by mitotic division.  Apoptosis is one of the primary mechanisms affected 
within cancerous cells.  Loss of apoptosis coupled with rapid proliferation is required 
for expansion of the tumour mass and the eventual progression towards angiogenesis 
and metastasis.  It is also central to progression in terms of resistance to therapy and 
survival against anti-neoplastic agents.    
 
Broadly, apoptosis can be brought about through two separate pathways.  The 
extrinsic pathway is induced by the actions of certain ligands binding to death 
receptors on the surface of cells.  These include members of the TNF receptor 
(TNFR) superfamily, which includes TNF-related apoptosis-inducing ligand (TRAIL) 
receptors and the aforementioned FAS (Ashkenazi and Dixit, 1998; Rath and 
Aggarwal, 1999; Schultz and Harrington Jr., 2003).  In the case of FAS, once FAS-L 
is bound, the adaptor protein FAS-associated death domain (FADD) becomes bound.  
With other TNF receptors, once ligation takes place, TNF receptor-associated death 
domain (TRADD) is bound, recruiting FADD and RIP (Hsu et al., 1995; Wajant, 
2002; Elmore, 2007).  FADD can subsequently bind to pro-caspase 8, leading to the 
formation of the death-inducing signalling complex (DISC), activating caspase 8 
(Kischkel et al., 1995), which brings about the execution phase and cell death 
(Schultz and Harrington Jr. 2003; Elmore, 2007).    
 
Comparatively, the intrinsic apoptosis pathway involves signals originating from a 
cell’s internal environment.  Effects that are derogatory to a cell, for example loss of 
growth factors, radiation, action of chemicals and viral infection, can result in 
activation of apoptosis.  In this case, events such as these can act on the mitochondrial 
membrane, releasing pro-apoptotic mediators such as cytochrome c and 
Smac/DIABLO.  The latter represses IAP, while secreted cytochrome c causes the 
activation of both pro-caspase 9 and APAF-1, creating a complex referred to as the 
apoptosome (Hill et al., 2004, Schultz and Harrington Jr., 2003, Elmore, 2007), which 
induces the execution phase.  Intrinsic apoptosis is controlled by members of the 
BCL-2 family, including BID, BAD and BAX (Cory and Adams, 2002; Schultz and 
Harrington Jr., 2003; Elmore, 2007).  This pathway can also be activated through the 
action of caspase 8 (Schultz and Harrington Jr., 2003), therefore showing overlap 
between the extrinsic and intrinsic cascades.   
 
Malignant changes to apoptotic machinery can occur in numerous different ways.  
Molecules that serve to promote apoptosis can be limited or altered.  This is perhaps 
most noticeable with loss of function of p53.  Amongst the consequences of this 
includes the loss of transcription of BAX, for which p53 is involved in, limiting 
apoptosis (Miyashita and Reed, 1995).  Oncogenic expression of AKT and aberrant 
expression of HSP can also lead to increased survival of cells and reduced apoptotic 
activity (Garrido et al., 2003).  Caspase enzymes, the effectors of cell death 
signalling, can be affected, as seen with major members of this groups including 
caspases 3, 7, 8 and 9; affecting both the intrinsic and extrinsic pathways (Schultz and 
Harrinton Jr., 2003; Elmore, 2007).  Therefore, a tumour cell can manipulate both 
promoting influences and mediators of cell death.  Inhibitors of apoptosis (IAP) 
molecules, which include survivin, play a large role in preventing apoptosis and so in 
turn, could provide pivotal influence in tumour survival to promote malignant 
development (LaCasse et al., 1998; Sah et al., 2006).  The combination of IAP and 
other survival molecules may permit cells to avoid anoikis and contribute to the 
metastatic spread of a tumour. 
 
Loss of apoptosis is core to problems experienced with lack of cancer drug 
effectiveness.  Central to both radio- and chemotherapy is the principle of inducing 
widespread genomic damage, such that it is beyond repair, resulting in the death of 
the cell.  Drug resistance in tumours is a well-known phenomenon and is associated 
with poor patient prognosis.  Development of resistance hints towards expansion of 
apoptosis inhibition to convey protection against therapeutic agents. For example, 
PI3K/AKT expression has been linked to radio-/chemo-resistance in head and neck 
carcinoma and therefore poorer prognosis in these patients (Bussink et al., 2008).  
IAP have been implicated in protecting cultured cells against a wide range of 
different agents that trigger apoptosis, such as X-linked IAP (XIAP) in protecting 
MCF-7 cells against cisplatin (Duckett et al., 1998; LaCasse et al., 1998).  Hence, 
loss of apoptosis is a process closely associated with tumour progression.  It is 
especially important when designing drugs for late-stage patients, as it represents one 
of the biggest issues with therapy. 
 
6.1.2 Immune Escape 
 
6.1.2.1 Down-Regulation of the Immune System in a Healthy Environment 
 
The collected components of the immune system are highly effective at preventing 
pathological harm coming to the body.  However, it is important that this system can 
be controlled, as if immune reactions, especially those originating from the adaptive 
system, were not mediated, there would be a considerable risk of auto-immunity.  
Various mechanisms are in place to prevent the possibility of auto-immune reactions.  
Once T cells become activated by MHC-bound peptide, they become increasingly 
sensitive to apoptosis and up-regulate various death receptors such as TRAIL-R and 
FAS.  In this manner, surface bound or secreted ligands to these receptors can bind to 
them and cause immune cell apoptosis via a process referred to activation induced 
cell death (AICD) (Shi et al., 1989; Hildeman et al., 2002; Lu and Finn, 2008).  This 
brings about apoptosis through the extrinsic pathway described above and acts as a 
feedback system to prevent prolonged T cell activity.  Closely related to this is the 
action of cytotoxic T lymphocyte antigen-4 (CTLA-4), an antigen found on the T cell 
surface.  Once T cells become activated, expression of this marker increases and has 
affinity for the co-stimulatory molecule B7.1 and when bound to it, prevents its signal 
being transmitted (Oosterwesgel et al., 1999).  Since T cell activation is dependent on 
the second signal provided by antigens such as B7.1, the action of CTLA-4 acts as 
another form of negative feedback.  Other mechanisms include the secretion of 
inhibitory cytokines such as TGF-, IL-10 and IL-17, which act to suppress the action 
of CTL and create immune homeostasis (Murugaiyan and Saha, 2009; Saraiva and 
O’Garra, 2010).  One of the most effective suppression methods involves TReg.  
Though these cells can be found naturally within the population of T cells, following 
T cell activation by antigenic peptide, their formation can be induced (Sakaguchi et 
al., 2009; Sakaguchi et al., 2010).  These then repress CTL activity by using either 
FAS-L-FAS interaction or the perforin/granzyme pathway to bring about apoptosis in 
CTL and control their actions (Grossman et al., 2004; Strauss et al., 2009; Sakaguchi 
et al., 2010).   
 
6.1.2.2 Manipulation of Immune Inhibition by Malignant Cells 
 
Though homeostatic mechanisms are in place to curtail the immune system, tumours 
possess various methods to escape the attentions of the immune system.  These 
involve either directly affecting key components involved in immunity or 
deregulating processes vital to it for the advantage of the tumour (Whiteside, 2003).  
Malignant cells can affect MHC processing to prevent the presentation of antigenic 
peptide to T cells and thus avoiding immune detection (Hicklin et al., 1999).  This 
can be achieved by affecting MHC expression itself by down-regulation of molecules 
associated with it such as 2M or TAP (Zagzag et al., 2005; Chang et al., 2006; 
Ferris et al., 2006; Setiadi et al., 2007).  Similarly, cancerous cells have been shown 
to reduce their expression of co-stimulatory molecules.  As with CTLA-4 action, loss 
of secondary signalling results in T cell anergy and renders them unresponsive to 
transformed cells (Macián et al., 2004).  Alternatively, tumours can either down-
regulate their expression of FAS or up-regulate FAS-L expression, to avoid T cell 
mediated apoptosis or to cause apoptosis of T cells respectively (O’Connell et al., 
1999; Peli et al., 1999).  Since tumours have the ability to avoid detection and 
clearance by the immune system, better understanding of this and finding molecules 
that are able to mediate this phenomenon is vital in helping restrict tumour 
progression.     
 
6.1.3 Metastasis 
 
By its very nature, metastasis heralds a major step in tumour progression (Ahmad and 
Hart, 1997; Meyer and Hart, 1998; Geiger and Peeper, 2009).  If a malignant mass 
can be held in its original site, then efforts to treat it are relatively easier.  Therefore 
dissemination of a tumour from its primary site to other regions poses the greatest 
threat to patient health and the biggest challenge to clinicians.  Like most aspects of 
cancer biology, metastasis comes from a fine balance of communication and 
expression of key molecules.  For example, the matrix metalloproteinase (MMP) 
enzymes are central to solid tumour metastasis for their ability to degrade basement 
membrane (BM) (Westermarck and Kähäri, 1999; Hofmann et al., 2005).  Their 
expression can up-regulated by the action of certain oncogenes such as RAS, hence 
associating such tumorigenic molecules with malignant progression (Campbell and 
Der, 2004).  MMP can be inhibited naturally by the action of the tissue inhibitor of 
metalloproteinase (TIMP) group of proteins (Woessner Jr., 1991).  They do this by 
binding in an irreversible manner to MMP and inhibiting MMP-substrate binding 
(Jezierska and Motyl, 2009).  There is a belief that even in the face of raised MMP 
function, TIMP proteins have the ability to stop them.  This means that increase in 
MMP expression should coincide with reduced activity of the inhibitory molecules, 
thereby indicating a balance of molecular expression required to promote metastasis 
(Ahmad and Hart, 1997).   
 
Both groups of molecules are complicit in angiogenesis, with MMP required for neo-
vascular formation and TIMP being able to stop it (Ahmad and Hart, 1997).  Since 
these two processes are closely linked together, it stands to reason that targeting 
angiogenesis aids in combating metastasis.  In spite of this, no completely curative 
regimen exists for cancer as yet, and it is therefore important to design new therapies 
against both of these phenomena in an attempt to limit tumour progression.  The 
identification and characterisation of more molecules that can influence either pro- or 
anti- angiogenic/metastatic molecules before targeting them is a pre-requisite.  
 So far HAGE has been linked with increased proliferation in tumours.  However, 
emerging data in Chapters 4 and 5 suggest further roles for this antigen.  Preliminary 
microarray analysis highlighted genes involved in processes aside from tumour 
growth HAGE could be involved in.  Meanwhile, retrospective examination of this 
data was able to find a possible relationship with N-RAS, an oncogenic molecule also 
linked to other aspects of malignant biology including metastasis.  For that reason, 
preliminary work was performed to investigate the potential contribution HAGE 
makes in various activities connected to malignant progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
6.2 Results 
 
6.2.1 HAGE and Protection against Drug-Induced Apoptosis 
 
Microarray analysis showed that HAGE expression led to down-regulation of genes 
linked with apoptosis, insinuating that other than proliferation, antigen expression 
could confer protection against induced cell death.  In order to examine this, HAGE 
shRNA stable transfectants were exposed to two different drugs capable of initiating 
apoptosis; staurosporine and cisplatin.  Initially, both sets of cells were exposed to 
different concentrations of both drugs.  Light microscopy of these cells over 48 hours 
observing morphological changes was used to determine the concentration to be used 
in future work, specifically whereby 50% of the observed cells were dead. 
 
FM-82/Ctrl and FM-82/shRNA were subsequently grown overnight in a 96-well 
plate.  The following day, they were treated with either 0.3g staurosporine or 
cisplatin for four hours prior to detection.  Cells were run alongside a blank, 
consisting of media alone laced with the drug, or a negative control, where cells were 
not treated.  As shown in Figure 6.1(B), when treated with cisplatin, the FM-
82/shRNA cell line demonstrated a higher level of caspase 3/7.  However, when 
staurosporine was added (Figure 6.1 (A)), the knockdown line appeared to have a 
lower amount of caspase compared to the control line.  The suggestion from this was 
that HAGE expressing cells were able to have a lower amount of active caspase 3/7 
upon exposure to cisplatin, but expression was not able to lead to the same effect 
against staurosporine.   
 
Since it seemed that HAGE expression was leading to greater protection towards the 
actions of cisplatin, this was verified further using preliminary FACS analysis.  Cells 
were again treated with the drug for four hours, stained using Annexin/7-AAD, and 
measured.  After Kaluza® analysis of FACS data, it was found there that was a greater 
number of FM-82/shRNA cells undergoing apoptosis than FM-82/Ctrl.  Figure 6.2 
shows images of Kaluza® data with the ‘C+-’ quadrant used to detect cells 
undergoing early apoptosis.  0.92% FM-82/Ctrl compared to 3.82% of FM-82/shRNA 
cells experienced this, suggesting that loss of HAGE expression led to reduced 
resistance against cisplatin.  
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Figure 6.2: Images taken from Kaluza® software analysis of FACS examination of drug 
induced apoptosis in stable knockdown cells (n=1).  Either (A) FM-82/Ctrl or (B) FM-
82/shRNA were treated for four hours with cisplatin prior to staining with Annexin/7-AAD and 
FACS analysis.  The C+- quadrant (Red arrow) contained cells undergoing early apoptosis
and used to measure the effects of cisplatin.
Figure 6.1: Average readings to determine levels of caspase 3/7.  Either staurosporine (Green 
bars (A)) or cisplatin (Yellow bars (B)) were used to treat stable knockdown cells.  Cells were 
treated for four hours prior to addiction of detection reagent and scanning using a luminometer.  
Readings were normalised using values gained for blank control wells.    
6.2.2 HAGE and Tumour Immune Escape 
 
In Chapter 4, it was noted that there was a reduction in FAS-L expression following 
HAGE siRNA treatment.  The implication of this is expression of HAGE could lead 
to a raised level of FAS-L on tumour cells.  Expression of this latter antigen on the 
surface of tumour cells could potentially cause CTL death via FAS-L-FAS interaction 
to avoid immune reactivity.   
 
To examine this, an antibody specific against FAS-L (CD178) was obtained and used 
for FACS screening of cell lines.  Data gained from FACS was analysed using 
Kaluza® software to determine expression of the antigen, detected using specific 
antibody compared to cells stained using an isotype control and cells alone.  This is 
shown in Table 6.1. 
 
Table 6.1 shows a significantly greater level of FAS-L surface expression on cells 
that had significantly higher HAGE expression (p=<0.05).  With cDNA transfectants, 
it could be seen that stable expression of HAGE in FM-3 led to over a 4% increase in 
FAS-L.  A similar situation was noted with stable knockdown.  On this occasion, 
there was over 6% decrease once FM-82 cells had been treated with HAGE-specific 
shRNA.  Hence, HAGE expression would appear to lead to increased surface FAS-L 
and correlated with the increased mRNA expression seen in Chapter 4. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.1: Expression of FAS-ligand (FAS-L) on the surface of both sets of stable 
transfectant cell lines determined by FACS analysis involving a FAS-L specific 
antibody (n=2).  Values were gained following interpretation of FACS data using 
Kaluza® software. (*=p<0.05) 
10..37% (+/- 0.85) *FM82-shRNA
16.42% (+/- 2.1)FM82-ctrl
14.68% (+/- 1.20)* FM3/HAGE
10.14% (+/- 0.61)FM3/-Ve
FAS-L ExpressionCell Line
Secondly, cells were co-cultured with CTL clones to see if HAGE-expressing cells 
were able to cause a greater level of CD8+ cell death compared to HAGE-negative 
cells.  This latter experiment was done in collaboration with Prof. Francine Jotereau 
and Dr. Nathalie Labarrière (Université de Nantes, France).  For this experiment, only 
HAGE cDNA stably transfected cells were tested, as creation of shRNA stable 
transfection had not been performed.  The CTL clones used for co-culture were 
specific for the Melan-A/MART-1 melanoma antigen.  Real-time qPCR confirmed 
high expression of this antigen in the cell lines (Data not shown) prior to the cells 
being sent to collaborators.  Cells were cultured for 48 hours alongside either the 
10C10 CTL clone (Apoptosis resistant; negative control) or 24B7 clone (Apoptosis 
sensitive; test clone).  FACS analysis was performed with Annexin/PI staining to 
examine cell death in CD8+ cells and TNF- detection to measure the extent of 
apoptotic cytokine released by CD8+ T cells.  Data gained from these experiments is 
summarised in Tables 6.2 and 6.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6.2: Extent of apoptosis found in CD8+ cells using FACS analysis following 
co-culture of HAGE cDNA stable transfectants with apoptosis resistant (10C10) and 
susceptible (24B7) CTL clones (n=1).  Cell death was determined using Annexin/PI 
staining and analysis was performed on gated CD8+ cells.
18.19%14.68%8.07%7.37%24B7
3.40%3.32%14.06%14.45%10C10
FM3/HAGEFM3/-VeFM3/HAGEFM3/-Ve
48h co-culture24h co-cultureCD8+ T cell 
clone
Table 6.3: Degree of TNF- release from CD8+ cells after co-culture of HAGE 
cDNA stable transfectants with apoptosis resistant and susceptible CTL clones 
(n=1).  TNF- was measured using FACS analysis and gating of CD8+ gated cells.
68.57%63.41%24B7
59.90%59.61%10C10
FM3/HAGEFM3/-VeCD8+ T cell clone
There was little difference after 24 hours of co-culture between FM-3/-Ve and FM-
3/HAGE in the amount of CD8+ T cell death detected using Annexin/PI staining.  
After 48 hours however, there was nearly a 4% increase in the amount of Melan-
A/MART-1 specific 24B7 CTL grown with FM-3/HAGE undergoing apoptosis as 
opposed to the same clone grown with FM-3/-Ve (Table 6.2).  Screening for TNF- 
release from the above clones seemed to further such a notion, with a five-point 
increase of TNF- producing 24B7 CTL clone cultured with FM-3/HAGE compared 
to the same clone grown with FM-3/-Ve.  In both experiments, there was little 
difference in readings for the 10C10 CTL clone, which is apoptosis resistant (Table 
6.2 and 6.3).  Increased amounts of apoptosis taking place in CTL were therefore 
obtained when confronted with HAGE expressing cells, possibly linked to the 
expression of FAS-L.  Significance of these results could not be determined for co-
culture experiment as they were only performed once and require repetition 
 
6.2.3 HAGE and Tumour Invasion 
 
Data gained here have begun to indicate a possible relationship between HAGE 
expression and aggressive tumour phenotype.  Retrospective analysis of microarray 
data indicated the down-regulation of the pro-invasion genes, FAK and MMP-9, 
when HAGE was knocked down, implying the antigen up-regulates them when 
expressed.  Conversely, expression of the MMP inhibitor TIMP-4 was up-regulated 
following a reduction in HAGE expression, suggesting inhibition of this molecule by 
HAGE.  During the creation of the stable knockdown cells, it was noted that once 
HAGE specific shRNA was stably transfected, there seemed to be a reduction in the 
number of dendrites normally shown by FM-82 cells (Figure 6.3).  Loss of dendrites 
upon HAGE knockdown gave rise to a possible notion linking HAGE to cell 
migration and from that metastasis.  To see if cell migration was affected by 
expression of the antigen, an in vitro invasion assay was carried out using HAGE 
stable knockdown cells.  Migration of cells was monitored in Matrigel containing test 
plates and compared to passage of cells through control membrane plates.  Readings 
from both allowed the calculation of percentage invasion (Test plate reading/control 
plate reading x 100) and allowed the comparison of migration between FM-82/Ctrl 
and FM-82/shRNA.  The plot showing the percentage invasion for each cell line is 
shown in Figure 6.4. 
 
It was found that a greater number of FM-82/Ctrl cells had passed through the 
Matrigel at each points during the experiment compared to cells where HAGE 
expression had been reduced.  At certain time points, the difference in invasion 
between the two cell lines was statistically significant (p=<0.05; p=<0.01).  This 
implied that expression of the antigen was leading to cells being more capable of 
migration across a barrier.   
 
As previously described, there was a change in the gene expression of certain 
molecules involved in metastasis.  To investigate if these changes were also evident at 
the protein level, antibodies specific to FAK, MMP-9 and TIMP-4 were obtained and 
used in western blotting.  Images from blots and respective densitometry are shown in 
Figure 6.5. 
 
There was an evident change in the levels of both FAK and TIMP-4.  Levels of FAK 
markedly decreased after HAGE knockdown while TIMP-4 showed the opposite 
effect.  These findings were reflected in the densitometry ratios gained for both these 
proteins.  From this, it could be seen that HAGE expression could lead to an 
up/down-regulation of a proteins known in promoting and inhibiting metastasis in 
FAK and TIMP-4 respectively.  With MMP-9, there seemed to be more protein 
visually present in FM-82/shRNA cells. Ratios calculated from densitometry 
indicated that there was an increase of the protein in cells where HAGE expression 
had been reduced.   
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FM-82/Ctrl
FM-82/shRNA
Figure 6.3: Light microscopy images (Magnification X20) of HAGE stable knockdown 
cell lines used to recognise the reduction in evident dendrites (Exemplified by red 
arrows), following stable transfection of HAGE shRNA.
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Figure 6.4: In vitro invasion assay readings taken for HAGE stable knockdown cells (n=1).  
Readings were taken over a 25 hour period after cells had been stained with DilC12(3) to 
allow luminometer measurements to be collected in real-time (*=p=<0.05; **=p=<0.01).
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Figure 6.5: Images of bands for proteins with known involvement in metastasis detected 
by western blotting (n=2).  Proteins were separated using 10% acrylamide SDS gels 
except TIMP-4, which was performed using a 15% gel.  Membranes were stained 
overnight specific with anti-human antibodies diluted in 10% Marvel milk.  Antibodies 
were optimised to a 1/250 concentration apart from -actin, optimised to 1/500.  
Densitometry ratios calculated as for p21CIP1 and N-RAS. 
6.3 Discussion 
 
Gene expression analysis suggested the possibility of HAGE being involved in other 
malignant processes.  If evidence could be found to support this then it could mean 
that the expression of the antigen in tumours results in a more aggressive phenotype.  
Initial analysis had suggested HAGE involvement in apoptosis and immune escape 
while further study implicated a possible role in invasion.   
 
Suppression of apoptosis is a malignant phenomenon not only in terms of 
proliferation but also in respect to cell survival, which adds to the complication of 
drug resistance.  Preliminary work involved treatment of stable knockdown cells with 
either staurosporine or cisplatin, two drugs known to cause apoptosis in cells.  These 
cells were used as part of a basic screen to specifically detect relative levels of the 
effector caspases 3 and 7.  There was a significant increase in the amount of caspase 
3/7 detected in FM-82/shRNA treated with cisplatin (p=<0.05), implying HAGE 
expression could result in a reduction in the levels of these two caspase enzymes.  
Interestingly, when the same cell lines were treated with staurosporine, the level of 
caspase 3/7 showed the opposite effect (p=<0.05).  This could mean that HAGE 
expression offered more protection against cisplatin than staurosporine.   
 
Further confirmation of this was achieved using FACS analysis, where results showed 
an increase in the number of FM-82/shRNA cells entering apoptosis compared to the 
control cell line.  Taken together these data seemed to show that a reduction in HAGE 
expression was making cells more susceptible to drug-induced apoptosis.  In other 
words, the presence of this molecule in tumours could confer protection against 
certain drugs.  
 
Resistance to platinum compounds such as cisplatin and carboplatin can be caused by 
a variety of different mechanisms in tumour cells (Stewart, 2007).  These can include 
alterations to drug uptake and drug efflux mechanisms in malignant cells (Siddik, 
2003; Stewart, 2007).  IAP could also play an important role in resistance.  For 
example, up-regulation of survivin has been linked with the ability to withstand 
effects of cisplatin (Nomura et al., 2005; Wang et al., 2005).  Furthermore, the up-
regulation of XIAP can have the same effect (Nomura et al., 2005).  Interestingly, 
evidence has shown a potential interaction between XIAP and the PI3K pathway to 
mediate resistance (Cheng et al., 2002).  XIAP appears to increase resistance to 
cisplatin and inhibit the action of caspase 3 and therefore apoptosis in different cell 
lines (Amantana et al., 2004; Yang et al., 2005).  It may be that in HAGE expressing 
cells, such a situation is taking place.  Evidence gained from this study has shown the 
possible effects HAGE expression has on this signal network, again providing a link 
to reduced caspase 3 in cells treated with cisplatin.   PI3K also acts to inhibit pro-
caspase 9 (Vara et al., 2004), stopping its cleavage to an active form and from that 
initiating effector caspases.  Future work would involve examining the levels of this 
caspase in HAGE positive cells to see if there is more data to connect HAGE, PI3K 
and apoptosis repression. 
 
Other evidence collected in this study could be associated with this.  Chapter 4 details 
the apparent increase in HSP-27 and 70 mRNA in HAGE positive cells, while 
Chapter 5 details RAS expression.  All of these chaperones have a role in suppressing 
apoptosis by either acting on caspase 3 (HSP) or inhibiting caspases through 
unknown mechanisms (RAS).  If work could match protein expression with the 
observed mRNA results, it may further the link between HAGE and the results seen 
with response to cisplatin and apoptosis.      
 
Caspases 3 and 7 are important in apoptosis as they, along with caspase 6, make up 
the effector members that bring about cell death (Cohen, 1997; Elmore, 2007).  All 
three of these share some of the same targets such as PARP and NuMA (Slee et al., 
2001; Elmore, 2007).  Caspase 3 and 7 bear protein homology to each other and can 
recognise the same DXXD sequence motif of target proteins.  However, caspase 3 is 
considered to be the most important of the effectors, as it can be activated by any of 
the initiating caspases (Caspases 8, 9 and 10).  Additionally, it exclusively acts on 
ICAD to release CAD, leading to cell death (Sakahira et al., 1998; Elmore, 2007).  
Therefore, repression of caspase 3 in HAGE expressing cells, possibly mediated by 
the PI3K network could explain cisplatin resistance. 
 
Aside from protecting itself from apoptosis, data collected here would seem to 
indicate that HAGE expressing cells could induce the reaction in immune cells.  Gene 
expression analysis detailed in Chapter 4 found increased FAS-L mRNA in HAGE 
expressing cells.  Expression of FAS-L has the potential to bind to FAS/CD95 
expressed by activated T cells and survive anti-tumour immunity.  Using FACS 
examination of stable knockdown cell lines, it was possible to show HAGE 
expressing cells had significantly more of the FAS-L protein on their surface 
(p=<0.05).  Increased protein expression in this instance would seem to have 
confirmed the genetic data gained previously.  In turn, it is possible that this could 
confer protection against CTL.  Data collected from collaborative co-culture 
experiments appeared to begin corroborating this theory.  With this experiment, 
annexin staining and TNF- detection found a greater level of apoptosis in CD8+ 
positive cells grown alongside HAGE positive compared to control cells.  
Confirmation of this would be needed; however there may be an association between 
FAS-L expression of HAGE-positive cells and increased CD8+ cell death.   
 
FAS-L (CD178/APO1-L) is a death inducing ligand, which upon binding to the 
antigen FAS (CD95), initiates apoptosis in the cell that bears FAS (Nagata and 
Golstein, 1995; Minas et al., 2007).  FAS-L-FAS interaction results in activation of 
the extrinsic apoptotic signalling pathway, initiating caspase 8 to induce caspase 3 
(Schultz and Harrington Jr., 2006; Elmore, 2007).  There is a belief that in certain 
cases, tumours are able to express FAS-L on their surface to offer protection against 
possible action by CTL: the so-called counter-attack mechanism (O’Connell et al., 
1999).  Anti-CTL killing is a process close to transplant immunity and the provision 
of immune tolerance (Bellgrau et al., 1995; Griffith et al., 1996).  This suggests 
tumours can avoid immune reactions by helping to generate a tolerogenic 
environment.  Expression has been detected in gastric, colorectal and ovarian 
carcinomas (O’Connell et al., 1996; Bennett et al., 1999; Houston et al., 2003; Minas 
et al., 2007).  It is also found in haematological tumours, as FAS-L killing has been 
found in mycosis fungoides (Ni et al., 2001).  Furthermore, this phenomenon has 
been shown in vivo (Bennett et al., 1998).  Indeed, since FAS induced killing of CTL 
is linked to progression (Kim et al., 2004), there could be a link with prognosis of 
patients (Okada et al., 2000).  In this instance, data collected for HAGE could agree 
with the above and are potentially promising in terms of a factor that could increase 
this situation. 
 
As with a lot of malignant biology, there is controversy surrounding FAS 
counterattack (Maher et al., 2002).  It has been argued FAS counterattack is not 
responsible for the generation of immune tolerance (Favre-Felix et al., 2000; Maher 
et al., 2002).  In part this is due to possible issues surrounding the techniques used to 
detect tumour FAS-L expression (Maher et al., 2002).  There seems to be a large 
degree of contradiction involved with FAS-L expression.  A good example of this can 
be seen with Chappell et al. (1999), who found that no human melanoma tested 
expressed FAS-L mRNA.  This is thought to be contrary to other work performed by 
Hahne and co-workers (Hahne et al., 1996; Maher et al., 2002).  Evidence presented 
here contradicts the work of Chappell et al.    Furthermore, it seems interesting that 
HAGE expression led to increased FAS-L expression, despite increased AKT 
activity, a molecule known to suppress FAS-L transcription by inhibiting FOXO 
(Calhoub and Baker, 2009).  Therefore, HAGE expression could lead to the increased 
expression of FAS-L through another mechanism or pathway as yet unrecognised.  
Further work would be needed to investigate this phenomenon.  
 
There is emerging data to support HAGE expression being connected to tumour 
invasion.  Preliminary data from an in vitro invasion assay indicated reduction of 
HAGE expression in tumour cells seemingly impairing their migration through 
Matrigel.  Although this came from an initial experiment and would require repeating, 
early impressions of phenotype would look as if HAGE positive cells were more 
competent at invasion.  Western blotting of protein extracted from the same cell lines 
seemed to support the above.  Expression of the pro-metastatic protein FAK appeared 
to be increased, both in terms of visual recognition and ratios calculated from 
densitometry.  On the other hand, there was a decrease in the expression of the 
inhibitory protein TIMP-4.  Initially, it seemed some molecular basis to initially 
associate HAGE expression and increased invasive ability of malignant cells, though 
some of the data could be considered paradoxical.  Densitometry analysis of these 
bands seemed to agree with the visualisation of the proteins.  Much like previous 
densitometry, the calculated changes were not considered statistically significant.  
However, some of the changes could be considered biologically significant, 
especially if one refers to the change seen in FAK protein level noted by western 
blotting.  Again the extent of error seen with this analysis could be explained due to 
the variability in band intensity between western blots, as mentioned in Chapter 5. 
 FAK is a well described molecule in tumour biology with its expression is heavily 
linked to malignant cell invasion and other tumorigenic behaviour (Luo and Guan, 
2010).  It is a highly important factor in the formation of invasion in cells (Hsia et al., 
2003) and increased expression could be connected with cells gaining independent 
invasive phenotype (Luo and Guan, 2010).  Indeed, loss of FAK expression can lead 
to reduction in invasiveness of tumour cells (Hauck et al., 2002).  There is also 
evidence that FAK has a controlling role in the epithelial-mesenchymal transition 
(EMT), an important stage in tumour invasion (Avizienyte and Frame, 2005; Luo and 
Guan, 2010).  The evident increase of FAK noted in cells with greater HAGE 
expression could therefore be associated with raised metastatic potential and 
increased in vitro invasive ability.   
 
The reduction in TIMP-4 protein expression seen in western blotting could further 
this.  TIMP proteins are known inhibitor of the MMP series of proteases prevalent in 
tumour metastasis, acting to prevent MMP interacting with substrates (Jezierska and 
Motyl, 2009).  Whereas other members of the TIMP family and their links to 
metastasis inhibition are better known, there is relatively less evidence surrounding 
TIMP-4 (Melendez-Zajgla et al., 2008).  In spite of this, studies have shown the 
expression of TIMP-4 is decreased in progressive tumours (Riddick et al., 2005) and 
the presence of the molecule can curb malignant growth and invasion by interacting 
with molecules such as MMP-9 (Wang et al., 1997; Groft et al., 2001; Zhao et al., 
2004; Riddick et al., 2005).  Interestingly, other work has found that expression of 
TIMP-4 can actually result in development of tumourigenic behaviour (Jiang et al., 
2001; Tunuguntla et al., 2003).  Commentary of all these studies point out possible 
difference in TIMP-4 induction causing changes in cellular function (Riddick et al., 
2005).  Moreover, opposing roles of the same molecule may come down to a balance 
existing between that molecule, its promoters and effectors and the produced 
phenotype. 
 
This latter point regarding balance could be used to explain findings for MMP-9.  
Here, seemingly higher protein expression was found in FM-82/shRNA cells, 
implying increased production following HAGE expression knockdown.  Such a 
result would appear strange through the apparent increased invasion capability of 
HAGE positive cells, but having less MMP-9 compared to the knockdown cells.  
MMP-9 (Gelatinase B) belongs to a large group of metalloproteinases involved in 
metastasis (Ahmad and Hart, 1997; Hoffman et al., 2005).  Along with MMP-2 
(Gelatinase A), it has been found to be highly expressed in tumours (Johnsen et al., 
1998; Westermarck and Kähäri, 1999).  So, findings presented here would appear to 
be contradictory to previous work, especially if one considers that both RAS and 
FAK, were found to be up-regulated in this group of work, are capable of initiating 
MMP-9 (Hsia et al., 2003; Campbell and Der, 2004).   
 
 However, various concepts still need to be taken into account.  The activation status 
of MMP-9 was not evaluated in this study.  Therefore, while HAGE expressing cells 
may have had relatively less protein compared to cells with less antigen expression, it 
has yet to be seen if HAGE bearing cells have more active MMP-9 within them.  It 
may also be that increased protein seen in FM-82/shRNA is due to abundance of 
inactive MMP-9.  As yet it is impossible to tell and future work investigating HAGE 
and metastasis would need to examine this along with the status of other MMP and 
TIMP members.  As has been seen in Chapter 5 with AKT and GSK-3, activation 
could be considered very important.  Foremost though, balance of promoters and 
inhibitors is perhaps the most important factor here.  Though cells with higher HAGE 
expression have lower MMP-9 levels, this may not detract from metastatic potential 
thanks to the decreased level of TIMP-4 seen.  If there is a decrease in MMP 
inhibitors, then it may be that changes to MMP may have little impact in stopping 
metastasis.  Coupled with the increased level of N-RAS, this molecular pattern could 
be sufficient to drive tumour cell invasion.  Ultimately, work presented here has 
begun to indicate that HAGE expression might result in a more aggressive phenotype 
and further work need to be performed in order to establish if this is the case.    
 
 
 
 
 
 
 
Chapter 7 
 
Discussion 
 
7.1 Discussion 
 
The prevalence of cancer as a public health concern necessitates continued work to 
refine and discover therapeutic options.  Such research has led to the detection of a 
large number of molecules that can be used to target a wide range of tumours.  
Therapy is now at a stage where agents can be designed to selectively act against 
specific targets and is highly promising.  In part, this has come about through better 
understanding of target molecules and the signalling networks in which they are 
involved.  Despite this knowledge, efforts to therapeutically inhibit significant 
pathways, for example proliferation or angiogenesis, have had limited impact.  
Therefore, it is possible these signal pathways could be influenced by other means, 
either due to as yet unknown means or known molecules having abilities or functions 
not yet described.   
 
Overall, the role of cancer/testis (CT) antigens remains elusive.  Certain members 
have a known function but this is restricted to normal cell homeostasis, while their 
role in malignant biology is poorly understood.  If CT antigens are to be considered 
realistic targets for tumour therapy, then their position in the cancer environment 
should be made clear.  For the most part, previous work performed on HAGE has 
matched its CT antigen counterparts, focusing on gene expression in different 
tumours (Martelange et al., 2000; Adams et al., 2002; Condomines et al., 2007; 
Roman-Gomez et al., 2007).  Work performed in this laboratory was the first to 
demonstrate the protein form of the molecule and investigate its possible use for 
immunotherapy (Mathieu et al., 2007; Riley et al., 2009; Mathieu et al., 2010).   
 
Preliminary studies by this group also began to focus on the potential cell processes 
HAGE could be involved in.  Here, transient cDNA transfection into a HAGE-
negative cell line resulted in the significant increase of cell proliferation (Unpublished 
data).  Classification of this antigen as a DEAD-box RNA helicase implies its 
possible role in proliferation as seen with other members (Nakagawa et al., 1999; 
Janknecht, 2010; Por et al., 2010).  So in the first instance, the preliminary work 
seemed to match the possible action of the antigen.  The data provided by this study 
attempted to define what processes HAGE is involved in following cell transfection 
and whether its role as a potential target for therapy could be confirmed. 
 
Initial evidence appeared to corroborate the hypothesis that HAGE could be involved 
in tumour proliferation, shown in Chapter 3.  Reduction of antigen genetic 
expression, either in a transient or longer lasting manner led to a significant decrease 
in the ability of human melanoma cell lines to increase their number.  This 
phenomenon was not restricted to the in vitro environment as in vivo studies using 
NOD/SCID mice complemented the findings.  Additionally, murine investigations 
using a cell line stably transfected with HAGE cDNA acted as a reciprocal set of data.   
 
Together, these data supplied a strong argument to suggest that HAGE had some 
involvement in promoting tumour proliferation.  Other published evidence has shown 
the involvement of the CT antigen CAGE in the same process (Por et al., 2010), this 
is interesting as this molecule is also a member of the DEAD-box family (DDX53) 
and shares 55% homology with HAGE (Linder, 2006).  Results for HAGE therefore 
seem to complement these findings.  Additionally, in vivo data gained here was 
similar to those found with its counterpart. 
 
Cancerous cells are able to proliferate due to the modification of many molecules and 
subversion of numerous signalling pathways.  This means they would be more than 
able to proliferate without expressing HAGE.  Results gained with the FM-3/-Ve cell 
line in vivo exemplify such a notion.  By their very nature, tumours undergo genetic 
diversity and are highly heterogeneous (Yegnasubramanian et al., 2008), meaning not 
all cells within a mass would express HAGE and there would be variations between 
those that did.  Immune staining was able to highlight this.  However, results 
presented here could suggest expression of HAGE leads to tumour cells having an 
increased capacity to proliferate.  Therefore as such, expression of this antigen could 
serve to greatly exaggerate this aspect of malignant cell biology. 
 
Heightened proliferation in HAGE-expressing cells appears to be brought about 
through changes to a variety of different molecules.  Chapter 4 details how gene 
expression profiling using the Affymetrix Genechip® platform made it possible to 
examine the genome of a human melanoma cell line to investigate the impact of 
HAGE.  Genes such as CCNE2, E2F2 and WNT-1, involved in cell cycle progression 
and proliferation, seem to be up-regulated by HAGE and could help explain 
heightened proliferation shown by HAGE-expressing cells.  Genetic examination 
alone is not sufficient to draw conclusions and so protein expression analysis was 
performed to further examine HAGE molecular interactions leading to increased 
proliferation.  This involved looking at molecules with strong influence over 
signalling pathways that could provide this phenotype, shown in Chapter 5.  The 
results showed here strongly support the hypothesis linking HAGE expression with 
modification to cellular signalling.  
 
In the first instance, this came from the observed changes to AKT and GSK-3 
phosphorylation.  Proteome Profiler arrays and western blotting were able to indicate 
increased amounts of both p-AKT (Ser473) and p-GSK-3 (Ser9) in cells with higher 
HAGE expression.  Though as previously described in Chapter 5, GSK-3 has a 
prominent role in glucose metabolism and has been implicated in neurodegenerative 
disorders; it could also play a highly important one in cancer.  GSK-3 acts to restrict 
the activity of -catenin, phosphorylating it and maintaining it in a complex along 
with APC, and axin, promoting catenin degradation (Rayasam et al., 2009).  -
catenin represents one of the major components of WNT signalling and since 
WNT/-catenin signalling has been shown to be altered in different tumours (Luo et 
al., 2007; Rayasam et al., 2009), this means as such, GSK-3 could inhibit tumour 
growth.   
 
As also mentioned previously, AKT has been shown to inactivate GSK-3 through 
phosphorylation, which in turn permits -catenin signalling (Nicholson and 
Anderson, 2002) and  WNT can also act to inactivate GSK-3 to cause the same 
effect (Rayasam et al., 2009).  Microarray data implied an increase in the mRNA 
expression of WNT-1 in cells expressing HAGE, although no protein investigations 
were performed to confirm this was the case.  However, demonstrating an increase in 
the protein levels for WNT would suggest an interesting connection between HAGE 
and the expression of these molecules.  This is made even more evident through the 
knowledge that this signalling pathway is found in embryogenesis (Logan and Nusse, 
2004) and it has been suggested that CT antigens could be involved in this process 
(Lucas et al., 1998).  Cancer/testis antigen expression in healthy tissue would appear 
to agree with this idea.  Indeed, expression of the CT antigens, MAGE-A3 and NY-
ESO-1, has been correlated to proliferation taking place at this stage of development 
(Gjerstorff et al., 2007).  The notion that HAGE expression could up-regulate 
signalling involved in this way could agree with its potential function. Other than its 
involvement with -catenin, GSK-3 has been implicated in the separation of 
chromosomes (Tighe et al., 2007), meaning that loss of function could lead to genetic 
abnormality.   
 
The effect of -catenin activity requires the interaction with the transcription factor 
lymphoid enhancer factor (LEF), whose substrates include cyclin D and c-MYC,  
both of which are involved in cell cycle progression (Nicholson and Anderson, 2002; 
Jope and Johnson, 2004; Patel et al., 2004; Rayasam et al., 2009).  So from this data, 
there is the possibility that HAGE expression causes an accumulation of -catenin as 
a result of increased AKT activity and reduced action of GSK-3.  Increased cell 
cycle progression brought on by this series of interactions may explain the increased 
proliferation seen in HAGE-expressing cells.  Data shown in Chapter 3 indicated 
there was greater cell cycle progression in HAGE-expressing cells, again associating 
the antigen with this phenomenon.  Results gained here echoed those found with 
CAGE, where it was shown that CT expression led to progression in the cycle 
involving cyclins D1, E and the E2F transcription factors (Por et al., 2010).  In this 
study, microarray data indicated both CCNE2 and E2F mRNA could be increased by 
HAGE expression.  Though this would require confirmation at the protein level, there 
is interesting similarity between the works involving these antigens.   
 
In contrast to the work of Por and colleagues (2010), it was possible to show an 
increase in the level of the cyclin inhibitor p21CIP1 in HAGE knockdown cells. This 
means that within HAGE expressing cells, there is a reduction in the level of p21CIP1.  
Por’s study showed little change in this protein’s expression in cells over-expressing 
the CAGE antigen (Por et al., 2010).  Since p21CIP1 acts to repress cell cycle 
progression, its down-regulation at the protein level would seem to further the 
impression of HAGE-expressing cells being able to proliferate faster.  Furthermore, 
this protein is a target substrate for AKT (Vara et al., 2004) providing even more 
evidence to support this hypothesis.     
 
Though identification of key effector molecules in signalling is important, two 
problems persist.  While molecules at the highest points of cascades are notoriously 
affected in malignancy, it has been difficult to find one that could be easily targeted 
for therapy.  To compound this further, downstream pathway events become more 
diverse, making target selection far more complex. The advantage of employing 
genome expression profiling analysis using techniques such as oligonucleotide 
microarray and NGS is the ability to refer back to the data to expand a specific area of 
work.  This method was used to identify the change in expression to the N-RAS 
oncogene.   
 
Initial evidence could be found in PCR experiments used to confirm expression 
profiling results, shown in Chapter 5.  Here it was shown once HAGE expression was 
reduced, N-RAS expression did also.  This was not matched at the mRNA level using 
shRNA-treated cells; however there was a marked reduction in N-RAS protein when 
HAGE expression had been knocked down.  Reciprocal silencing of N-RAS using 
specific siRNA did not lead to reduction in HAGE mRNA expression, implying 
HAGE existing upstream of the RAS molecule.  Taken collectively, there is now a 
strong argument to promote the possibility of HAGE acting to promote N-RAS 
protein expression in tumour cells.  If this is the case, then it would explain the 
change in expression seen in molecules described earlier, such as AKT, GSK-3 and 
p21CIP1.  This is due to the knowledge that RAS can influence PI3K to promote both 
survival and proliferation (Pacold et al., 2000; Sheilds et al., 2000).   
 
DEAD-box involvement with RAS has been shown in the past, with work describing 
the splicing of H-RAS by p68/DDX5 (Guil et al., 2003; Camats et al., 2008).  So far, 
it is impossible to determine the exact effect HAGE may have on N-RAS.  Evidence 
gained here using stable knockdown cell lines would suggest possible effect on the 
protein.  DEAD-box proteins have been connected to translation (Linder, 2006), 
meaning that HAGE could promote the translation of N-RAS mRNA into protein.  To 
date, no published data has been able to associate DEAD-box proteins or CT antigens 
with N-RAS expression, meaning in this instance, this work represents the first to do 
so.  Speculation exists to say RAS mutation could be one of the primary genetic 
events to occur in tumours (Kranenburg et al., 2004).  Possible up-regulation of N-
RAS by HAGE could therefore come about through a feedback loop following up-
regulation of one of the substrates of RAS.  Since CT antigen re-expression in 
malignant cells is poorly understood, this needs further investigation. 
 
The group of proteins HAGE belongs to acts by unwinding double-stranded RNA 
(Fuller-Pace, 2006; Linder, 2006).  Studies into DEAD-box helicase function in other 
species have been able to demonstrate the action of some members of this family 
(Marsden et al., 2006).  Therefore in the future, work will be carried out to examine if 
the HAGE protein is able to exclusively and directly target N-RAS RNA to allow 
better understanding towards HAGE promotion of N-RAS expression. 
 
RAS is one of the most frequently mutated molecules in malignancy.  Approximately 
30% of all human tumours demonstrate mutation to one of the three major members 
(Bos, 1988).  K-RAS is the most frequently mutated isoform with around 85% of 
RAS mutations affecting it.  This is followed by N-RAS with approximately 15% and 
finally H-RAS with less than 1% of mutations (Downward, 2003).  High frequency of 
K-RAS compared to the other family members was thought to be a result of its 
apparent necessity for cell development.  Indeed, in mice, germline mutation of K-
RAS is fatal, whereas this is not the case for H- or N-RAS (Umanoff et al., 1995; 
Johnson et al., 1997; Koera et al., 1997; Esteban et al., 2001).  This has led to the 
assumption of K-RAS being vital for healthy development as loss of the other RAS 
members does not have such dramatic consequences.  This could be due to the 
prevalence of K-RAS involvement in organelle localisation and trafficking in the 
cytoplasm, which seems greater than N- or H-RAS (Omerovic et al., 2007).   
 
However, while N-RAS mutants are not as frequent as K-RAS, it represents the most 
common isoform mutant in myeloid leukaemias including AML, chronic 
myelomonocyctic leukaemia (CMML), and juvenile myelomonocytic leukaemia 
(JMML).  It is also common in MDS, melanoma and hepatocellular carcinoma and 
can bring about haematological tumours in mice (Downward, 2003; Parikh et al., 
2006; Koike and Matsuda, 2008).  Theoretically therefore, there is the possibility of 
HAGE exerting some influence in these tumours.  If HAGE is able to control the 
expression of an oncogene with the potency of RAS, therapy against it could be 
designed in order to inhibit the effects of RAS.  This, therefore, makes HAGE a very 
inviting novel target for therapy, though as already stated, more work is required to 
confirm the relationship between the two molecules. As mentioned above, N-RAS 
mutations appear to have more prevalence in haematological malignancies, a group of 
tumours frequently associated with HAGE expression (Adams et al., 2002; 
Condomines et al., 2007; Roman-Gomez et al., 2007).  However, work is still 
required to confirm the co-existence of N-RAS and HAGE in cancers.         
 
Analysis of relative expression for K-RAS and H-RAS in FM-82/Ctrl and FM-
82/shRNA showed a decrease in these isoforms upon HAGE silencing.  This requires 
further investigation and future work will involve examination of protein levels of the 
other RAS members to determine if they conform to the same pattern of expression as 
N-RAS.  If this were to be the case, HAGE could recognise an mRNA sequence 
common to all isoforms.  This would be understandable since RAS members are 
thought to be 85% homologous (Downward, 2003).  Other work could involve 
examining the helicase activity of HAGE on K- and H-RAS RNA. 
 
The possible up-regulation of RAS by HAGE could go some way to explain the 
phenotype displayed by cells with higher HAGE expression.  This is evident in terms 
of proliferation, where RAS is able to increase the activity of AKT by acting upon the 
PI3K signalling pathway (Cox and Der, 2002).  If more data could be gained to 
confirm the HAGE-NRAS or HAGE-RAS interaction, this would act as significant 
evidence as to assigning a role to the CT antigen.  Apart from this, up-regulation of 
the protein expression of a RAS isoform and through this, AKT, could also go some 
way to explain the results of other phenotypic aspects of HAGE-expressing cells.   
 
The serine/threonine kinase AKT can inhibit apoptosis and has links to therapy 
resistance.  It can down-regulate pro-caspase 9 (Vara et al., 2004), which can stop 
initiation of caspase 3 thus preventing cell death (Schultz and Harrington, 2003).  
FM-82/Ctrl cells treated with cisplatin showed lower levels of caspase 3/7 compared 
to the FM-82/shRNA line, perhaps linking increased p-AKT (active) with reduced 
effector caspase levels.  PI3K signalling involving AKT can also prevent apoptosis 
through interactions with IAP (Cheng et al., 2002), inferring a potential mechanism 
for HAGE to prevent cell death.  If this is the case, then expression of the antigen 
could act as a biomarker for aggressive disease or disease progression.  It also re-
emphasises the potential usefulness of HAGE as a target for therapy to at least limit 
disease progression. 
 
Yet another association for RAS, HAGE and disease progression was the initial data 
connecting expression of the CT antigen with increased invasiveness.  RAS 
expression has association with angiogenesis and metastasis, two very closely related 
processes in tumours (Campbell and Der, 2002; Kranenburg et al., 2004).  In terms of 
metastasis specifically, HAGE expression seemed to lead to an increase of the pro-
metastatic FAK.  The importance of this molecule in cell motility, such as leading 
edge formation in migrating cells, and invasion is well known and underscored by the 
demonstration that loss of FAK can result in loss of invasion in certain cases (Hauck 
et al., 2002; Hsia et al., 2003; Tilghman et al., 2005).  One could argue that HAGE 
expression contributes towards metastatic potential.  Yet again, RAS and PI3K 
involvement can be brought into play, since it has been shown in breast cancer that 
FAK is required to support tumorigenesis and progression involving these two onco-
proteins (Pylayeva et al., 2009).  The only area of contradiction came with MMP-9 
expression.  RAS has been shown to induce expression of this metalloprotease, as has 
FAK (Kranenburg et al., 2004). Yet there was no increase of MMP-9 in HAGE-
expressing cells.  However as already mentioned, there is a great deal of focus placed 
on the balance between pro- and anti-invasion mediators in metastasis (Ahmad and 
Hart, 1997).  Therefore, the reduction of TIMP-4 seen in FM-82/Ctrl could play a part 
in promoting metastasis in HAGE expressing cells.  Future work should focus on 
developing a more in-depth picture of HAGE and tumour invasion and in particular 
the changes in expression of TIMP and MMP relative to cell invasion. 
 
Tumour-driven neo-vascularisation is necessary for malignant survival and a pre-
requisite for dissemination to other parts of the body (Kranenburg et al., 2004).  This 
is why many proteins, aberrantly expressed to cause new vessel development, are 
additionally implicated in metastasis.  RAS is not only important for angiogenic 
behaviour in malignant cells, but also affects healthy cells in the surrounding 
environment, such as stroma to cooperate in promoting the process (Rak et al., 1995; 
Kranenburg et al., 2004).  Furthermore, AKT has been shown to promote 
angiogenesis, hinting at another way in which RAS can act to bring this about (Jiang 
and Liu, 2008).  Though angiogenesis was not specifically looked at in this work, one 
of the genes found to be down-regulated by microarray analysis was JUN-D.  This 
has been shown to down-regulate angiogenesis induced by processes mediated by 
RAS to prevent oxidative stress (Gerald et al., 2004).  This preliminary finding 
necessitates further work investigating the role of HAGE in angiogenesis. 
 
The role of HAGE in immune escape is a more complex relationship, requiring 
further investigation.  Seemingly raised level of FAS-L surface expression on tumour 
cells positive for HAGE along with increased T cell death caused by the co-culture 
with HAGE expressing cells would point towards evidence of immune escape.  
Certain organs of the body bear immune privilege and for obvious reasons, this 
includes the brain, eye, testis and placenta.  The testis have been shown to have FAS-
L expression (Francavilla et al., 2000), which could confer immune privilege by 
helping to deter T cell activity.  Since HAGE is a CT antigen and therefore normally 
expressed by healthy testis, there is the possibility this molecule is repeating its 
function in healthy cells upon re-expression in malignant cells.  In terms of the 
possible HAGE-RAS relationship, RAS has been shown to down-regulate FAS 
expression (Peli et al., 1999), allowing tumour cells to avoid apoptosis possibly 
induced by FAS-L expressing CTL.  Expression of the latter, along with FLIP, would 
need to be analysed to gain confirmation of RAS-mediated immune survival.     
 
Avoidance of immune reactivity by the up-regulation of FAS-L is contentious.  Work 
focusing on melanoma has indicated that FAS-L is not expressed, while others claim 
the opposite (Hahne et al., 1996; Chappell et al., 1999; Ugurel et al., 1999).  As 
stated previously, the results obtained in this thesis would appear to agree with the 
latter.  There has been speculation on the role of RAS and increased expression of 
FAS-L by tumours (Urquhart et al., 2002).  A study by Urquhart and co-workers 
(2002) examined a possible link between N-RAS and FAS-L in a melanoma cell line.  
Their data suggested FAS-L was not expressed, which runs contrary to data obtained 
in the present study.  However, this was analysis based on one cell line, so there is a 
need to further examine this concept using different cell lines of different tissue 
origin.  It would seem the data presented here adds to the confusion in terms of FAS-
L expression on tumour cells. 
 
7.2 Conclusion and Future Work 
 
Cancer/testis antigens represent one of the most promising targets for cancer therapy.  
Very little is known as to their role in cancer cells, though hypotheses have been 
proposed.  The pattern of their expression, being predominantly confined to tumours 
and healthy testis and placenta, would imply that they become re-expressed during 
transformation to carry out a role in malignant cells.  One way of improving the 
development of therapy targeting CT antigens could be to increase knowledge into 
the function they possess in cancer.  Since HAGE is also classified as a DEAD-box 
protein, there was the initial hypothesis that it could be involved in proliferation.  
 
From the data collected and presented here, there is now a strong argument to 
implement HAGE not just in proliferation, but other aspects of malignant cell 
biology.  Gene silencing and phenotypic studies have shown the possible involvement 
of this antigen in different processes disrupted in cancer.  HAGE action seems to be 
most prominent in proliferation, not just in vitro, but in vivo as well.  Microarray 
analysis and western blotting demonstrated the expression changes of different 
molecules within HAGE-expressing cells that could promote cell cycle progression 
and proliferation.  Change in expression of N-RAS, AKT, GSK-3 and p21CIP1 has 
been shown using protein extracted from cell lines.  Since increased proliferation has 
been shown in vivo, protein will be extracted from tumours grown in NOD/SCID 
mice and used for western blotting to confirm expression pattern of these mediators at 
this level.  To increase understanding for the role of HAGE in proliferation, NGS 
analysis will be used in the first instance to validate the expression of genes shown to 
be altered by HAGE such as CCNE2, E2F2 and WNT-1.  Following this, western 
blotting will be carried out to discover if changes to these molecules also takes place 
at the protein level. 
 
Proliferation, along with a large proportion of other aspects of the malignant 
phenotype can be controlled by RAS members.  Due to the position of RAS within 
cell signalling, its level of influence in cells is substantial, hence its importance in 
cancer in response to its mutation.  The discovery of the possible relationship between 
HAGE and the N-RAS oncogene acts as a novel finding potentially linking CT 
antigen expression and the phenotype described here.  Due to the prevalence of RAS 
in human cancer, the discovery of a tumour-specific molecule with possible control 
over it represents a significant finding.  While N-RAS expression change was 
indicated at the gene and protein level, this was carried out in melanoma.  In the first 
instance, silencing of HAGE will be reduced in other tumour types that express the 
antigen to confirm if this relationship could be applied other malignancies.  Gene 
studies, in the form of real-time qPCR and protein studies involving western blotting 
will be employed to confirm expression.  In addition to this, studies using the above 
techniques will be used to investigate if this interaction is specific for N-RAS or also 
applies to both H- and K-RAS.  Further to N-RAS, mechanistic unwinding studies 
will be performed and a helicase assay will be developed to examine if HAGE can 
specifically and directly target N-RAS mRNA in order to confirm the hypothesis that 
it could promote RAS protein translation.  HAGE protein will also be extracted from 
cells using immuno-precipitation, which combined with either mass spectrometry or 
ChIP-Prot sequencing could help determine what molecules HAGE binds to.   
 
For tumours to pose the biggest threat to a patient, they must be as aggressive as 
possible.  Data obtained in this study have begun to indicate that HAGE could help to 
promote this, such as invasion.  In order to gain a better understanding of this, a study 
will be performed in HAGE-expressing cell lines of different tumours to examine the 
levels of metastatic promoters and inhibitors such as MMP and TIMP to examine the 
balance of these molecules and how this could influence tumour invasion.  
Additionally, an in vivo metastasis model will be established in NOD/SCID mice 
using the stable shRNA cell line to investigate if HAGE-expressing tumours have 
greater potential to invade compared to cells where its expression is reduced.  
Validation of key mediators in this process such as MMP, TIMP, as well as RAS 
signalling substrates will be looked into, either by extracting RNA from these 
tumours for use with PCR or proteins for use in conjunction with western blotting. 
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